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Introduction
Progressive renal disease
Patients with renal disease are at risk for progressive renal injury which may
lead to end-stage renal failure [1]. The pathophysiological mechanism which
underlies the progressive nature of renal disease has been subject for extensive
research in the last decades and several potential causal factors have been
identified. At first, renal hemodynamic alterations have been considered to be the
major contributor to progressive deterioration of renal function [2]. Independent from
the cause of the initial renal injury, a critical loss of nephrons is followed by a
compensatory glomerular hyperfiltration in remnant nephrons to preserve renal
function in the short-term. This glomerular hyperfiltration is considered maladaptive
in the long-term since the concomitant increase of glomerular capillary pressure is
associated with the development of glomerulosclerosis and tubulointerstitial injury in
the remnant nephrons which enhances the progressive loss of renal function. It has
been postulated that increased glomerular capillary pressure leads to
glomerulosclerosis by generation of growth-promoting factors which induce
mesangial cell proliferation and collagen synthesis [3-6].
Urinary protein excretion has been considered as a consequence of
glomerular injury due to the increased glomerular capillary pressure in progressive
renal disease [7-10]. In the last decade however, the glomerular leakage of
macromolecules is rather considered to be an important determinant than a
reflection of progressive glomerulosclerosis and tubulointerstitial injury [11-13].
Glomerulosclerosis can indeed be induced by proteinuria due to a toxic- or immune-
mediated increase of glomerular permeability without the presence of elevated
glomerular capillary pressure [14]. Proteinuria may affect progressive renal injury by
different mechanisms [13]. In short, glomerular epithelial cells exposed to large
amounts of proteins undergo structural and functional changes which further
increase the passage of macromolecules across the glomerular capillary wall. An
increase of filtered proteins through enhanced glomerular permeability results in
mesangial cell proliferation, increased production of extracellular matrix, direct
tubular toxicity as well as tubular cell dysfunction, and activation of mononuclear
cells which leads to progressive glomerulosclerosis and tubulointerstitial
inflammation. The development of glomerulosclerosis can furthermore be
aggravated by secondary effects of proteinuria such as hyperlipidemia [15-16]. In
accordance with these data which are largely derived from in vitro studies,
proteinuria is independently related with glomerulosclerosis and progressive renal
function loss in experimental and human renal disease [17-18], next to systemic
hypertension and several other clinical risk factors for progressive deterioration of
renal function (Table 1) [19-20].
In summary, proteinuria is nowadays considered as an independent risk factor
for progressive renal disease due to its intrinsic renal toxicity and its secondary
metabolic effects.Introduction
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Table 1. Clinical risk factors for progression of kidney diseases [20].
Persistent activity of underlying disease
Commonly amplifiers of risks Uncontrolled hypertension
Obstruction/reflux
Infection
Analgesic or nephrotoxins
Calcium or urate deposits
Marked reduction in nephron number Congenital
Acquired
Other factors promoting increased PGC High-protein diet
Diabetes mellitus
Chronic corticosteroid therapy
Pregnancy
Diastolic blood pressure > 95 mmHg
Hyperlipidemia
Proteinuria
Cigarette smoking
Black race
Obesity
Glomerular permeability
The normal glomerular capillary wall is a very efficient sieve which allows the
filtration of large amounts of fluid, but progressively restricts the passage of
macromolecules with increasing molecular size, increasing anionic charge, and more
spherical configuration into the urine [21].  All components of the glomerular capillary
wall seem to be involved in the size and charge selective filtration of
macromolecules [22]. Endothelial cells are the first component which line the
glomerular basement membrane (GBM) on the inner aspect of the capillary wall and
have endothelial fenestrae with a width up to 100 nanometer. The presence of
endothelial cell surface sialoglycoproteins such as podocalyxin may contribute to the
restricted filtration of anionic macromolecules. The second component is the GBM
which consists of a three dimensional lattice-like network of fibrils mainly composed
of type IV collagen and proteoglycans. Tightly packed fibrils in the lamina densa of
the GBM allow integrity of the glomerular capillary wall in a wide range of
intraglomerular hemodynamic changes. The laminae rarae of the GBM exist of more
loosely packed fibrils and proteoglycans which ensure the attachment of endothelial
and epithelial cells to the GBM. The GBM has been considered to be the major size
selective barrier for filtration of albumin and larger proteins due to the presence of
pores with a maximal diameter of 25Å in the compact network of fibrils in the lamina
densa [23-24]. In addition, the net negative charge in the lamina rara interna of the
GBM due to the proteoglycans has been considered to be the major charge selective
barrier for albumin [25-26]. The third component of the glomerular capillary wall isIntroduction
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made up of the interdigitating epithelial foot processes with intervening spaces
spanned by the slit diaphragms. The slit diaphragms themselves consist of a fine
meshlike network with pores, whereas the foot processes are covered by a
negatively charged sialoglycoprotein coat. This coat is essential to maintain the
dynamic geometry of the epithelial foot processes. Several recent experimental
studies suggest that the epithelial cells contribute to glomerular size and charge
selectivity to a greater extent than the GBM [27-32].
Figure 1. Glomerular size selectivity reflected by fractional dextran clearances in patients with
proteinuria (solid lines) in comparison to healthy subjects (dotted lines). Left panel: patients with
membranous glomerulopathy; middle panel: patients with focal segmental glomerulosclerosis; right
panel: patients with minimal change disease [35-36].
Proteinuria of non-diabetic origin is associated with a glomerular size and/or
charge selective defect [33-37]. Impaired glomerular size selectivity has been
demonstrated by a shift of the fractional dextran clearances with increases in the
high molecular size range and decreases  in the low molecular size range (Figure 1).
Minimal change disease demonstrates a different dextran sieving profile because it
is rather associated with a charge selective defect than a size selective defect [34].
The fractional clearances of dextrans with a broad molecular size distribution are
preferably used to measure glomerular size selectivity because dextrans are only
filtered by the kidney, and not subject to tubular reabsorption or secretion [38]. It can
0.001
0.01
0.1
1
0.001
0.01
0.1
1
30 40 50 60 30 40 50 60
0.001
0.01
0.1
1
30 40 50 60
F
r
a
c
t
i
o
n
a
l
 
d
e
x
t
r
a
n
 
c
l
e
a
r
a
n
c
e
s
R
a
d
i
u
s
 
(
A
n
g
s
t
r
o
m
)Introduction
5
be theoretically calculated from a model which represents the glomerular capillary
wall as a membrane perforated by cylindrical pores with a lognormal pore size
distribution that the decreased fractional clearance of dextrans smaller than 44Å is
due to a concomitant reduction of the mean pore size and the ultrafiltration
coefficient Kf of the glomerular capillary wall [39]. This additionally explains the
profound reduction of the glomerular filtration rate (GFR) in conditions of proteinuria
[40]. The increased fractional clearance of dextrans greater than 54Å is the result of
an increased ultrafiltrate flow through an increased number of pores with an
increased pore size and is not dependent of the increased glomerular capillary
pressure in progressive renal disease [39]. The increased ultrafiltrate flow through
large pores explains the urinary loss of albumin and IgG, although the extent of
albuminuria cannot entirely be attributed to this flow in focal segmental
glomerulosclerosis and membranous glomerulopathy [34-35]. Albuminuria is thus at
least partially the consequence of impaired glomerular charge selectivity in these
renal disorders. In accordance, fractional clearances of anionic macromolecules
such as dextran sulfate, IgG4, and salivary amylase are relatively increased in
comparison to the fractional clearances of neutral to cationic macromolecules such
as dextran, IgG, and pancreatic amylase, respectively, in patients with proteinuria
compared to healthy subjects [36, 41-44]. The fractional clearance of negatively
charged dextran sulfate compared to neutral dextran is preferably used to measure
glomerular charge selectivity, since it is not influenced by tubular handling [36]. Its
applicability for clinical research is however limited because: dextran sulfate in high
concentration induces toxic effects in humans; it is prone to desulfatation during
ultrafiltration; it binds size-dependently to serum proteins; and its molecular size is
only 18Å and thus not comparable to albumin (36Å) which is the natural occurring
protein for charge selective filtration [36, 45]. The fractional clearance indices of IgG
versus IgG4 as well as pancreatic amylase versus salivary amylase are more easy
to perform in clinical research. Both protein indices though are affected by charge-
dependent differences in tubular reabsorption of proteins [46]. In addition, urinary
excretion of IgG (55Å) is more dependent of the extent of the size selective defect of
the glomerular capillary wall than amylase (29Å) which has a molecular size
comparable to albumin [33]. Differently charged horseradish peroxidase or albumin
which have been used to monitor glomerular charge selectivity in experimental renal
disease are not applicable in humans because of their intrinsic toxicity [47-48].
Horseradish peroxidase is a globular protein which is hardly reabsorbed by tubular
cells, but it is charge-dependently degraded during filtration [49]. Native anionic
albumin can be charge modified to neutral or cationic albumin without change in
molecular size or risk of in vivo degradation, but fractional clearances of differently
charged albumin are influenced by the charge-dependent tubular reabsorption [48].
The structural equivalents of the size and charge selective defects of the
glomerular capillary wall have been subject of extensive research. The most
characteristic and common histological finding which is related to increased
glomerular permeability to proteins is the complete loss of epithelial cell architecture
resulting in fusion of epithelial foot processes and focal detachment of epithelial cellsIntroduction
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from the GBM [21-22]. The fusion of foot processes decreases the hydraulic
permeability and contributes to the reduction of GFR, whereas focal detachment of
epithelial cells is strongly related with impaired glomerular permeability to proteins
[39]. It has been suggested that the loss of anionic surface sialoglycoproteins of
epithelial cells precedes and induces these epithelial lesions [50]. Proteinuria is also
associated with biochemical and structural changes of the GBM. Several human
glomerular disorders are characterized by an impaired expression of the negatively
charged glycosaminoglycan side chains of heparan sulfate proteoglycan in the GBM,
whereas the expression of the core protein heparan sulfate proteoglycan is not
affected [51]. In addition, the glomerular synthesis of heparan sulfate proteoglycan
appears to be altered in nephrotic conditions [52]. These biochemical alterations of
the GBM may lead to: reduced charge selectivity by loss of effective negative
charge; reduced size selectivity due to disruption of the compact network of fibrils;
and reduced GFR due to accumulation of macromolecules in the GBM which
decreases the hydraulic permeability [22]. High-resolution electron microscopy of the
GBM in renal tissue of nephrotic patients indeed demonstrates great irregularities in
the network of fibrils with tunnels and cavities up to a diameter of 200Å which appear
to be a pathway for protein leakage [24, 53]. A reduced expression of anionic
sialoglycoproteins and heparan sulfate proteoglycans in endothelial cells has been
associated with the increased permeability to proteins in minimal change disease
[54].
In summary, proteinuria is the consequence of impaired glomerular size
and/or charge selectivity which is primarily due to structural changes in the
glomerular capillary wall. The increased glomerular capillary pressure in progressive
renal disease seem not to be directly responsible for this increased glomerular
permeability to proteins, although it may enhance the urinary loss of proteins.
Reduction of proteinuria
One of the major aims of clinical nephrology today is to arrest or retard the
progression rate of renal function loss in chronic renal disease. Considering the
impact of proteinuria on the progression of renal function loss, an optimal reduction
of proteinuria has become an important intervention strategy. Nephrotic-range
proteinuria in patients with minimal change disease, focal segmental
glomerulosclerosis, and membranous glomerulopathy can be curatively treated with
corticosteroids in combination with cytotoxic agents or not and therefore prevent
progressive loss of renal function [55]. Several large, prospective trials recently
demonstrated that the progressive loss of renal function can also be retarded by
symptomatic antiproteinuric treatment with dietary protein restriction or angiotensin-
converting enzyme (ACE) inhibition [56-60]. ACE inhibitors are established drugs of
first choice for the pharmacological reduction of proteinuria, since ACE inhibitors
have a greater ability to reduce proteinuria than other antihypertensive drugs
including calcium channel antagonists, whereas their blood pressure lowering
efficacy is comparable [61-63]. The ability of ACE inhibitors to reduce proteinuria
beyond the effect which is attributed to blood pressure reduction may explain theirIntroduction
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greater ability to retard progressive loss of renal function [58-60]. In contrast to
dihydropyridine calcium channel antagonist such as nifedipine, the non-
dihydropyridine calcium channel antagonists verapamil and diltiazem have a
comparable ability to reduce proteinuria and to retard the progressive loss of renal
function as ACE inhibitors in hypertensive patients with non-insulin dependent
diabetes mellitus [64-70]. Combination treatment of an ACE inhibitor and verapamil
even induces an additional antiproteinuric effect in this population which lead to a
better renoprotection by combination treatment than by each agent alone [66-67,
69].
Non steroidal anti-inflammatory drugs (NSAID) and a low protein diet also
symptomatically reduce proteinuria [71-72]. The use of NSAID is however frequently
compromised by their gastrointestinal side-effects, although their antiproteinuric
efficacy is comparable to that of ACE inhibitors, whereas a low protein diet reduces
proteinuria to a smaller extent than ACE inhibitors. Both the long-term use of NSAID
and a low protein diet have been related to renoprotection through their
antiproteinuric effect [57, 73]. The combination of a NSAID or a low protein diet with
an ACE inhibitor also induces an additional antiproteinuric effect [71-72].
In summary, ACE inhibitors are drugs of first choice for symptomatic
antiproteinuric treatment in the clinical practice of today. This potent antiproteinuric
capacity seems to be related to a superior renoprotective effect of ACE inhibitors.
The non-dihydropyridine calcium channel antagonists may have a similar beneficial
renoprotective profile, although this has only been demonstrated in non-insulin
dependent diabetic patients with hypertension so far.
Antiproteinuric treatment and glomerular permeability
Effective reduction of proteinuria has been associated with restoration of
glomerular size selectivity in experimental and clinical studies in non-diabetic renal
disease (Table 2 and 3). Restoration of glomerular size selectivity is reflected by an
increase of fractional clearances for small dextrans (<40Å) and a decrease of
fractional clearances for large dextrans (>50Å). In only two experimental studies a
significant reduction in proteinuria is not associated with restored glomerular size
selectivity [74, 80]. Two clinical studies observed increased fractional clearances for
dextrans smaller than 50Å, but failed to detect significant changes in fractional
clearances for dextrans greater than 50Å [82, 91]. Measurement of fractional
clearances of exogenous macromolecules such as dextran or polyvinylpyrrolidone in
comparison to endogenous proteins reveals discrepant results with respect to
changes in glomerular size selectivity during antiproteinuric treatment. Tiggeler et al.
[81] demonstrated improvement of glomerular size selectivity to polyvinylpyrrolidone,
but not to proteins during NSAID. In contrast, de Zeeuw et al. [84] detected
improvement of glomerular size selectivity to proteins during ACE inhibition, but not
to dextran. Only Zietse et al. [89] observed improved glomerular size selectivity to
dextran as well as to proteins during cyclosporin A in patients with membranous
glomerulopathy.Introduction
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Table 2. Overview of experimental studies which analyzed the effect of
antiproteinuric treatment on glomerular permselectivity in non-diabetic renal disease.
 Authors Model Therapy D D Uprotein D D Selectivity Parameter
%
Olson
50 RRM LPD -84 › charge HRP
Remuzzi
74 ADR LPD -42 = size dextran
Alfino
75 NSN Tripple -68 › size dextran
Cartwright
76 RRM LPD -88 › size dextran
Cartwright
76 RRM ACEi -92 › size dextran
Neugarten
77 NSN NSAID -75 › size dextran
Yoshioka
78 RRM Verapamil -41 › size dextran
Remuzzi
39 MWF/Ztm ACEi -57 › size dextran
Mayer
79 RRM AIIA -57 › size dextran
Mayer
79 RRM AIIA -57 = charge DS
Oliver
80 RRM ACEi -70 = size ficoll
Abbreviations are: Uprotein = proteinuria; RRM = reduced renal mass model; ADR = adriamycin model;
NSN = nephrotoxic serum nephritis model; MWF/Ztm = spontaneous glomerulosclerosis model; LPD
= low protein diet; tripple = hydralasin/hydrochlorothiazide/reserpine; ACEi = ACE inhibitors; NSAID =
non-steroidal anti-inflammatory drugs; AIIA = angiotensin II antagonist; › size/charge = improved
size/charge selectivity; = size/charge = unchanged size/charge selectivity; HRP = horseradish
peroxidase; DS = dextran sulfate.
The role of glomerular charge selectivity during antiproteinuric treatment in
non-diabetic renal disease is underexposed and inconclusive. Olson et al. [50]
showed a concomitant improvement of glomerular charge selectivity during low
protein intake by a relatively greater reduction of the fractional clearance of anionic
horseradish peroxidase in rats with reduced renal mass, whereas Mayer et al. [79]
showed no change of glomerular charge selectivity during angiotensin I receptor
blockade by measurement of fractional dextran sulfate clearances in a similar model.
Shemesh et al. [82] did not observe restored glomerular charge selectivity to
differently charged fractions of IgG by NSAID in human membranous
glomerulopathy. Zietse et al. [89] showed improved glomerular charge selectivity by
an increase of the IgG to IgG4 clearance index during cyclosporin A in human
minimal change disease.Introduction
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In summary, different types of symptomatic antiproteinuric intervention are
associated with improved glomerular size selectivity in non-diabetic renal disease.
The role of glomerular charge selectivity during effective reduction of proteinuria is
underexposed and inconclusive.
Table 3. Overview of clinical studies which analyzed the effect of antiproteinuric
treatment on glomerular permselectivity in non-diabetic renal disease.
Authors Diagn Therapy D D Uprotein D D Selectivity Parameter
(%)
Tiggeler
81 NS NSAID -50 › size PVP
Tiggeler
81 NS NSAID -50 = size IgG/alb
Shemesh
82 MGP NSAID -74 › size dextran
Shemesh
82 MGP NSAID -74 = charge IgG
Rosenberg
83 NS LPD -33 › size dextran
Golbetz
84 MGP NSAID -43 › size dextran
de Zeeuw
85 NS ACEi -63 = size dextran
de Zeeuw
85 NS ACEi -63 › size joachim
Remuzzi
86 NS LPD +12 = size dextran
Remuzzi
87 IgA ACEi -47 › size dextran
Thomas
88 MGP ACEi -50 › size dextran
Zietse
89 MCD CsA -86 › charge IgG/IgG4
Zietse
89 MGP CsA -82 › size dextran+IgG/alb
Zietse
89 FSGS CsA +20 = size dextran+IgG/alb
Hartmann
90 NS nifedipine -2 = size dextran
Ambalavanan
91
MGP CsA -56 › size dextran
Ambalavanan
91
MGP ACEi -16 = size dextran
Abbreviations are: Diagn = renal diagnosis; Uprotein= proteinuria; NS = nephrotic syndrome of various
non-diabetic origin; MGP = membranous glomerulopathy; IgA = IgA nephropathy; MCD = minimal
change disease; FSGS = focal segmental glomerulosclerosis; NSAID = non-steroidal anti-
inflammatory drugs; LPD = low protein diet; CsA = cyclosporin A; ACEi = ACE inhibitors; ›
size/charge = improved size/charge selectivity; = size/charge = unchanged size/charge selectivity;
PVP = polyvinylpyrrolidone; joachim = joachim slope as estimate of glomerular size selectivity.
Mechanism of the antiproteinuric effect of ACE inhibition
The beneficial antiproteinuric effect of ACE inhibitors in non-diabetic renal
disease has been attributed to their interference in the renin-angiotensin system
which reduces the generation of angiotensin II [92]. Experimental studies
demonstrated that angiotensin II has a potent constrictive action on vascular smooth
muscle cells [93]. This results in a rise in blood pressure as well as in localIntroduction
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vasoconstrictive effects amongst which the rise in glomerular capillary pressure
through a predominant vasoconstriction of the efferent arteriole is one of the most
characteristic effects of angiotensin II [93]. The antiproteinuric efficacy of ACE
inhibitors has been associated with their ability to vasodilatate the efferent arteriole
which results in a reduction of the glomerular capillary pressure [94-95]. It is
however unlikely that angiotensin II dependent changes in glomerular capillary
pressure have a direct role in the antiproteinuric effect of ACE inhibition in non-
diabetic renal disease. First, the time course of the antiproteinuric response is
dissociated from that of the renal hemodynamic changes during ACE inhibition
(Figure 2). Renal hemodynamic changes are already maximal within the first hours
after administration of ACE inhibition, whereas the reduction of proteinuria shows a
gradual increase and becomes maximal after 4 weeks of ACE inhibition [96].
Second, the maximal antiproteinuric effect of ACE inhibition is not affected by a
complete reversal of renal hemodynamic changes during exogenous angiotensin II
infusion [97]. Only the acute reduction of proteinuria after administration of ACE
inhibition may be related to changes in systemic or renal hemodynamics [98-99].
ACE inhibition restored glomerular size selectivity at the time of the maximal
antiproteinuric effect in non-diabetic renal disease [39, 76, 85, 87-88, 100]. A
theoretical calculation of the pore characteristics of the glomerular capillary wall
suggested that this restoration of glomerular size selectivity is primarily the
consequence of intrinsic changes of the pores in the glomerular capillary wall,
whereas the concomitant reduction of glomerular capillary pressure did not
significantly contribute to this phenomenon [39, 87]. The gradual increase of the
antiproteinuric effect may therefore be related to slowly appearing structural changes
in the glomerular capillary wall which restore glomerular size selectivity. It is
unknown whether the antiproteinuric effect of ACE inhibition is also associated with
restored glomerular charge selectivity. The only clinical study so far on this issue
demonstrated no change of charge selectivity as reflected by the IgG to IgG4 index
during effective reduction of diabetic micro-albuminuria by ACE inhibition [101].
In summary, the antiproteinuric effect of ACE inhibition shows a gradual time
course with a maximal reduction in proteinuria after 4 weeks treatment. This time
course of the antiproteinuric response cannot be directly the consequence of
hemodynamic alterations. Hemodynamic alterations may initiate the antiproteinuric
response, but it is unknown whether this concerns the systemic or renal
hemodynamic effects of ACE inhibition. Since ACE inhibition restores glomerular
size selectivity, the time course of the antiproteinuric response may be the
consequence of a gradual restoration of glomerular size selectivity. The role of
changes in glomerular charge selectivity during effective reduction of proteinuria by
ACE inhibition in non-diabetic renal disease is unknown.Introduction
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Figure 2. The course of the effects of ACEi (enalapril 10 mg) on glomerular filtration rate (GFR),
effective renal plasma flow (ERPF), filtration fraction (FF), mean arterial pressure (MAP), and
proteinuria (Uprot) [96].
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Aim of the thesis
The present thesis aims to elucidate some of the remaining questions on the
mechanism of the antiproteinuric effect of ACE inhibition in non-diabetic renal
disease with emphasis on the role of alterations in hemodynamic conditions and
glomerular charge selectivity.
Chapter 1
It has been suggested that the non-dihydropyridine calcium channel
antagonist verapamil is an antihypertensive agent with a similar antiproteinuric
capability as ACE inhibitors. The evidence for such a beneficial renal effect of
verapamil is derived from a limited number of open-label studies in non-insulin
dependent diabetic patients with diabetic nephropathy. To elucidate whether
verapamil has also a similar antiproteinuric capability in non-diabetic renal disease,
the antiproteinuric effect of verapamil is compared to that of the ACE inhibitor
trandolapril in patients with non-diabetic renal disease. In addition, the
antiproteinuric effect of treatment with a fixed combination of both agents is
compared to that of each agent separately, since combination treatment induces
additional antiproteinuric efficacy in non-insulin dependent diabetic patients with
diabetic nephropathy.
Chapter 2
The time course of the antiproteinuric effect of ACE inhibition demonstrates a
small acute antiproteinuric effect followed by a gradual increase of the
antiproteinuric effect during the first 4 weeks of treatment. Only the small acute
antiproteinuric effect may be directly mediated by hemodynamic changes during
ACE inhibition. To elucidate whether blood pressure reduction or renal
vasodilatation contribute to the acute antiproteinuric effect of ACE inhibition in non-
diabetic renal disease, the acute hemodynamic and antiproteinuric effects of the
ACE inhibitor enalaprilat are compared to those of the antihypertensive control agent
nitroprusside which does not induce renal vasodilatation. The importance of the renin-
angiotensin system (RAS) in the acute antiproteinuric response to ACE inhibition is
tested by an infusion of angiotensin II during acute ACE inhibition.
Chapter 3
The gradual increase of the antiproteinuric effect of ACE inhibition after the
small acute reduction of proteinuria may be related to slowly appearing structural
changes in the glomerular capillary wall which improves glomerular size and/or
charge selectivity. To elucidate whether ACE inhibition restores glomerular charge
selectivity, the fractional clearance index of charge-modified neutral rat albumin to
native anionic rat albumin will be analyzed during the antiproteinuric effect of the
ACE inhibitor lisinopril in adriamycin nephrotic rats. In addition, it will be analyzed
whether the time course of the antiproteinuric effect is related to feasible time-related
changes in glomerular charge selectivity.Introduction
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Chapter 4
To elucidate whether glomerular charge selectivity is restored at the time of a
maximal antiproteinuric effect of ACE inhibition in patients with non-diabetic renal
disease, the fractional clearance indices of IgG to IgG4 and pancreatic to salivary
amylase as markers of glomerular charge selectivity and fractional dextran
clearances as marker of glomerular size selectivity are measured during effective
reduction of proteinuria by the ACE inhibitor trandolapril in patients with non-diabetic
renal disease who are characterized by a concomitant glomerular size and charge
defect at baseline.
Chapter 5
The fractional clearances indices of IgG to IgG4 and pancreatic to salivary
amylase have never been directly compared as markers of glomerular charge
selectivity in non-diabetic renal disease. To elucidate whether both indices reflect
glomerular charge selectivity in a comparable way, the fractional clearances indices
of IgG to IgG4 and pancreatic to salivary amylase are directly compared in non-
diabetic subjects with albuminuria over a wide range. In addition, it will be analyzed
to which degree impaired glomerular charge selectivity as measured by the fractional
clearances indices of IgG to IgG4 and pancreatic to salivary amylase contributes to
albuminuria in non-diabetic subjects with a concomitant size-selective defect.
Chapter 6
The laboratory procedure for the measurement of fractional dextran
clearances shows considerable variations during the last decade. To elucidate
whether methodological differences in this laboratory procedure have repercussions
for the accuracy and reproducibility to measure fractional dextran clearances,
different methodological aspects of the laboratory procedure for the measurement of
fractional dextran clearances will be compared. In addition, it will be analyzed which
of the laboratory procedures most accurately detects a glomerular size-selective
defect in non-diabetic patients with proteinuria.Introduction
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Introduction
Meta-analyses on antiproteinuric efficacy of different antihypertensive agents
show that ACE inhibitors are superior to all other classes of antihypertensive drugs
in diabetic and non-diabetic nephropathy at similar blood pressure reducing levels
[1-3]. It has been demonstrated that this greater reduction of proteinuria by ACE
inhibition is associated with better preservation of long-term renal function [4-7]. The
antiproteinuric efficacy of calcium channel antagonists is overall significantly less
than that of ACE inhibitors [1-3]. However, dihydropyridine and non-dihydropyridine
calcium channel antagonists seem to differ with respect to their antiproteinuric
efficacy [8-9]. Dihydropyridine calcium channel antagonists do not reduce proteinuria
in long-term studies and may have adverse effects on GFR in diabetic nephropathy
despite efficient blood pressure reduction [2]. In contrast, the non-dihydropyridine
calcium channel antagonists verapamil and diltiazem reduce proteinuria to a similar
extent as ACE inhibitors, but to a greater extent as other antihypertensive drugs [10-
13]. Combination of verapamil or diltiazem with ACE inhibitors even induced a
greater reduction of proteinuria in comparison to each agent alone [11,13].
All available data on non-dihydropyridine calcium channel antagonists are
derived from a limited number of open label studies which are carried out in
hypertensive non-insulin dependent diabetic patients with overt nephropathy [10-13].
To date, it is unknown whether verapamil reduces proteinuria to a similar extent as
ACE inhibitors in patients with non-diabetic renal disease. We therefore performed a
double-blind, random cross-over and placebo-controlled study on the antiproteinuric
efficacy of the non-dihydropyridine calcium channel antagonist verapamil, the ACE
inhibitor trandolapril, as well as the fixed combination of both agents in patients with
non-diabetic proteinuria.
Methods
Patients and protocol
Patients were selected from the population who attended our outpatient renal
department. Entry criteria for this study were biopsy proven non-diabetic renal
disease, diastolic blood pressure below 110 mmHg, creatinine clearance more than
40 ml/min, proteinuria more than 2.0 g/day, and no need for concomitant medication.
Patients with diabetes mellitus, edema or renovascular hypertension were not
allowed to participate in the study. Antihypertensive, diuretic and
immunosuppressive drugs were withdrawn for at least 4 weeks before enrollment. A
50 mmol/day sodium restricted diet as well as stable protein intake was prescribed.
All patients gave their informed consent for participation in this protocol, which was
approved by the local Medical Ethical Committee.
The study was designed as a double-blind, random crossover, placebo-
controlled trial existing of 6 consecutive periods of 6 weeks duration (Figure 1).
Patients received verapamil SR 360 mg o.i.d., trandolapril 4 mg o.i.d., and vera/tranChapter 1
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(verapamil SR 180 mg and trandolapril 2 mg o.i.d.) in double dummy capsules.
Patients took their medication at each study day between 7.00-10.00 a.m. Patient
compliance was estimated by capsule count at the end of each period by which
patients should have taken at least 70% of placebo capsules and 90% of drug
capsules. At the end of each study period patients collected 24-hr urine during three
days. 24-Hour systolic and diastolic blood pressure, and pulse rate, were recorded
at 30 minute intervals with an automated device (Spacelab®) during the last 24 hour
urine collection. Renal function measurement was carried out at our outpatient renal
function laboratory. At 8.00 a.m. a bolus injection of renal function tracers 
125I-
iothalamate and 
131I-hippuran was followed by a constant infusion of these tracers in
an anticubital vein. After a 2-hr equilibration period, two clearance periods were
performed from 10:00 to 12:00 hr. and 12:00 to 14:00 hr. During the clearance
periods blood was drawn to bracket each urine collection. Throughout the study day
patients remained in sitting position, except when voiding. Patients were allowed to
take their usual breakfast at 8:30 hr and to drink at least 250 ml/hr beverages during
the study day to establish a sufficient diuresis. Before the intake of study medication
at 8.00 a.m., blood was drawn for determination of chemistry, ACE, PRA, and
angiotensin II.
Figure 1. Study design. Drug = treatment phase with in random order trandolapril 4 mg o.i.d.,
verapamil SR 360 mg o.i.d., and vera/tran (trandolapril 2 mg/verapamil SR 180 mg o.i.d.); BP = 24
hour blood pressure recording; Ur = 24 hour urine collections at three consecutive days; RF = 
125I-
iothalamate and 
131I-hippuran clearances.
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Clinical and laboratory procedures
Serum and urinary chemistry were determined with an automated multi-
analyzer (SMA-C-II®, Technicon Instruments Inc.,Tarry Town, NY, USA). Urinary
protein excretion was determined by the pyrogalloll red-molybdate method [14].
Proteinuria was calculated as the mean of three 24-hr urine collections. Mean
arterial pressure was calculated as the sum of one-third of the systolic blood
pressure and two-thirds of the diastolic blood pressure for each measurement during
24 hours. GFR and ERPF were estimated as the mean renal clearance of 
125I-
iothalamate and 
131I-hippuran during two clearance periods according to a previously
described method [15]. Filtration fraction was calculated as the ratio of GFR and
ERPF. Serum ACE was measured using a HPLC assisted assay [16]. PRA was
assessed by the quantification of generated angiotensin I as measured by
radioimmunoassay (intra-assay variation < 7.8%; inter-assay variation < 8.2%; lower
detection range of 0.15 ng/ml/hr). Blood for determination of angiotensin II was
collected in prechilled tubes which contained a mixture of EDTA, enalaprilat,
ofenantroline, ethanol and neomycin-B-sulfate to prevent in-vitro generation or
degradation of angiotensin II. Immediately after centrifugation at 4￿C, plasma was
stored at -20￿C until analysis. Angiotensin II was determined by radioimmunoassay
(intra-assay variation < 4.0%; inter-assay variation < 9.3%; lower detection range of
3.8 ng/l).
Table 1. Baseline characteristics.
Pat Sex Age Diagn SBP DBP Clcr Uprotein Salbumin Schol
yr mmHg mmHg ml/min g/day g/l mmol/l
1 m 49 FSGS 139 96 85 7.0 35 4.4
2 f 37 MGP 136 85 87 5.0 34 4.6
3 m 23 FSGS 137 77 52 7.5 41 6.8
4 m 44 FSGS 122 75 112 4.6 45 6.3
5 m 40 MGP 124 74 107 6.6 28 9.6
6 m 33 IgA 131 80 121 4.6 42 6.9
7 f 20 MPGN 116 61 120 9.6 27 7.7
8 f 48 MGP 132 86 80 6.1 37 6.4
9 m 60 FSGS 197 108 76 3.8 41 6.4
10 f 36 FSGS 161 109 91 13.2 34 8.3
11 m 54 FSGS 158 95 57 8.7 37 6.7
Abbreviations are: Pat = patient no.; Diagn = renal diagnosis; SBP = 24-hr systolic blood pressure;
DBP = 24-hr diastolic blood pressure; Clcr = creatinine clearance; Uprotein = proteinuria; Salbumin = serum
albumin; Schol = serum cholesterol; FSGS = focal segmental glomerulosclerosis; MGP = membranous
glomerulopathy; IgA = IgA nephropathy; MPGN = membranoproliferative glomerulonephritis.Chapter 1
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Analysis
A meta-analysis of Gansevoort et al. [1] on the antiproteinuric capacity of
antihypertensive drugs in comparative studies demonstrated that ACE inhibition
induced an antiproteinuric response of 40%, whereas non-dihydropyridines induced
an antiproteinuric response of 21%. Power analysis based on a 20% or greater
difference in the antiproteinuric response between verapamil and trandolapril
revealed that at least 9 patients were to be included in the present study to achieve
a b-error of 0.15 and an a-error of 0.05.
Data are expressed as a Wilcoxon-based estimated median with 95%
confidence interval [17], unless otherwise indicated. Parameters are expressed as
absolute value or as percentage change from the preceding placebo value. A
Friedmann two way non-parametric ANOVA for paired observations was performed,
followed by Duncan’s correction for multiple comparisons, to test for differences
between the placebo periods in consecutive order as well as for differences between
active treatment efficacy [18-19]. Wilcoxon’s rank sum test for paired observations
was performed to test for carry-over effects of each active treatment by comparison
of two placebo periods which preceded and followed active treatment. In addition,
differences between active treatment and preceding placebo were tested by
Wilcoxon’s rank sum test for paired observations. Correlation’s between parameters
were tested using Spearman’s rank sum test. Statistical significance was assumed at
a p-level less than 0.05.
Results
Thirteen patients were included in this study. Eleven patients completed the
protocol, whereas 2 patients dropped out: one patient needed diuretics because of
progressive edema during the first placebo phase and another patient underwent
surgery because of acute appendicitis during the first treatment phase with
verapamil. Both reasons for discontinuation were not related to the study medication.
Baseline characteristics of the patients at the end of the first placebo treatment are
presented in table 1. All patients but one were of Caucasian origin. Four of 11
patients (no. 1, 9, 10, and 11) demonstrated hypertension with a mean 24-hr blood
pressure higher than 140/90. Renal function was normal to moderately impaired as
reflected by a creatinine clearance ranging from 52 to 121 ml/min. Patients had
proteinuria ranging from 3.8 to 13.2 g/day without signs of edema. Two patients (no.
5 and 7) demonstrated a serum cholesterol of more than 7.0 mmol/l in combination
with a serum albumin below 30 g/l at the start of the study.
The primary parameters MAP, FF and proteinuria did not significantly change
during the placebo periods in consecutive order. This excludes presence of time
related changes due to changes in intrinsic renal disease. In addition, no significant
carry-over effects of any of the active treatments could be demonstrated. Patient
compliance met the criteria in all study periods, whereas no significant differences inVerapamil and trandolapril in non-diabetic renal disease
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patient compliance were observed between active treatment periods. Dietary
conditions monitored by 24-hr urinary sodium and urea excretion as well as
parameters of biochemistry were not significantly different during the entire study.
The effects of each treatment compared to its preceding placebo period are shown
in table 2.
Verapamil
Verapamil did not change 24-hr MAP compared to its preceding placebo
period. Pulse rate, GFR, ERPF, and FF did neither change significantly. Verapamil
slightly reduced proteinuria compared to its preceding placebo period from 6.3 (5.0-
7.0) to 5.9 (4.5-6.4) g/day (p<0.05). Hypertensive patients tended to have a greater
mean reduction of MAP (120 to 112 versus 95 to 96 mmHg; p=0.16) and proteinuria
(6.3 to 5.4 versus 5.8 to 5.5 g/day; p=0.16) than normotensive patients, whereas
change in FF did not differ between both groups (Figure 2). Neither ACE, PRA or
angiotensin II levels changed. Three patients showed peripheral edema during
treatment with verapamil, which spontaneously resolved in the following placebo
period.
Figure 2. Individual data on mean arterial pressure (MAP), filtration fraction (FF) and proteinuria
during placebo (Pla) and verapamil (CCB). Closed circles represent hypertensive patients and open
circles represent normotensive patients.
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Trandolapril
Twenty-four hour MAP was significantly reduced by trandolapril. The pulse
rate and GFR remained unchanged, whereas ERPF increased (p<0.05) and filtration
fraction decreased (p<0.05). Trandolapril reduced proteinuria compared to its
preceding placebo period from 6.2 (4.9-7.7) to 3.7 (2.6-4.6) g/day (p<0.05). The
responses of MAP, FF and proteinuria to trandolapril were comparable in
normotensive and hypertensive patients. The relative changes of MAP, filtration
fraction, and proteinuria during trandolapril were significantly greater than those
during verapamil (Figure 3). ACE activity significantly fell, whereas PRA significantly
increased and angiotensin II levels remained unchanged. Two patients experienced
cough during trandolapril which spontaneously resolved in the following placebo
period.
Vera/tran
Vera/tran significantly reduced 24-hour MAP. The pulse rate and GFR did not
change significantly, whereas ERPF increased (p<0.05) and FF decreased (p<0.05).
Vera/tran reduced proteinuria compared to its preceding placebo period from 6.3
(4.3-8.4) to 3.2 (2.6-5.4) g/day (p<0.05). The responses of MAP, FF and proteinuria
to vera/tran were comparable in normotensive and hypertensive patients. The
relative changes in MAP, ERPF, FF, and proteinuria during vera/tran were
comparable to those during trandolapril, whereas the relative changes in MAP, FF
and proteinuria during vera/tran were significantly greater than those during
verapamil (Figure 3). ACE activity was significantly reduced, whereas PRA was
significantly increased. Angiotensin II levels showed no significant change. One
patient experienced cough during vera/tran which spontaneously resolved in the
following placebo period.
Correlation’s
Baseline MAP was significantly related with relative changes in blood
pressure during verapamil (r=-0.70; p<0.02), whereas such a relation just did not
reach statistical significance during trandolapril (r=-0.60; p<0.10) or vera/tran (r=-
0.59; p<0.10). Baseline MAP only tended to be significantly related to the relative
changes of proteinuria during verapamil (r=-0.55; p<0.10). Relative changes in MAP
or FF were not related to relative changes in proteinuria during any of the
treatments. Daily sodium excretion was not significantly related to relative changes
in MAP, FF or proteinuria during any of the active treatments.
Discussion
In the present study we show that the antiproteinuric and antihypertensive
response of the non-dihydropyridine calcium channel antagonist verapamil is less
compared to the ACE inhibitor trandolapril in patients with non-diabetic proteinuria.Chapter 1
29
Figure 3. Changes of mean arterial pressure (MAP), filtration fraction (FF) and proteinuria during
trandolapril (ACEi), verapamil (CCB) and Vera/tran. Data are expressed as median and 95%
confidence interval. *
 p<0.05 versus verapamil.
Treatment with a fixed half dose of trandolapril and verapamil in combination showed
similar effects on blood pressure, renal hemodynamics, and proteinuria compared to
treatment with trandolapril alone at full dose.
Meta-analyses revealed that ACE inhibitors are superior to all other
antihypertensive drugs including calcium channel antagonists with respect to their
antiproteinuric response at similar blood pressure reducing levels [1-3]. It has
previously been observed that blood pressure reduction mediates the initial 20%
reduction of proteinuria by ACE inhibitors which is comparable to the complete
antiproteinuric effect of other antihypertensive agents [20]. The additional 30%
reduction of proteinuria by ACE inhibition seems to be mediated by a reduction of
intraglomerular pressure which is independent from systemic blood pressure
reduction and/or non-hemodynamical intrarenal effects of ACE inhibitors [21-22].
Non-dihydropyridine calcium channel antagonists such as verapamil and diltiazem
show an antiproteinuric capacity comparable to that of ACE inhibitors, but greater
than other antihypertensive drugs, in moderate to severe hypertensive non-insulin
dependent diabetic patients with overt nephropathy [10-13]. It has also been
observed that non-dihydropyridine calcium channel antagonists slowed progressive
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loss of renal function to a similar extent as ACE inhibitors, but to a greater extent
than b-blockers in NIDDM [23-24]. This suggest that ACE inhibitors and non-
dihydropyridine calcium channel antagonists induce beneficial renal effects beyond
their blood pressure lowering effect in diabetic renal disease. The present study
firstly elucidated the antiproteinuric capacity of verapamil in comparison to ACE
inhibitors in non-diabetic renal disease. Surprisingly, verapamil revealed a smaller
antiproteinuric response compared to the ACE inhibitor trandolapril.
Can we explain that verapamil and trandolapril did not reveal a comparable
antiproteinuric efficacy? The most important issue seems to be the difference in
blood pressure reduction between both treatments in the present study, whereas all
previous comparative studies showed equal reductions of blood pressure [10-13].
This difference in blood pressure reduction is the consequence of the absence of
blood pressure reduction during treatment with verapamil. Several factors such as
study design, study conditions, drug dosage, and patient characteristics may have
contributed to this the lack of blood pressure effect during verapamil. The cross-over
study design may have induced carry-over and time dependent effects on study
parameters. Although the exact time-dependence of the antiproteinuric effect of
verapamil is unknown, its antihypertensive effect is maximal after 4 weeks treatment
[25]. ACE inhibitors reach their maximal hemodynamic and antiproteinuric effect after
4 weeks treatment, whereas 4 weeks withdrawal of ACE inhibition induces a
complete reversal of its hemodynamic and antiproteinuric response [22]. We
therefore assumed 6 weeks to be an appropriate study period duration to achieve a
maximal efficacy for verapamil and trandolapril. Furthermore, each active treatment
is followed by 6 weeks placebo which allows an effective wash-out period of 12
weeks duration for each active treatment. Since blood pressure and other
parameters did not significantly change during three placebo periods in consecutive
order and carry-over effects could be excluded, it is unlikely that our study design
induced a difference in response of blood pressure or other parameters during
verapamil or trandolapril. Another factor which has to be taken into consideration is
the application of dietary salt restriction in the present study. The hemodynamic and
antiproteinuric responses of ACE inhibition are enhanced by dietary salt restriction
[26]. However, controversial data exist on the influence of dietary salt restriction on
the blood pressure response during calcium channel antagonism. On the one hand,
dietary salt restriction attenuated the blood pressure lowering response to verapamil
in patients with salt-sensitive essential hypertension [27]. On the other hand,
changes in dietary salt intake did not change the blood pressure lowering response
of verapamil in hypertensive patients with chronic renal failure [28-30]. Since we
could not observe a significant relation between the intake of sodium and the relative
change of blood pressure during verapamil, it is unlikely that dietary salt restriction
contributed to the lack of blood pressure lowering during verapamil. Drug dosage is
another factor which may have a role in the lack of blood pressure reduction during
verapamil. The used dosage of verapamil in the present study induces a maximal
reduction of blood pressure as well as a reduction of blood pressure comparable to
that of ACE inhibitors in hypertensive patients [9,11,23,25]. In contrast, verapamil atChapter 1
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a dose of 160 mg did not acutely reduce blood pressure in normotensive patients
[31]. Since no data are available which reveal that higher dosages of verapamil
induce a long-term reduction of blood pressure in normotensive patients, it is
unlikely that a higher dosage of verapamil would have induced a greater reduction of
blood pressure or renal hemodynamic vasodilatation in our population. Lastly,
patient characteristics may have contributed to the difference in blood pressure and
antiproteinuric response between verapamil and trandolapril. Our population showed
a large heterogeneity with respect to blood pressure and renal function. It has been
demonstrated that the antiproteinuric response of ACE inhibitors is partly dependent
from changes in blood pressure or GFR, but not from baseline patient characteristics
[1]. The antiproteinuric response of calcium channel blockers is greatly dependent
from change in blood pressure, initial GFR, and type of calcium channel antagonist
[1]. Furthermore, calcium channel blockers do not induce systemic or renal
hemodynamic changes in normotensive conditions [32-33]. The fact that the majority
of our patients are normotensive may thus explain the overall lack of blood pressure,
renal hemodynamic and antiproteinuric response during verapamil. Hypertensive
patients indeed tended to show greater reductions of blood pressure and proteinuria
during verapamil. Higher baseline blood pressure was also related with greater
reductions of blood pressure during verapamil. No significant relations could be
observed between relative changes of proteinuria and relative changes in blood
pressure or GFR, or baseline GFR during any of the treatments. Although our
analysis is affected by the small number of included patients, these observations
suggest that the antiproteinuric effect of the non-dihydropyridine calcium channel
antagonist verapamil is greatly dependent of blood pressure reduction in non-
diabetic renal disease, in contrast to the antiproteinuric response of ACE inhibitors.
In support of this, an unpublished study revealed that diltiazem induced a smaller
reduction of proteinuria compared to ACE inhibition in hypertensive patients with
non-diabetic renal disease, despite equivalent blood pressure reductions [34]. It has
also been demonstrated that treatment with antihypertensive drugs other than ACE
inhibitors, including calcium channel blockers, induces a smaller reduction of blood
pressure and proteinuria in non-diabetic than in diabetic patients [1]. It therefore may
be that differences between non-diabetic and diabetic renal disease also contributed
to the disappointing antiproteinuric efficacy of verapamil in the present study.
Combination treatment of verapamil and ACE inhibitors in half their usual
doses reduced proteinuria significantly more than treatment with one of each agent
at full dose in hypertensive diabetics with micro-albuminuria and overt nephropathy
[9,11,13]. In this respect it is again important to stress that blood pressure reduction
during combination and single treatments was comparable in those studies. In the
present study, half of the dose of trandolapril and verapamil resulted in a similar
response of blood pressure, renal hemodynamics and proteinuria as single
treatment with full dose of trandolapril. It has been previously shown that the
antiproteinuric effect of ACE inhibition is dose related [35]. Halving the dose of
trandolapril should therefore result in less reduction of proteinuria. Since this is notVerapamil and trandolapril in non-diabetic renal disease
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the case in our study, it could well be that the combination of verapamil and
trandolapril exerts additional antiproteinuric effects in non-diabetic patients.
Nevertheless, trandolapril already induces a maximal blood pressure lowering effect
at a dose of 2 mg [36]. In case the dose response profile of reduction in proteinuria
mimics that of blood pressure lowering, a maximal antiproteinuric response may
already be induced with half the dose of trandolapril. This would exclude an
additional antiproteinuric effect of combination treatment. It is clear that our study
does not allow a firm conclusion on the potential additional antiproteinuric effect of
treatment with trandolapril and verapamil in combination.
In conclusion, calcium channel blockade with verapamil is not as effective as
ACE inhibition with trandolapril in reducing proteinuria and blood pressure in
patients with non-diabetic renal disease. In contrast to the antiproteinuric response
of trandolapril, the antiproteinuric response of verapamil seems to be greatly
dependent from effective blood pressure reduction. The fixed combination of
verapamil and ACE inhibition at half doses has similar effects as ACE inhibition at
full dose, which suggests, but not prove, that the combination provide additional
antiproteinuric efficacy in non-diabetic renal disease.
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Introduction
Although the capacity of ACE inhibitors to lower blood pressure is comparable to
that of other antihypertensive drugs, long term treatment with ACE inhibition results in a
40-50% lowering of proteinuria, whereas other antihypertensive agents have a slight or
no effect on proteinuria [1-4]. Many studies have tried to clarify the mechanism involved
in this additional reduction of proteinuria by ACE inhibitors. At first, the renal efferent
vasodilatation characteristic of ACE-inhibition was held responsible [5-9]. Several
following observations however, question the role of renal hemodynamic changes in the
long-term antiproteinuric effect of ACE inhibition. First, the antiproteinuric effect has a
slow onset reaching a maximum approximately four weeks after start of treatment,
whereas the blood pressure and renal hemodynamic effect appear maximal already after
several hours of ACE-inhibition [10]. Second, the blood pressure and renal
hemodynamic changes after three months ACE-inhibition can be completely reversed by
acute exogenous angiotensin-II, whereas the antiproteinuric response is unaffected [11].
These data suggest that both blood pressure and renal hemodynamic factors play a
minor role in the antiproteinuric effect at least during long-term ACE-inhibition.
The acute lowering of proteinuria by ACE inhibitors, however, may well be
explained by their concomitant blood pressure or renal hemodynamic changes. Several
reports in non-diabetic [10,12] and diabetic renal disease [13,14] showed the 15-20%
reduction of proteinuria after a single dose of an ACE inhibitor to be related to changes
in blood pressure and/or renal hemodynamics. The magnitude of the acute
antiproteinuric response to ACE inhibition is well comparable to that of the long-term
reduction of proteinuria by other antihypertensive drugs. It may therefore be
hypothesized that blood pressure reduction, rather than renal hemodynamic changes,
mediates the acute small reduction of proteinuria by ACE inhibitors, whereas the long-
term more marked reduction is governed by non-hemodynamic factors. To date, no
study has been performed evaluating the causal role of blood pressure reduction and/or
that of renal hemodynamic effects in the acute antiproteinuric response of ACE
inhibition. Since it has been demonstrated in rat models that exogenous angiotensin II
infusion or increased levels of endogenous angiotensin II are able to increase urinary
protein loss in parallel with increases in blood pressure and renal efferent
vasoconstriction [15-19], it may be hypothesized that the acute, hemodynamically
mediated antiproteinuric response of ACE inhibition can well be reversed by angiotensin
II.
In the present study, we therefore compared the acute effects of the ACE inhibitor
enalapril on proteinuria, blood pressure, and renal hemodynamics to those of
nitroprusside.  To study the importance of the renin-angiotensin system (RAS) in the
acute response to ACE inhibition, we furthermore tested whether the acute
antiproteinuric effect of enalapril could be reversed by an infusion of exogenous
angiotensin II.Chapter 2
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Methods
Patients and protocol
Nine non-diabetic patients with chronic renal disease were enrolled in this study
(Table 1). Entry criteria were stable proteinuria exceeding 3.0 g/day, a stable creatinine
clearance of 50 ml/min or more, and a diastolic blood pressure of less than 110 mmHg.
Patients with diabetes mellitus, edema, or renovascular hypertension were excluded.
Before entry all antihypertensive drugs were withdrawn for at least four weeks, except for
one patient who needed diuretic treatment to avoid edema. The responses in this patient
were not different from the other patients. All patients adhered to a 100 mmol sodium
restricted diet. The study was approved by the local Medical Ethical Committee and all
subjects gave their informed consent to participate in this study.
Table 1. Patient characteristics at entry.
Patient Gender Age Diagnosis BP Clcr Uprotein
(years) (mmHg) (ml/min) (g/day)
1 m 30 FSGS 143/96 108 18.6
2 m 43 IgA 160/95  80  3.0
3 f 40 FSGS 116/74  71  5.6
4 m 62 FSGS 118/78 110  7.0
5 m 32 FSGS 145/91  47  5.5
6 m 32 IgA 122/77  93  4.0
7 m 44 MGP 132/81 165 12.1
8 m 59 MGP 139/87 104 7.8
9 m 39 MGP 119/70  82  3.4
Mean 42 133/83  96 7.4
SE 4 5/3  11 1.7
Abbreviations are: f, female; m, male; FSGS, focal segmental glomerulosclerosis; IgA, IgA
nephropathy; MGP, membranous glomerulopathy; BP = blood pressure; Clcr = creatinine clearance;
Uprotein = proteinuria.
Patients underwent four in-hospital renal function assessments once weekly
during four weeks. One 24-hour urine collection was performed the day before each
visit. During the study day patients remained in supine position, except when voiding. AThe acute antiproteinuric effect of ACE inhibition
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bolus injection of renal function tracers was administered at 8:00 hr followed by a
constant infusion of these tracers in the right antecubital vein. At 8:30 hr the patients
received their regular breakfast and 150 ml/hr of beverages were permitted, except for
coffee. After a two-hour equilibration period to 10:00 hr, in which a constant plasma level
of renal function tracers was obtained, two 1-hour baseline clearance measurements
were performed from 10:00 to 12:00 hr. At day A patients received an intravenous bolus
of placebo (dextrose 5%) at 12:00 hr, followed by a continuous placebo infusion from
12:00 to 17:00 hr. At day B enalaprilat (10 mg i.v.) was given at 12:00 hr, followed by a
continuous placebo infusion from 12:00 to 17:00 hr. At day C a continuous intravenous
infusion of nitroprusside was administered from 12:00 to 17:00 hr, titrated between 12:00
and 12:30 hr to obtain a hypotensive effect comparable to that of enalaprilat in each
patient. At day D patients again received enalaprilat (10 mg i.v.) at 12:00 hr, followed by
a continuous placebo infusion from 12:00 to 17:00 hr, and a concomitant continuous
exogenous angiotensin II infusion from 14:30 to 17:00 hr. The dose of exogenous
angiotensin II was titrated between 14:30 and 15:00 hr to increase blood pressure to
placebo level in each patient. Study days A and B as well as C and D were performed in
a random cross-over and single-blinded order. A 30-minutes placebo titration was
performed when appropriate between 12:00 and 12:30, as well as between 14:30 and
15:00 hr, to assure a uniform study day design (figure 1). The total amount of infused
fluids was 150 ml/hr. Blood pressure was measured every five minutes during the
clearance periods and every 2 minutes during the two 30 minutes titration intervals.
Blood and urine samples were obtained for determination of renal hemodynamic
parameters and proteinuria during each clearance period. At 12:00, 14:30, and 17:00 hr
blood was drawn for determination of plasma renin activity (PRA), ACE, and angiotensin
II. After completion of the study protocol, all but one patient were admitted to prolonged
treatment with the ACE inhibitor enalapril 10 mg o.i.d. Blood pressure, creatinine
clearance and proteinuria were measured after 1, 7 and 28 days of treatment.
Clinical and laboratory procedures
Serum and urine electrolytes, urea and creatinine were determined with an
automated multi-analyzer (SMA-C, Technicon®), while urinary protein concentration was
determined with the pyrogallol red-molybdate method [20]. The intra-assay coefficient of
variation of this method is less than 3.3%, while the inter-assay coefficient of variation is
less than 3.0%. Blood pressure was recorded with an automated device (Dinamap®).
Mean arterial pressure was calculated as the sum of one-third of the systolic and two-
thirds of the diastolic blood pressure. The mean blood pressure during each 1-hour
clearance period was used for data analysis. GFR and ERPF were measured by a
constant infusion of 
125I-iothalamate and 
131I-hippuran, respectively [21]. The intra-patient
day-to-day coefficient of variation of this method is 2.2% for GFR and 5.0% for ERPF.
Filtration fraction was calculated as the ratio of GFR and ERPF. Renal vascular
resistance (RVR) was defined as MAP divided by ERPF. Serum ACE was measured
using an HPLC-assisted assay [22]. PRA was assessed by the quantification of
generated angiotensin I as measured by radioimmunoassay (Rianen® angiotensin I RIA
kit). Blood for the determination of angiotensin II was collected in prechilled glass tubesChapter 2
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containing 1,10-phenantroline, EDTA, enalaprilat and neomycin in order to prevent in
vitro generation of angiotensin II. Blood was immediately centrifuged at 4°C and plasma
samples were stored at -20°C until analysis. Angiotensin II was determined using the
Nichols Institute Diagnostics Angiotensin II radioimmunoassay with a inter-assay
variation of 5.1% and a intra-assay variation of 4%. The lower detection range is 3.6
pg/ml.
Figure 1. Study protocol. Eq = equilibration period.
Data analysis
Data are expressed as mean ± standard error (SE), unless otherwise indicated.
The effects of placebo, enalaprilat, nitroprusside, and angiotensin II during enalaprilat
were tested as the percentage change from the mean of the two one-hour baseline
values. To exclude the influence of circadian variation of the various parameters, the
response to enalaprilat, nitroprusside, and angiotensin II during enalaprilat were also
tested against the time corresponding placebo response. Statistical analysis was
performed using a paired, non-parametric ANOVA (Friedmann) for repeated
measurements or a paired Wilxocon's signed rank test. Correlation’s were calculated by
Spearman's linear regression analysis. Statistical significance was assumed at a 5%
level.
Renal function tracers and dextrose 5%
8:00 10:00 12:00 14:00 16:00
Eq 1 2
Bolus and infusion I
Infusion II
3 4 5 6 Eq EqThe acute antiproteinuric effect of ACE inhibition
40
Results
Patient characteristics at entry are given in table 1. None of the patients had signs
of peripheral edema. None of the study parameters did show significant differences
during the baseline clearance periods on each of the study days as shown in table 2.
Proteinuria, daily urinary excretion of sodium and urea, and body weight remained stable
during the entire study period. Figure 2 shows the percentage change from baseline for
each of the study parameters after infusion of placebo, enalaprilat, nitroprusside as well
as angiotensin II during enalaprilat. The influence of the interventions on parameters of
the renin-angiotensin system are given in table 3.
Table 2. Baseline characteristics at each of the study days. The upper part contains
parameters measured in the 24-hour urine collection. The bottom part contains
parameters of the study day.
PLA ENA NIP ENA+AII
UNaE (mmol/day) 103±15 104±16 106±18 112±20
UureaE (mmol/day) 301±36 303±58 322±33 325±46
Uprotein (g/day) 7.8±1.4 7.0±1.2 7.6±1.1 7.2±1.6
Body weight (kg) 79.6±3.3 79.3±3.1 79.4±3.3 79.4±3.3
MAP (mmHg) 103±2 103±3 102±2 102±3
GFR (ml/min) 91.9±7.0 92.3±6.5 91.9±7.3 95.8±7.9
ERPF (ml/min) 477±50 477±45 490±51 486±47
FF (%) 20.7±1.2 20.5±1.1 20.1±1.1 20.8±1.2
RVR (10
-2 mmHg/ml/min) 27.3±3.7 26.7±3.8 26.7±3.9 26.2±3.6
Uprotein (g/hr) 0.25±0.03 0.30±0.04 0.26±0.03 0.28±0.04
Abbreviations are: PLA, placebo; ENA, enalaprilat; NIP, nitroprusside; AII, angiotensin-II; UNaE,
urinary sodium excretion; UureaE, urinary urea excretion; Uprotein = proteinuria; MAP, mean arterial
pressure; GFR, glomerular filtration rate; ERPF, effective renal plasma flow; FF, filtration fraction;
RVR, renal vascular resistance.
Placebo
During placebo infusion no significant changes in ACE, PRA, and angiotensin II
were observed. MAP increased from 103±2 to 109±4 mmHg (p<0.01). Although GFR
and ERPF did not change, filtration fraction increased from 20.7±1.2% to 21.9±1.8%
(p<0.01), and RVR increased from 27.3±3.7 to 30.2±5.5 10
-2 mmHg/ml/min (p<0.01).Chapter 2
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Urinary protein excretion fell from 0.25±0.03 to 0.23±0.05 g/hr (p<0.05). Fractional
sodium excretion did not change significantly.
Enalaprilat
Infusion of 10 mg enalaprilat induced a complete inhibition of ACE (p<0.05), an
increase in PRA (p<0.05), and a decrease in angiotensin II (p<0.05). MAP lowered from
103±3 to 95±3 mmHg (p<0.01). ERPF increased from 477±45 to 532±73 ml/min
(p<0.05). Since GFR non-significantly fell from 92.3±6.5 ml/min to 89.9±9.7 ml/min, FF
decreased from 20.5±1.1% to 18.2±1.7% (p<0.05). RVR decreased from 26.7±3.8 to
21.7±4.4 10-2 mmHg/ml/min (p<0.01). Proteinuria fell from 0.30±0.04 to 0.24±0.05 g/hr
(p<0.01). Fractional sodium excretion did not change significantly from baseline. When
compared to placebo, enalaprilat induced a decrease in MAP (p=0.004), FF (p=0.004),
RVR (p=0.004), proteinuria (p=0.05), and an increase in ERPF (p=0.004), and fractional
sodium excretion (p=0.01). In patient no. 4 and 6 enalaprilat did not decrease proteinuria
compared to placebo.
Nitroprusside
Infusion of nitroprusside (0.46±0.14 µg/kg/min) had no effect on ACE, PRA, or
angiotensin II levels. It resulted in a lowering of MAP from 102±2 to 91±2 mmHg
(p<0.001). Although GFR and ERPF did not significantly change, filtration fraction
increased from 20.1±1.1% to 21.2±1.6% (p<0.05). RVR decreased from 26.7±5.8 to
24.2±4.5 10
-2 mmHg/ml/min (p<0.05). Proteinuria also decreased during nitroprusside
from 0.26±0.03 to 0.20±0.04 g/hr (p<0.05). In comparison to placebo, nitroprusside
induced a decrease in MAP (p=0.004), RVR (p=0.004), proteinuria (p=0.02), and
fractional sodium excretion (p=0.03). In comparison to enalaprilat, nitroprusside induced
a slightly greater decrease in MAP (p<0.05), and a smaller decrease in RVR (p<0.05).
Those 2 patients who showed no antiproteinuric response to acute ACE inhibition also
had the lowest antiproteinuric response to nitroprusside.
Angiotensin II during enalaprilat
The repeated enalaprilat infusion induced similar responses of all parameters as
the previous enalaprilat infusion (figure 2). The 2 patients who had no antiproteinuric
response to the first enalaprilat infusion did again fail to respond during the second.
Concomitant infusion of angiotensin II (2.4±1.0 ng/kg/min) during the last two clearance
periods completely abolished the enalaprilat-induced increase in PRA and decrease in
angiotensin II (p<0.05). MAP increased from 94±3 mmHg during enalaprilat to 110±4
mmHg during the concomitant angiotensin II infusion (p<0.01).  GFR increased from
73.1±17.5 to 80.9±18.0 ml/min (p<0.05), ERPF decreased from 559±78 to 412±55
ml/min (p<0.01), and as a consequence FF increased from 18.1±1.8% to 24.4±2.3%
(p<0.01). RVR increased from 20.9±4.1 to 31.5±5.1 10-2 mmHg/ml/min (p<0.01) and
fractional sodium excretion fell from 6.66±0.99 to 3.44±0.88 mmol/hr (p<0.01).
Angiotensin II increased proteinuria from 0.23±0.05 to 0.26±0.05 g/hr.The acute antiproteinuric effect of ACE inhibition
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Figure 2. The acute effects of placebo (closed circles), enalaprilat (open circles), nitroprusside (closed
squares), and angiotensin II during enalaprilat (closed triangles) on mean arterial pressure (MAP),
glomerular filtration rate (GFR), effective renal plasma flow (ERPF), filtration fraction (FF), renal vascular
resistance (RVR), and proteinuria (Uprot). Parameters are expressed as percentage change from the mean
of two one-hour baseline values. Data are given as mean±SE.
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In comparison to placebo, angiotensin II decreased ERPF (p=0.008) and
fractional sodium clearance (p=0.008), and increased FF (p=0.02) and RVR (p=0.008).
In comparison to enalaprilat without a concomitant angiotensin II infusion, angiotensin II
increased MAP (p=0.004), FF (p=0.004) and RVR (p=0.004), and decreased ERPF
(p=0.004) and fractional sodium excretion (p=0.004). Proteinuria during angiotensin II
was not significantly different from the corresponding placebo periods suggesting a
complete reversal of the acute antiproteinuric response of ACE inhibition. However, the
increase in proteinuria during angiotensin II compared to the preceding enalaprilat
periods did not prove to be significantly different due to a great variability in the
angiotensin II response. This analysis on the proteinuria response to angiotensin II may
be confounded by the fact that two patients repeatedly showed no antiproteinuric
response to enalaprilat. Repeated analysis excluding these 2 non-responders, however,
still showed similar results. The 2 non-responders showed similar blood pressure and
renal hemodynamic responses compared to the other patients during concomitant
angiotensin II infusion whereas proteinuria remained unchanged.
Table 3. Parameters of the renin-angiotensin system at each of the study days.
Time (hr) PLA ENA NIP ENA+AII
ACE (U/l) 12:00 24.2±4.0 24.3±3.0 27.0±3.3 22.0±3.2
14:30 20.1±3.0  1.7±0.2* 25.0±2.8  1.7±0.2*
17:00 21.3±2.9  2.4±0.2* 25.9±3.4  3.1±0.6*
PRA (Ang I/l/hr) 12:00 1.6±0.2 1.9±0.3 1.9±0.5 1.9±0.4
14:30 1.6±0.4  7.9±5.9*  2.4±0.4  6.7±4.6*
17:00 1.5±0.4  5.8±3.9*  2.1±0.3  1.7±0.4
#
Ang II (pg/ml) 12:00 19±3 20±2 21±3 19±4
14:30 17±5  9±2 22±4 11±3
17:00 22±4 10±2* 23±6 33±9
b
Abbreviations are: PLA, placebo; ENA, enalaprilat; NIP, nitroprusside; Ang II, angiotensin II; ACE,
ACE activity; PRA, plasma renin activity. *p<0.05 compared to time corresponding PLA,
 #p<0.05
compared to time corresponding ENA.The acute antiproteinuric effect of ACE inhibition
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Correlation’s
 The change in proteinuria during ACE inhibition and nitroprusside was related
with the accompanying change in MAP in the last clearance period (n=18, r=0.54,
p<0.05). No relation could be observed with the changes in renal hemodynamics. The
change in proteinuria during angiotensin-II infusion was not related to changes in blood
pressure or renal hemodynamics.
Prolonged ACE inhibition
During prolonged treatment with 10 mg enalapril o.i.d. in 8 patients proteinuria
fell gradually by -18.9±8.7% after 1 day treatment, -32.2±8.2% after 7 days treatment,
and -43.3±9.1% after 28 days treatment. The decrease in MAP was -6.7±3.3% after 1
day and -10.4±1.9% after 7 days, and remained stable by -10.8±2.4% after 28 days of
treatment. Creatinine clearance did not change during continued ACE inhibition.
Discussion
In the present study enalaprilat as well as nitroprusside acutely reduced blood
pressure and proteinuria to a similar extent, whereas only enalaprilat induced a renal
efferent vasodilatation. These data suggest that the acute lowering of proteinuria during
single dose ACE inhibition is mediated by reduction in blood pressure, rather then by its
specific renal hemodynamic effects. Exogenous angiotensin II infusion completely
reversed the blood pressure and renal hemodynamic effect of acute ACE inhibition,
whereas the acute antiproteinuric response of ACE inhibition was non-significantly
reversed.
The acute effects of ACE inhibition compare well to those of previous reports in
non-diabetic and diabetic patients with proteinuria. A recent study from our department
showed that infusion of 10 mg enalapril induced a placebo-corrected decrease in blood
pressure of 11%, an increase in ERPF of 30%, a decrease in FF of 30%, and a fall in
proteinuria of 15% in non-diabetic patients with proteinuria [10]. Other studies did show
a reduction of proteinuria of approximately 20 to 25% during single dose ACE inhibition
[12-14]. These studies were not placebo-controlled, but the numbers are in accordance
with our non-placebo corrected data. The observed changes in MAP, FF, and proteinuria
during placebo infusion, which may be explained by the sustained supine position or
diurnal rhythm [23], emphasizes the importance of a placebo-controlled study design. To
date no reports on the effects of nitroprusside in nephrotic patients have been
presented. The potent and generalized vasodilatation of nitroprusside resulted in a
lowering of blood pressure without specific renal hemodynamic effects. By comparing
the effects of the two antihypertensive drugs, one with and one without renal
hemodynamic effects, we are the first to differentiate whether systemic or renal
hemodynamics mediate the acute lowering of proteinuria by ACE inhibitors. The
combined nitroprusside and ACE inhibition data clearly show that the acute fall in
proteinuria is associated with a fall in blood pressure, and not with changes in renal
hemodynamics. This acute lowering of proteinuria may thus be explained by theChapter 2
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transmission of a lower systemic blood pressure into the glomerulus. In that case
however, one might also expect noticeable changes in GFR. Since we could only
demonstrate slight, non-significant, changes in GFR during infusion of enalaprilat and
nitroprusside, the techniques used to measure renal hemodynamics in humans may not
be sensitive enough to detect subtle GFR changes. The mechanism of the acute fall in
proteinuria thus remains as yet unexplained apart from the fact that it is associated with
a fall in blood pressure.
The renal and systemic responses to exogenous angiotension II in the present
study are opposite to the effects of acute ACE inhibition and as such in accordance with
those found in several animal [15-19] and human studies [11,24,25]. Reversing the
blood pressure lowering effect of ACE inhibition through angiotensin II should have
induced a return of proteinuria to pretreatment values. Although this did indeed happen
in some patients, the acute antiproteinuric response to ACE inhibition could not
statistically significant be reversed by angiotensin II. It may well be that systemic delivery
of angiotensin II to the kidney, besides renal efferent vasoconstriction, also constricts the
preglomerular vessel considerably, thus preventing the rise in blood pressure to fully
affect the intraglomerular pressure [26]. Both Heeg et al [11] and Loon et al [23] indeed
found a reduced GFR together with an increased FF during angiotensin II infusion
reflecting renal afferent and efferent vasoconstriction. In contrast, we found an increase
in GFR and FF during angiotensin II infusion reflecting predominantly renal efferent
vasoconstriction. This may explain why the acute antiproteinuric response of ACE
inhibition was influenced by angiotensin II in some of our patients. In retrospect,
exogenous infusion of angiotensin II may not have been the ideal tool to test the blood
pressure dependence of the acute antiproteinuric effect, since it may also have induced
renal hemodynamic changes different from those of intrarenal angiotensin II
perturbations [27].
The prevailing hypothesis to explain the antiproteinuric effect of chronic ACE
inhibition suggests a relation between reduction in proteinuria and the ACE inhibition
induced changes in renal hemodynamics [9]. The predominantly postglomerular
vasodilatation by ACE inhibitors which results in a decrease of intraglomerular pressure
has been suggested to be responsible for lowering of proteinuria [5,6]. We conclude that
the short term antiproteinuric effect of ACE inhibition in humans appears to be mediated
by blood pressure reduction and does not require the specific renal hemodynamic
effects of ACE inhibition. This acute reduction of proteinuria is relatively small (20%),
whereas a gradual increase of the antiproteinuric response to approximately 50% occurs
during prolonged ACE inhibition in our patients. As was demonstrated previously, this
gradual increase is not associated with any further change in blood pressure or renal
hemodynamics [10]. Together with the results of the angiotensin II infusion during long-
term ACE inhibition [11] this leads us to hypothesize that the long term effects are
mediated by tissue angiotensin II or by slowly appearing structural effects on the
glomerular filtration barrier. This is supported by several studies which show that long
term ACE inhibition has beneficial effects on glomerular permselectivity [28-32].
Although the specific renal hemodynamic changes of ACE inhibition initially play no roleThe acute antiproteinuric effect of ACE inhibition
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in the antiproteinuric response, it may well be that they are still important because such
hemodynamic changes may form the basis and may gradually induce the structural
changes of the glomerular filtration barrier. This may also explain why other
antihypertensive drugs without a specific renal hemodynamic profile like ACE inhibitors
do not lower proteinuria beyond their initial small effect. Indeed, several studies suggest
a relation between renal hemodynamic conditions and structural alterations. It has been
shown that angiotensin II induced intrarenal vasoconstriction is associated with early
growth response genes [33] and increased hyperproliferative responses to mechanical
strain [34]. Further studies should clarify whether the antiproteinuric mechanism of ACE
inhibition requires a renal hemodynamic mediated phase which gradually induces renal
structural changes that prevent the abundant passage of proteins.
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Introduction
Proteinuria has become an important determinant of progressive renal
disease. Excessive filtration of proteins induces toxic effects to glomerular,
mesangial, and tubular cells which results in glomerulosclerosis and tubulointerstitial
fibrosis [1-3]. Clinical studies observed a relation between the degree of proteinuria
and progressive loss of glomerular filtration rate in chronic renal disease [4-5]. Since
reduction of proteinuria retards progressive loss of renal function in renal disease, it
has become a therapeutically target [6]. A meta-analysis on comparative trials
revealed that ACE inhibitors are superior to other antihypertensive agents with
respect to their antiproteinuric capacity [7], whereas this greater antiproteinuric
capacity of ACE inhibitors is recently associated with a better preservation of renal
function in non-diabetic renal disease [8-9].
The mechanism of the antiproteinuric effect of ACE inhibition is not completely
elucidated. Proteinuria is the consequence of a defect in the permeability of the
glomerular capillary wall either glomerular size or charge selectivity being
compromised [10]. Previous experimental and clinical studies showed improvement
of glomerular size selectivity during the maximal antiproteinuric effect of ACE
inhibition in non-diabetic renal disease [11-14]. It could be theoretically calculated
that ACE inhibition improved glomerular size selectivity by intrinsic changes of the
glomerular filtration barrier which are independent of hemodynamic alterations
induced by ACE inhibition. This latter observation can be of importance for the
mechanism of the typical time course of the antiproteinuric response during ACE
inhibition. Acute administration of ACE inhibition reduces proteinuria by 10 to 20%,
whereas continued treatment gradually reduced proteinuria further to 50 till 60%
after approximately 4 weeks [15]. It has been suggested that the acute
antiproteinuric response of ACE inhibition is mediated by blood pressure reduction
[16]. A gradual restoration of glomerular permselectivity may mediate the additional
increase of the antiproteinuric response during prolonged ACE inhibition, since it
cannot be explained by changes in blood pressure or filtration fraction [15,17].
The antiproteinuric effect of ACE inhibition can be the result of restored
glomerular charge selectivity, since we demonstrated that ACE inhibition increased
the heparan sulfate content of the glomerular basement membrane in established
adriamycin nephrosis [18]. However, no in vivo data on glomerular charge selectivity
during the antiproteinuric response of ACE inhibition are available. The present
study is set up to clarify whether effective reduction of proteinuria by ACE inhibition
in adriamycin nephrotic rats is mediated by restoration of glomerular charge
selectivity to albumin. In addition, it will be investigated whether this restoration of
glomerular charge selectivity to albumin is a time-dependent phenomenon which
explains the time course of the antiproteinuric response of ACE inhibition.
MethodsChapter 3
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Experimental design
The study was performed in male Wistar rats of 250-300 g (Harlan, Zeist, The
Netherlands). Adriamycin nephrosis was induced in 10 rats by intravenous injection
of 2 mg/kg bodyweight adriamycin (Doxorubicin￿, Pharmachemie BV, Haarlem, The
Netherlands) at week 0. Since nephrotic-range proteinuria established after
approximately 6 weeks [19], rats receive 5 mg/kg/day lisinopril in tap water from
week 6 to 9. Subsequently, lisinopril was withdrawn from week 9 to 12. During the
study all rats were housed in a temperature controlled room with a 12 hour light/dark
cycle and were fed with a low sodium diet consisting of commercially available rat
chow which contains 0.05% sodium chloride and 20% protein (Hope Farms Inc.,
Woerden, The Netherlands). They received fresh tap water daily ad libitum. During
the study 24-hour urine protein excretion and systolic blood pressure were measured
once weekly.
A time-controlled study was performed in 10 healthy rats which received a
vehicle of 0.9% sodium chloride intravenously at week 0 as well as in 10 adriamycin
nephrotic rats which were not treated with lisinopril.
Renal clearance studies
Renal clearance studies were performed in unrestrained and conscious rats in
individual metabolic cages. We aimed to perform serial renal clearance studies in at
least 6 rats of each group. All rats were instrumented one week before the first
clearance study which allows one week recovery from surgery. After induction of
anesthesia with 4% isoflurane and N2O:O2 (1:2), the right jugular vein is catheterized
with a silicone tube and a silicone catheter was implanted in the peritoneal cavity
through the abdominal wall. The proximal ends of both catheters were tunneled
subcutaneously and exteriorized on the head. The catheters were fixed on the skull
by a modified method previously described by Steffens [20]. The catheters were
filled with a 60% polyvinylpyrrolidone solution in saline with 500 IE/ml heparin closed
with a piece of heat-sealed polyethylene tubing. Because of a high occlusion rate of
jugular or intraperitoneal catheters in nephrotic rats, remaining rats of each group
replaced rats with catheter occlusion during the further renal clearance studies.
Adriamycin rats treated with lisinopril underwent renal clearance studies at baseline
(week 6; n=6), and after 3 days (week 6½; n=6), 1 week (week 7; n=6), and 3 weeks
of treatment with lisinopril (week 9; n=7), as well as after 3 days (week 9½; n=6), 1
week (week 10; n=6), and 3 weeks of withdrawal of lisinopril (week 12; n=5). Healthy
control rats and untreated adriamycin rats underwent renal clearance studies at
baseline (week 6) and at the end of the study (week 12).
Each renal clearance study started with a continuous infusion of 2 ml/hr
dextrose 5% via the jugular vein from 7.00 a.m. to induce diuresis. At 9.00 a.m. each
rat received a 0.3 ml bolus of 0.18 MBq 
131I-native anionic rat serum albumin (RSA)
and 0.18 MBq 
125I- charge modified neutral  rat serum albumin (nRSA) via the jugular
vein, whereas a 0.3 ml bolus of 0.22 MBq 
99Tc-DTPA was given via theACE inhibition restores glomerular charge selectivity
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intraperitoneal catheter followed by a 1 ml/hr continuous infusion of 0.8 MBq/hr 
99Tc-
DTPA in dextrose 5% to estimate GFR. After an equilibration period of at least 2
hours, three clearance measurements were performed based upon spontaneous
urine voiding. Blood samples (0.25 ml) were drawn via the jugular catheter to bracket
each urine voiding.
Experimental and laboratory procedures
Twenty-four hour urine was collected in metabolic cages with free access to
food and water. Urinary protein was determined by the biureet method [21]. Systolic
blood pressure was measured in conscious rats by the tail-cuff method with an
automated multichannel system (Apollo 179; IITC Life Science, Woodland Hills, Ca,
USA) [22]. All animals were trained during two weeks before start of the study to
become accustomed to the blood pressure measurements. Systolic blood pressure
was taken as the mean of the last three of five measurements for each rat. Rats
which participated in a renal clearance study did not undergo measurement of
systolic blood pressure in a restrainer to prevent damage to the catheters fixed at
their skull.
The preparation of charge-modified neutral rat serum albumin (nRSA) was
carried out according to the method of Hoare and Koshland [23]. Carboxyl groups of
native anionic rat serum albumin (RSA; molecular weight 68 kD; pI 4.8-5.1) are
activated by water soluble 1-ethyl-3-(3-dimethyl-amino-propyl)-carbodiimide
hydrochloride (EDC; Pierce, Rockford, Illinois, USA). The activated carboxyl groups
react with the nucleophile ethylendiamine (EDA; Fisher Scientific Company, Far
Lawn, New Jersey, USA). We prepared one batch of nRSA for the entire study. Fifty
mg rat RSA (Sigma Chemical Co., St. Louis, MO, USA) was added to 1.67 ml EDA
(0.9 g/l) and 11 ml distilled water. The solution was cooled at 25￿C and titrated to a
pH of 4.75 with 10 N hydrochloric acid. EDC (10 mg/ml) was slowly added during 15-
30 minutes under stable conditions with respect to pH and temperature. The reaction
continued for 120 minutes and then was ended by addition of 0.37 ml 4 M acetate
buffer with pH 4.75. The solution was dialyzed at 4￿C against distilled water during
two days and finally lyophilized and stored at -80￿C. The recovery of nRSA was 40.6
mg (80%).
RSA and nRSA were characterized with respect to their isoelectric point (pI)
by isoelectrofocussing at commercially prepared PhastGel IEF media with a pI range
from 3 to 9 (Pharmacia, Uppsala, Sweden) according to the manufacturer’s
instructions. This charge modification procedure increased the pI of RSA from 5.0
(range: 4.6-5.1) to approximately 7.0 (range: 6.0-8.5) as shown in figure 1. The day
before each clearance study 10 ml RSA and nRSA (100 mg/ml) were radiolabelled
with 
131I and 
125I, respectively, by the chloramine-T method followed by a size-
exclusion procedure at a Sephadex G25 column to separate radiolabelled albumin
from free radioactive iodine [24]. Fractions containing radiolabelled RSA and nRSA
were pooled and stored at 4￿C. Autoradiography of PhastGel IEF gels did not reveal
any change of molecular charge due to the radiolabelling of RSA or nRSA (Figure
1).Chapter 3
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Figure 1. Molecular charge of rat serum albumin (RSA) and neutralized rat serum albumin (nRSA).
The left figure shows RSA (c and f) and nRSA (b, e and h) before radiolabelling with iodine, whereas
the right figure shows RSA (a and c) and nRSA (b and d) after radiolabelling with iodine.
Molecular size of RSA and nRSA was estimated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (Boehringer Ingelheim Bioproducts, Heidelberg,
Germany) [25]. Figure 2 shows that charge modification of RSA did not alter its
molecular size.
DTPA was radiolabelled with 
99Tc just before the start of each clearance
study. Blood samples obtained during the clearance study were collected in
heparinized tubes and immediately centrifuged during 1 minute (16000 rpm).
Distilled water was added to 100 µl plasma aliquots to a final volume of 580 µl and
stored at 4￿C. Urine samples obtained during the clearance study were collected in
preweighed tubes and volumes were measured gravimetrically. Of each urine
sample 100 µl was twice precipitated with 200 µl trichloroacetic acid (30%) after
addition of 100 µl unlabelled RSA (2%) and distilled water to ensure a final volume
of 580 µl. The final urine precipitate was solved in 200 µl 10 N NaOH and 380 µl
distilled water. Addition of unlabelled RSA provides an optimal recovery of labeled
RSA (>97%) after precipitation in urine samples with low protein concentration
obtained during forced diuresis. The final sample volume has to be greater than 500
ml for optimal determination of radioactivity during 4 minutes in a two-channel
scintillation counter (LKBG Compugamma Scintillation Counter, Wallace, Finland).
Immediately after ending the clearance study, radioactivity of 
99Tc-DTPA and 
131I-ACE inhibition restores glomerular charge selectivity
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RSA was determined in plasma and urine samples. Two days after counting,
radioactivity of 
131I-RSA and 
125I-nRSA was determined in plasma and urine samples,
since 
99Tc-DTPA is completely decayed at this time. The glomerular filtration rate
(GFR) is expressed as the renal DTPA clearance by the formula:
(U[DTPA] * V) / P[DTPA]
where U is counts/min per ml urine precipitate, V is the urine volume in ml/min, and
P is counts/min per ml plasma. Fractional clearances of RSA and nRSA were
calculated according to the formula:
U[albumin] * P[DTPA] / U[DTPA] * P[albumin]
Glomerular charge selectivity is represented by the renal clearance index of nRSA
relative to RSA.
Figure 2. Molecular size of rat serum albumin (RSA; a) and neutralized rat serum albumin (nRSA;  b).
Data analysis
Data are expressed as mean and standard deviation (SD), unless otherwise
indicated. Differences in proteinuria, systolic blood pressure, GFR, nRSA and RSA
clearances as well as their index during treatment and withdrawal of lisinopril wereChapter 3
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tested with the Kruskal-Wallis nonparametric ANOVA test followed by Duncan’s
correction for multiple comparisons. Differences between RSA and nRSA clearances
at a given time-point were tested with the Wilcoxon rank sum test for paired
observations. Differences between adriamycin rats treated with lisinopril and
untreated adriamycin rats or control rats at week 6 and 12 were tested by the Mann-
Whitney test for unpaired observations. Statistical significance was assumed at a p-
level less than 0.05.
Results
Time-control studies revealed no differences in systolic blood pressure or
GFR at baseline or at the end of the study between healthy rats, adriamycin rats to
be untreated, and adriamycin rats to be treated with lisinopril (Table 1). Both groups
of adriamycin rats demonstrated significantly higher proteinuria as well as fractional
nRSA and RSA clearances in comparison to healthy rats. The adriamycin rats to be
treated with lisinopril showed a stable proteinuria six weeks after adriamycin
injection (Figure 3). The increase of fractional RSA clearance is 3 to 6 times higher
than the increase of nRSA clearances in adriamycin rats. Comparison of these
parameters in both groups of adriamycin rats revealed no differences, except for a
higher fractional nRSA clearance at baseline in adriamycin rats to be treated with
lisinopril. Both group of adriamycin rats have an impaired glomerular charge
selectivity as reflected by a reduced nRSA to RSA clearance index in comparison to
healthy rats (0.4 and 0.7 versus  2.4, respectively).
ACE inhibition
Lisinopril reduced systolic blood pressure (123–10 to 83–10 mmHg; p<0.05),
whereas GFR did not significantly change (1.6–0.4 to 0.9–0.5 ml/min). Blood
pressure was maximally reduced after 1 week treatment and did not fall further. As
depicted in figure 3, proteinuria gradually fell from 276–129 to 83–106 mg/24hr
(p<0.05). Both the fractional RSA and nRSA clearances significantly fell in such a
way that they did not differ significantly from each other anymore. Since the
decrease of fractional RSA clearance was 2.4 times greater than that of nRSA, the
nRSA to RSA clearance index rose from 0.7±0.7 to 1.7±1.5 (p<0.01). Fractional
nRSA and RSA clearances as well as the nRSA to RSA clearance index in
adriamycin rats after 3 weeks lisinopril were comparable to those in healthy rats. The
change in proteinuria was significantly related with the concomitant change in the
nRSA to RSA clearance index during lisinopril (Figure 4).ACE inhibition restores glomerular charge selectivity
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Figure 3. Time course of primary study parameters in adriamycin rats treated with lisinopril.  The
upper part shows proteinuria in all 10 rats during the entire study (closed circles) as well as proteinuria
in adriamycin rats during the renal clearance experiments (bars). The middle part shows fractional
nRSA (closed circles) and RSA (open squares) clearances. The lower part shows the nRSA to RSA
clearance index (bars). ACEi = ACE inhibition by lisinopril. *p<0.05 versus wk 6,
 #p<0.05 versus wk 9,
**p<0.05 nRSA versus RSA
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Table 1. Experimental data of healthy rats (CON), untreated adriamycin rats (ADR) ,
and adriamycin rats treated with lisinopril (ADR+ACEi) at baseline (wk 6) and at the
end of the study (wk 12).
CON ADR ADR+ACEi
wk6 wk12 wk6 wk12 wk6 wk12
n 5 4 5 5 6 5
Uprotein (mg/day) 15±10 18±9 263±55* 381±96* 300±138* 471±311*
SBP (mmHg) 114±10 129±9 121±13 126±11 123±10 119±4
GFR (ml/min) 1.4±0.3 1.1±0.4 1.2±0.1 0.8±0.4 1.6±0.4 0.6±0.2
#
ClnRSA (10
-5) 11±3 27±2
# 37±26*
$ 136±39*
#$ 206±126*
&$ 465±520*
$
ClRSA (10
-5) 5±1 12±3
# 110±53* 498±178*
#
522±343* 1480±1625*
nRSA/RSA 2.4±0.8 2.5±1.0 0.4±0.1* 0.3±0.1* 0.7±0.7* 0.4±0.1*
Abbreviations are: Uprotein = proteinuria; SBP = systolic blood pressure; GFR = glomerular filtration
rate; ClnRSA = fractional clearance of 
125I-charge-modified rat albumin; ClRSA = fractional clearance of
131I-native rat albumin. *p<0.05 versus CON at corresponding time; 
#p<0.05 wk12 versus wk6 within
each group; 
&p<0.05 ADR versus ADR+ACEi at corresponding time; 
$p<0.05 ClnRSA versus ClRSA at
corresponding time.
In addition, the change in proteinuria, fractional RSA and nRSA clearances, and the
nRSA to RSA renal clearance index showed a similar time course during ACE
inhibition (Figure 3).
Recovery
Withdrawal of lisinopril induced a complete recovery of systolic blood
pressure (83–10 to 119–4 mmHg; p<0.05), whereas GFR had significantly
decreased at week 12 (0.9–0.5 to 0.6–0.2 ml/min). Proteinuria also returned to
baseline values after 3 weeks withdrawal of lisinopril. Although both the fractional
RSA and nRSA clearance significantly increased after withdrawal of lisinopril, the
fractional clearance of RSA is significantly higher than that of nRSA at the end of the
study. The nRSA to RSA clearance index completely recovered from 1.7±1.5 to
0.4±0.1 (p<0.05), since the increase of fractional RSA clearance was 2.9 times
greater than that of nRSA. The recovery of proteinuria, fractional RSA and nRSA
clearances, and the nRSA to RSA clearance index again showed a similar time
course which is a reflection of the time course during the antiproteinuric response of
lisinopril.ACE inhibition restores glomerular charge selectivity
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Discussion
The antiproteinuric effect of ACE inhibition is superior to that of other
antihypertensive drugs with equal capacity to reduce blood pressure [7]. This greater
capacity to reduce proteinuria is associated with a better preservation of renal
function in non-diabetic renal disease [8-9]. The mechanism of the antiproteinuric
effect of ACE inhibition has not completely been elucidated so far. The present study
demonstrates that effective reduction of proteinuria by the ACE inhibitor lisinopril is
associated with a restoration of glomerular charge selectivity to albumin in the
adriamycin nephrotic rat. This restoration of glomerular charge selectivity even
demonstrates a similar time course as the reduction of proteinuria by lisinopril.
These observations implicate that restoration of glomerular charge selectivity
contributes to the favorable antiproteinuric effect of ACE inhibitors.
Figure 4. Correlation between change in proteinuria and change in the nRSA to RSA clearance index
during ACE inhibition (n=12; r=-0.70; p<0.05).
Previous studies on the mechanism of the antiproteinuric effect of ACE
inhibition in non-diabetic renal disease focused on the role of alterations in
hemodynamics or glomerular size selectivity. The acute antiproteinuric response of
ACE inhibition is induced by systemic blood pressure reduction through reduced
generation of systemic angiotensin II [16]. Continued treatment with ACE inhibition
-4
-3
-2
-1
0
1
2
3
4
-400 -200 0 200 400 600 800
change in proteinuria (mg/24hr)
c
h
a
n
g
e
 
i
n
 
n
R
S
A
/
R
S
AChapter 3
59
gradually increases the antiproteinuric response from 15 to 50% in 4 weeks time,
whereas blood pressure or filtration fraction do not further fall [15]. In addition,
reversal of blood pressure and filtration fraction by systemic infusion of angiotensin II
does not reverse the established antiproteinuric response of ACE inhibition [17]. It
therefore is unlikely that hemodynamic alterations directly mediate the additional
reduction of proteinuria during continued ACE inhibition. In accordance, ACE
inhibition restores glomerular size selectivity to dextran at its maximal antiproteinuric
effect independently from its hemodynamic alterations [11-14]. Theoretical analysis
of intrinsic permeability characteristics of the glomerular capillary wall during ACE
inhibition reveals a reduction in mean pore size as well as a reduction of pore size
distribution which restricts the passage of large macromolecules [12]. ACE inhibition
may therefore induce structural changes of the glomerular filtration barrier through
indirect effects of hemodynamic changes which reduce the intraglomerular capillary
wall stress or by inhibition of intrarenal angiotensin II generation [26].
Proteinuria in non-diabetic renal disease is associated with impaired
glomerular charge selectivity which may be due to a reduction of anionic
glycosaminoglycan side chains of heparan sulfate proteoglycan in the lamina rarae
of the glomerular basement membrane [27-30]. This reduction of heparan sulfate
proteoglycan may increase glomerular permeability by the interference with the
attachment of glomerular epithelial cells to the glomerular basement membrane
which leads to retraction or detachment of the epithelial cells [31]. Although
restoration of glomerular charge selectivity may contribute to the antiproteinuric
response of ACE inhibition, no studies have been published so far which analyzed
glomerular charge selectivity during any antiproteinuric treatment. This lack of data
is probably the consequence of a limited sensitivity of the available methods to
measure changes in glomerular charge selectivity. Although dextran sulfate is the
only available marker of glomerular charge selectivity of which the fractional
clearance is not affected by tubular reabsorption or secretion, its fractional clearance
is affected by desulfatation during the filtration process, it is toxic in high
concentration, it binds size-dependent to serum proteins, and its molecular size of
18Å does not match the molecular size of albumin [27, 32-33]. All other available
markers of glomerular charge selectivity such as differently charged horseradish
peroxidases [34], IgG subclasses [35], and amylase iso-enzymes [36] are proteins
which are subject to charge-dependent tubular reabsorption [37]. In addition, anionic
horseradish peroxidase is more prone to degradation during the filtration process
than neutral or cationic horseradish peroxidase [38]. We decided to use fractional
clearances of differently charged autologous albumin to monitor glomerular charge
selectivity, since albumin is the naturally occurring plasma protein for charge
dependent filtration. It is known that the charge modification procedure which
increases pI of albumin does not alter its molecular size and does not induce
degradation of albumin during filtration [39]. Of course, use of differently charged
albumin’s for the monitoring of glomerular charge selectivity also inherits drawbacks.
Infusion of highly cationized albumin induces renal and extrarenal toxicity [40]. TheACE inhibition restores glomerular charge selectivity
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risk for this toxicity is negligible in the present study since molecular charge of
albumin was only neutralized. More importantly, fractional albumin clearances are
influenced by the charge-dependent tubular reabsorption of albumin [37].
Micropuncture studies in healthy rats demonstrated more than 90% tubular
reabsorption of albumin, whereas cationic albumin with a pI greater than 9.0 is 5
times more reabsorbed than native anionic albumin during infusion of low albumin
concentrations in the proximal tubule [37, 41]. Since we did not correct for this
charge-dependent tubular handling of albumin, the nRSA to RSA clearance index
has to be underestimated in our healthy rats. Tubular reabsorption of albumin
decreases progressively below 20% in nephrotic conditions, whereas the
reabsorption of highly cationic albumin is 2-3 times higher than that of anionic
albumin when higher albumin concentrations are infused in proximal tubules [37, 42].
Bertolatus et al. [39] observed a smaller difference in tubular reabsorption between
anionic BSA and neutral BSA (31 versus 42%, respectively) in adriamycin nephrotic
rats. Since we modified molecular charge of RSA in the same order, nRSA may thus
be preferentially reabsorbed which explains the higher fractional clearance of RSA
compared to nRSA in our adriamycin rats at baseline. It is not likely that differences
in molecular size or configuration due to the charge modification procedure of
albumin induced higher fractional clearance of RSA than nRSA. Molecular size of
nRSA is equal or even slightly smaller than that of RSA which excludes significant
polymerization of charge-modified albumin molecules leading to smaller fractional
clearances of nRSA. Cationization of albumin to a pI of 9.3 to 9.5 induced changes
in molecular configuration due to a 50% loss of ￿ -helical content of the native
molecule [43]. This would rather facilitate than attenuate the renal clearance of
highly cationized RSA in comparison to RSA in adriamycin rats at baseline.
Furthermore, the mild neutralization of albumin in the present study would not have
similar configurational effects. The relatively higher clearance of RSA in comparison
to nRSA which we observed in adriamycin rats at baseline has therefore to reflect
impaired glomerular charge selectivity. It is known that effective reduction of
proteinuria by ACE inhibition increases the tubular reabsorption of albumin due to a
smaller tubular protein load [44]. Since lower albumin concentrations at tubular level
facilitates the tubular reabsorption of nRSA more than RSA [37], the increase of the
nRSA to RSA clearance index during lisinopril is even underestimated in the present
study and therefore reflects a restoration of glomerular charge selectivity to albumin.
Would glomerular size selectivity restore with a similar time course as
glomerular charge selectivity in the adriamycin rat? The nature of the permselective
defect of the glomerular capillary wall in the adriamycin rat seems to depend on the
stage of the induced nephrosis [45]. Adriamycin induces a rapid and sustained
reduction of heparan sulfate charge density and epithelial membrane sialic acid
content in the glomerular capillary wall which precedes onset of proteinuria [46]. This
is followed by focal effacement of foot processes of podocytes and detachment of
podocytes from the glomerular basement membrane which leads to established
nephrotic-range proteinuria within 4 to 6 weeks. Impaired glomerular charge
selectivity has a predominant role at this stage of adriamycin nephrosis [39, 45].Chapter 3
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Glomerular size selectivity may be impaired in later stages of adriamycin nephrosis
since progressive focal and segmental glomerulosclerosis just develops from 12 to
16 weeks after induction of nephrosis [47-48]. We were unable to simultaneously
measure glomerular size and charge selectivity in the present study since this would
too much complicate our renal clearance protocol and laboratory assays.
Nevertheless, the simultaneous increase of fractional RSA and nRSA clearances in
adriamycin rats at baseline suggests the concomitant presence of impaired
glomerular size selectivity, whereas the simultaneous reduction of fractional RSA
and nRSA clearances during lisinopril suggests a concomitant restoration of
glomerular size selectivity. A time-dependent restoration of glomerular size
selectivity may therefore also contribute to the effective reduction of proteinuria by
ACE inhibition in adriamycin nephrotic rats.
In conclusion, restoration of glomerular charge selectivity to albumin is an
important determinant of the antiproteinuric response of ACE inhibition in adriamycin
nephrosis. The time course of the changes in glomerular charge selectivity and
proteinuria during ACE inhibition suggest a gradual restoration of structural anionic
sites in the glomerular capillary wall. Other interventions which restore structural
anionic sites of the glomerular capillary wall may extend the reduction of proteinuria
in renal disorders which are predominantly characterized by impaired glomerular
charge selectivity.
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Introduction
Proteinuria in non-diabetic renal disease is the consequence of a concomitant
size and charge selective defect of the glomerular filtration barrier [1-3]. The most
frequently applied markers of glomerular charge selectivity in clinical research are
the renal clearance indices of IgG to IgG4 and pancreatic to salivary amylase [4-6].
The preferential urinary loss of anionic charged macromolecules such as IgG4 and
salivary amylase compared to neutral macromolecules with similar molecular size
such as IgG and pancreatic amylase has been associated with the loss of negatively
charged components in the glomerular basement membrane such as
glycosaminoglycan side chains of heparan sulfate proteoglycan in conditions of
proteinuria [7-9]. To date, the IgG to IgG4 clearance index has only been used twice
as marker for glomerular charge selectivity during antiproteinuric treatment. Hansen
et al. [10] failed to detect a significant increase of the IgG to IgG4 clearance index
during significant reduction of diabetic micro-albuminuria by ACE inhibition. Zietse et
al. [11] demonstrated an increase of the IgG to IgG4 clearance index, which
suggests a restoration of glomerular charge selectivity, during effective reduction of
proteinuria by cyclosporin A in patients with minimal change disease. The pancreatic
to salivary amylase clearance index has never been used to monitor glomerular
charge selectivity during effective reduction of proteinuria.
Angiotensin-converting enzyme (ACE) inhibitors have been established as
superior antiproteinuric agents in comparison to other antihypertensive drugs [12].
This superior antiproteinuric effect is not directly the consequence of blood pressure
reduction or renal hemodynamic alterations during ACE inhibition in patients with
non-diabetic renal disease [13-15]. It has been demonstrated so far that ACE
inhibition restores glomerular size selectivity at the time of a maximal antiproteinuric
effect in non-diabetic renal disease [16-19]. Since this beneficial effect of ACE
inhibition at glomerular size selectivity is independent of the concomitant renal
hemodynamic alterations, the superior antiproteinuric effect of ACE inhibition may be
due to structural changes in the glomerular capillary wall which restore glomerular
size selectivity. The effect of ACE inhibition at glomerular charge selectivity during
effective reduction of proteinuria is unknown.
  The present study aims to elucidate whether restoration of glomerular charge
selectivity also contributes to the antiproteinuric effect of ACE inhibition in patients
with non-diabetic renal disease. For this purpose, we measured the IgG to IgG4 and
pancreatic to salivary amylase clearance indices as well as fractional dextran
clearances as marker of glomerular size selectivity during effective reduction of
proteinuria by the ACE inhibitor trandolapril in patients with a concomitant size and
charge selective defect of the glomerular capillary wall at baseline.
MethodsChapter 4
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Study design
We report on the effects of 6 weeks double-blind, placebo-controlled
treatment with the ACE inhibitor trandolapril 4 mg o.i.d. in 11 patients with non-
diabetic proteinuria. Data are obtained from a prospective study on the
antiproteinuric efficacy of trandolapril in comparison to the calcium channel
antagonist verapamil and their combination [20]. Patients were selected from the
population who attended our outpatient renal department. Entry criteria were biopsy
proven non-diabetic renal disease, diastolic blood pressure below 110 mmHg,
creatinine clearance more than 40 ml/min, proteinuria more than 2.0 g/day, and no
need for concomitant medication. Patients with diabetes mellitus, edema or
renovascular hypertension were not allowed to participate. Antihypertensive, diuretic
and immunosuppressive drugs were withdrawn for at least 4 weeks before
enrollment. A 50 mmol/day sodium restricted diet as well as stable protein intake
were prescribed. To obtain reference values similar renal clearance studies were
performed in 15 healthy subjects. All healthy subjects denied a history of renal
disease, hypertension, or diabetes. At the time of evaluation each subject was
normotensive, normoglycemic, and had no proteinuria. The study was carried out
according to the principles of the Declaration of Helsinki (1989). Patients and
healthy subjects gave their informed consent for participation in this protocol which
has been approved by the local Medical Ethical Committee.
At the end of each study period each subject collected 24-hr urine during
three days. Renal function measurement was carried out at our outpatient renal
function laboratory at the next day. Sitting blood pressure was recorded from 7:15
a.m. during 15 minutes at 1 minute intervals by an automated device (Dinamap®).
Fasting blood samples were drawn at 7:30 a.m. for determination of albumin (Mw 67
kD, pI 4.8), IgG (Mw 150 kD, pI 5.0-8.5), IgG4 (Mw 150 kD, pI 5.5-6.00), pancreatic
amylase (Mw 56 kD, pI 7.0), and salivary amylase (Mw 56 kD, pI 5.9-6.4). At 8.00
a.m. a bolus injection of renal function tracers 
125I-iothalamate and 
131I-hippuran was
followed by a constant infusion of these tracers in an anticubital vein. After a 2-hr
equilibration period, two clearance periods were performed from 10:00 to 12:00 hr.
and 12:00 to 14:00 hr. At 14:00 p.m. an injection of 20 ml dextran-1 (Promiten®,
Pharmacia, Uppsala, Sweden) was given to prevent anaphylactic reactions during
the subsequent infusion of a mixture of 60 mg/kg dextran-40 (Rheomacrodex®,
Pharmacia, Uppsala, Sweden) and 60 mg/kg dextran-70 (Macrodex®, Pharmacia,
Uppsala, Sweden). After 30 minutes equilibration one clearance period was
performed from 15:00 to 15:30 p.m. During the clearance periods blood was drawn
to bracket each urine collection. Throughout the study day subjects remained in
sitting position, except when voiding. Subjects were allowed to take their usual
breakfast at 8:30 hr and to drink at least 250 ml/hr beverages during the study day to
establish a sufficient diuresis. From 14:00 to 15:00 p.m. subjects received an oral
water load of 15 ml/kg to promote diuresis for estimation of renal dextran clearances.Glomerular charge selectivity  restored by ACE inhibition?
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Clinical and laboratory procedures
Serum and urinary chemistry were determined with an automated multi-
analyzer (SMA-C-II®, Technicon Instruments Inc., Tarry Town, NY, USA). Urinary
protein was determined by the pyrogalloll red-molybdate method [21]. Proteinuria
was estimated as the mean proteinuria during three urine collection days. Mean
arterial pressure (MAP) was calculated as the sum of one-third of systolic blood
pressure and two-thirds of diastolic blood pressure. GFR and effective renal plasma
flow (ERPF) were estimated from the mean of two clearance periods according to a
previously described method [22]. Filtration fraction (FF) was calculated as the ratio
of GFR and ERPF.
Fractional clearances of albumin, IgG, IgG4, total amylase and pancreatic
amylase were calculated as the clearance of the protein relative to the endogenous
creatinine clearance for the middle of three collected 24-hr urine samples. Urine
samples for the determination of albumin, IgG, and IgG4 were 1:1 diluted with a
mixture of 40 mM phosphate buffer, 100 mM glucose and 10 g/l BSA to prevent
degradation of proteins during storage by -20ºC until analysis [23]. Serum albumin,
and IgG were measured by nephelometry (Behring Nephelometer Analyzer,
Behringwerke AG, Marburg, Germany). The intra- and interassay coefficient of
variation were 3.6% and 5.0%, respectively. Urinary albumin and IgG were
measured by an in-house developed ELISA, as described previously [23]. The lower
detection limit of urinary albumin was 0.01 mg/l, whereas the intra- and interassay
CV were 4.2% and 7.0%, respectively. The lower detection limit of urinary IgG was
1.5 µg/l, whereas the intra- and interassay CV were 5.0% and 9.2%, respectively.
Urinary and serum IgG4 were measured by a solid phase immunoenzymatic
sandwich method [24]. The lower detection limit of IgG4 was 2 ng/l, whereas the
intra- and interassay CV were 6.6% and 9%, respectively. Urinary excretion of IgG4
was lower than the detection limit in 3 of the healthy subjects. Total and pancreas
amylase activity were measured within three weeks after the study day, since the
storage of sera and urine samples at 4ºC did not decrease amylase activity for at
least 4 weeks. Serum and urine amylase activity were estimated in duplicate using a
enzymatic colorimetric assay with ethylidine protected 4-nitrophenylmaltoheptaoside
as substrate (Boehringer, Mannheim, Germany). Serum and urine pancreatic
isoamylase activity was determined in duplicate by a commercially available
pancreatic a-Amylase EPS kit which uses double monoclonal antibodies to inhibit
salivary isoamylase (Boehringer, Mannheim, Germany) [25]. Salivary amylase was
calculated as the difference between total and pancreatic amylase. The intra- and
interassay CV for total amylase activity were 5.1% and 6.0%, respectively, and for
pancreatic amylase activity 5.4% and 10.6%, respectively.
Fractional dextran clearances were measured according to a previously
described method [26]. In short, plasma and urine samples were deproteinized by
100% TCA to a final concentration of 20% and fractionated according to molecular
size by gel permeation chromatography on a precalibrated Sephacryl-300 column
(Pharmacia, Uppsala, Sweden). The column was eluted with 0.01 mol/l Tris buffer
with 0.15 mol/l NaCl and 1 mmol/l EDTA at pH 7.0 and calibrated at 6 week intervalsChapter 4
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with 3 commercially available standard dextrans (F8, F40, and F75 from Serva,
Heidelberg, Germany) with specified molecular weights. Blue dextran and vitamin
B12 were used to determine the void volume (V0) and bed volume (Vt). The fractional
volume available to the solute (Kav) was calculated from:
Kav = (Ve - V0)/(Vt - V0)
where Ve is the elution volume of the solute. Effective molecular radii for the
individual dextran fractions were then calculated from Kav and Stokes-Einstein radius
(Rst) of the standard dextrans by the formula: Rst = (0.33 * M)
0.463, where M is
molecular weight corrected for polydispersity by M = (Mw*Mn)
½ [27]. Dextran
concentration in molecular size fractions was estimated by anthrone assay [28].
Renal clearances of dextrans relative to the iothalamate clearance were calculated
from ([U]macromolecule*[P]iothalamate)/([P]macromolecule*[U]iothalamate), where [U] is the urine
concentration and [P] is the plasma concentration. The fractional clearance of
dextrans is plotted against their molecular radius over a range from 30 to 60Å on a
semilogarithmic scale. Glomerular size selectivity is also expressed by the clearance
index of IgG to albumin, by which aselective proteinuria is characterized by an index
greater than 0.20 [29].
Analysis
To translate the dextran sieving data into size selective properties of the
filtration barrier we used the previously described heteroporous model by Deen et al.
[30]. This model is characterized by restrictive pores with identical radius (r0), a
shunt pathway which does not discriminate on size and allows unrestricted passage
of a fraction of the filtrate volume (w0), and the ultrafiltration coefficient Kf which is
the product of hydraulic permeability and glomerular capillary surface area. In this
model we assumed the transmembrane hydraulic pressure difference (DP) to be 35
mmHg in healthy subjects and in patients treated with trandolapril, and 40 mmHg in
patients at baseline. Extraction of hippuran is assumed to be 0.85 in normal
conditions and 0.7 in nephrotic conditions [31].
Data are expressed as a Wilcoxon-based estimated median with 95%
confidence interval, unless otherwise indicated. Differences were tested with the
non-parametric Wilcoxon’s rank sum test for (un)paired observations. Correlation’s
between parameters were tested using Spearman’s rank sum test. Statistical
significance is assumed at a p-level less than 0.05.Glomerular charge selectivity  restored by ACE inhibition?
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Table 1. Study parameters in healthy subjects (n=15), and in patients with non-
diabetic proteinuria (n=11) during placebo and trandolapril.
Healthy
subjects
Patients
Placebo Trandolapril
Uprotein g/day 0 6.2 [4.9-7.7]
# 3.7 [2.6-4.6]
#*
MAP mmHg 90 [85-93] 98 [87-115] 91 [81-101]*
GFR ml/min/1.73m
2 108 [99-116] 85 [63-95]
# 85 [62-99]
#
ERPF ml/min/1.73m
2
435 [402-494] 364 [280-448]
# 436 [323-530]*
FF % 24.8 [23.1-25.4] 22.7 [20.3-23.9]
#
18.3 [17.1-21.0]*
pa mmHg 23.5 [22.8-25.2] 20.3 [17.4-23.1]
#
22.4 [19.0-24.5]
r0 Å 55.9 [55.2-56.4] 56.4 [55.6-56.8] 55.9 [54.7-56.4]
w0 10
-3
0.8 [0.6-0.8] 2.7 [1.8-3.2]
# 1.7 [1.5-3.1]
#
Kf ml*mmHg/min 9.1 [6.8-10.1] 3.2 [1.8-3.7]
# 4.5 [3.1-5.9]
#*
Clalbumin 10
-6
0.7 [0.6-1.1] 711 [549-1060]
#
454 [186-930]
#
ClIgG 10
-6 1.0 [0.8-1.3] 167 [111-204]
# 91 [45-141]
#*
ClIgG4 10
-6
0.4 [0.2-0.6] 190 [128-312]
# 73 [58-144]
#*
ClPA 10
-3
11 [10-23] 17 [10-23] 14 [9-21]
ClSA 10
-3
7 [4-10] 10 [7-16] 8 [5-15]
IgG/albumin - 0.17 [0.14-0.29] 0.18 [0.11-0.33]
IgG/IgG4 2.64 [1.96-4.08] 0.88 [0.61-1.05]
#
0.81 [0.60-1.49]
#
PA/SA 2.29 [1.93-3.08] 1.44 [1.00-2.08]
#
1.50 [1.07-1.99]
#
Data are expressed as median and 95% confidence interval. Abbreviations are: MAP = mean arterial
pressure; GFR = glomerular filtration rate; ERPF = effective renal plasma flow; FF = filtration
fraction; pa = afferent oncotic pressure; Cl = fractional clearance; PA = pancreatic amylase; SA =
salivary amylase.
 # p<0.05 versus healthy subjects; * p<0.05 versus placebo.
Results
The distribution of renal histological diagnoses reveals 6 patients with focal
glomerulosclerosis, 3 patients with membranous glomerulopathy, 1 patient with IgA
nephropathy, and 1 patient with membranoproliferative glomerulonephritis. Patients
and healthy subjects demonstrate a comparable age (41 [32-47] versus 44 [36-50]
years), gender distribution (7 males and 4 females versus 10 males and 5 females),
body surface area (1.91 [1.81-1.98] versus 1.97 [1.87-2.10] m
2) and MAP (98 [87-
115] versus 90 [85-93] mmHg). GFR, ERPF, and filtration fraction are significantly
lower in the patients as compared to healthy subjects (Table 1). Patients
demonstrate proteinuria of 6.2 g/day (range: 3.8 to 10.7 g/day) and a higher serum
cholesterol (6.54 [5.62-7.83] versus 4.92 [4.59-5.53] mmol/l) as well as a lower
serum albumin (38 [33-41] versus 44 [43-46] g/l) than healthy subjects.Chapter 4
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Both the IgG to IgG4 as well as the pancreatic to salivary amylase index are
significantly lower in patients compared to healthy subjects (Table 1). Patients show
a median IgG to albumin clearance index of 0.17, whereas only 4 of the 11 patients
show an IgG to albumin clearance index greater than 0.20. The dextran sieving
profile reveals significantly lower fractional dextran clearances from 30 to 42Å in
patients compared to healthy subjects (Figure 1). Although there is a trend that
fractional clearances of dextrans greater than 50Å are higher in patients, it is not
statistically significant. Theoretical analysis of the size selective characteristics of
the glomerular filtration barrier reveals a lower Kf and a higher w0 in patients
compared to healthy subjects (p<0.05), whereas the restrictive pores show a
comparable radius in both groups.
ACE inhibition
ACE inhibition by trandolapril reduces mean arterial pressure and filtration
fraction, whereas ERPF increases and GFR does not change (Table 1). Proteinuria
is reduced from 6.2 [4.9-7.7] to 3.7 [2.6-4.6] g/day (p<0.05). Fractional clearances of
albumin, IgG, and IgG4 are reduced by trandolapril, although the reduction of the
fractional clearance of albumin is just not statistically significant (p=0.08). The
fractional clearances of pancreatic and salivary amylase do not change during
trandolapril. Both the IgG to IgG4 and the pancreatic to salivary amylase index do
not change during trandolapril (Figure 2). The reduction of proteinuria by trandolapril
is neither accompanied by changes in the fractional dextran clearances (Figure 1).
Although Kf increases significantly, r0 and w0 do not change during effective
reduction of proteinuria.
Correlation’s
The change in proteinuria is not related with a change in the IgG to IgG4
clearance index, but a reduction of proteinuria tends to be related to a decrease of
the pancreatic to salivary amylase clearance index during trandolapril (r=0.59;
p=0.07). A reduction of the IgG to IgG4 clearance index is related to a reduction of
w0 during trandolapril (r=0.64; p<0.05). The change in the IgG to IgG4 clearance
index is not related to the change in the pancreatic to salivary amylase clearance
index during trandolapril.
Discussion
The present study confirms previous findings that non-diabetic patients with
proteinuria have a concomitant glomerular size and charge selective defect [1-3].
Remarkably, effective reduction of proteinuria by the ACE inhibitor trandolapril in
these patients is not associated with changes in the fractional clearance indices of
IgG to IgG4 and pancreatic to salivary amylase or fractional dextran clearances.
Although this suggests that restoration of glomerular size and charge selectivity
doesGlomerular charge selectivity  restored by ACE inhibition?
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Figure 1. Left panel: fractional dextran clearances in patients with non-diabetic proteinuria (solid
circles) compared to healthy subjects (open squares). Right panel: fractional dextran clearances in
non-diabetic patients with proteinuria during placebo (solid circles) and during trandolapril (open
circles). * p<0.05 patients versus healthy subjects.
not contribute to the antiproteinuric response of ACE inhibition, we postulate that
these negative findings rather illustrate the shortcomings of the used markers of
glomerular size and charge selectivity to reflect changes during effective reduction of
proteinuria.
It has been demonstrated that ACE inhibition acutely reduced proteinuria by
10 to 15% through the transmission of a lower systemic blood pressure in the
glomerulus [11-12]. Subsequently, the antiproteinuric effect gradually increased
further to 50% after 4 weeks ACE inhibition [11]. This gradual reduction of
proteinuria was not directly the consequence of systemic or renal hemodynamic
alterations during continued ACE inhibition [11, 13]. It can be hypothesized the
gradual increase of the antiproteinuric effect during the first weeks of ACE inhibition
is mediated by slowly appearing structural changes of the glomerular capillary wall
which restore the glomerular size or charge selective defect. Two clinical studies
indeed demonstrated restoration of glomerular size selectivity at the time that the
antiproteinuric effect of ACE inhibition is maximal in patients with IgA nephropathy
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and membranous glomerulopathy [16-17]. To elucidate whether the antiproteinuric
effect of ACE inhibition is also mediated by restoration of glomerular charge
selectivity in non-diabetic renal disease, it is important that glomerular size and
charge selectivity are concomitantly impaired at baseline. Glomerular size selectivity
is mildly impaired in our patients at baseline. Fractional dextran clearances are
decreased in the small molecular size range, but not significantly increased in the
large molecular size range. In addition, only 4 of 11 patients show aselective
proteinuria as expressed by the fractional clearance index of IgG to albumin and the
calculated ultrafiltrate flow which passes unrestricted through large pores is smaller
than in previous studies on glomerular size selectivity in non-diabetic renal disease
[30, 32-33]. Glomerular charge selectivity is impaired at baseline in our patients,
since the observed reduction of the fractional clearance indices of IgG to IgG4 and
pancreatic to salivary amylase as a consequence of the preferential urinary loss of
anionic macromolecules is in perfect agreement with previous studies [4-6].
Considering this concomitant glomerular size and charge selective defect at
baseline, we are able to test whether ACE inhibition restores glomerular charge
selectivity in addition to glomerular size selectivity.
Figure 2. The IgG to IgG4 (left panel) and the pancreatic to salivary amylase (right panel) clearance
indices in healthy subjects (CON) and non-diabetic patients with proteinuria during placebo (PLA) and
trandolapril (ACEi). * p<0.05 patients versus healthy subjects.
Restoration of glomerular charge selectivity during effective reduction of
proteinuria has been demonstrated in one clinical study so far. Zietse et al. [19]
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observes an increase in the fractional clearance index of IgG to IgG4 during
treatment with cyclosporin A in minimal change disease. In contrast, Shemesh et al.
[32] does not demonstrate restoration of glomerular charge selectivity during
effective reduction of proteinuria with indomethacine in patients with membranous
glomerulopathy. The present study firstly demonstrates data on glomerular charge
selectivity during effective reduction of proteinuria by ACE inhibition in human non-
diabetic renal disease. We cannot demonstrate restoration of glomerular charge
selectivity by an increase in the IgG to IgG4 or pancreatic to salivary amylase
clearance indices during 50% reduction of proteinuria by the ACE inhibitor
trandolapril. This suggests that the antiproteinuric effect of ACE inhibition is only
mediated by the restoration of glomerular size selectivity. In contrast to two previous
clinical studies [16-17], glomerular size selectivity was not restored during ACE
inhibition in the present study. This discrepant finding is certainly not explained by
differences in study design. Our study design is comparable to that in previous
studies with respect to the number of included patients, treatment duration and
dosage of ACE inhibition, and the use of dextrans as markers of glomerular size
selectivity. In addition, the hemodynamic and antiproteinuric effect of ACE inhibition
is similar in all three studies. This leaves two explanations for our discrepant finding:
differences in the baseline patient characteristics or differences in the sensitivity of
the laboratory procedure for measurement of fractional dextran clearances. Our
patients have a smaller glomerular size selective defect at baseline as reflected by
the unchanged fractional dextran clearances in the large molecular size range and a
lower w0. This may be the consequence of a less severe renal injury, since our
patients have a lower blood pressure and better preserved GFR at baseline
compared to patients in previous studies [34]. Although we used a similar laboratory
procedure to measure fractional dextran clearances as Remuzzi et al. [16], we
cannot exclude that this laboratory procedure is not sensitive enough to detect
changes of glomerular size selectivity in patients with a smaller glomerular size
selective defect at baseline.
It may still have been that glomerular size selectivity is not restored at all, but
that a restoration of glomerular charge selectivity during ACE inhibition cannot be
detected by the IgG to IgG4 and pancreatic to salivary amylase clearance indices. A
recent analysis of both indices in patients with non-diabetic renal disease indeed
revealed serious doubts on their suitability to reflect glomerular charge selectivity
[35]. The fractional clearance of IgG subclasses was found to be affected by charge-
dependent differences in tubular reabsorption, whereas the pancreatic to salivary
amylase clearance index was adversely influenced by loss of tubular function. Our
correlation data additionally question the suitability of both indices to reflect changes
in glomerular charge selectivity. The change in pancreatic to salivary amylase
clearance index is related with the change in proteinuria, but in opposite to the
expected relation, whereas the change in the IgG to IgG4 clearance index is not
related to the change in proteinuria. Since the changes in both charge selective
indices do neither correlate with eachother during trandolapril, both indices certainly
not reflect glomerular charge selectivity in a comparable way. One may favor the useChapter 4
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of the IgG to IgG4 clearance index because it correlates with the change in w0 in an
expected way: a smaller glomerular size selective defect is accompanied by a larger
glomerular charge selective defect. The IgG to IgG4 clearance index may however
be more affected by a concomitant glomerular size selective defect than the
pancreatic to salivary amylase clearance index, since the urinary clearance of IgG
has been rather associated with impaired glomerular size selectivity due to its larger
molecular size [30]. Altogether, it is important to consider that the IgG to IgG4 and
the pancreatic to salivary amylase clearance indices should be very carefully
interpreted with respect to glomerular charge selectivity in non-diabetic renal
disease. Measurement of renal clearance of anionic dextran sulfate relative to that of
neutral dextran of similar molecular size has been considered to be a more
appropriate method to study glomerular charge selectivity [3]. Dextrans are inert
macromolecules which are neither reabsorbed or secreted by tubular cells [36]. A
greater suitability of dextran sulfate to reflect glomerular charge selectivity may
however be questioned since its molecular size is only 18Å, which is not
representative of that of albumin, and its prone to desulfatation during ultrafiltration
[3, 37].
In conclusion, ACE inhibition by trandolapril effectively reduces proteinuria in
patients with non-diabetic renal disease. Apart from an increase in ultrafiltration
coefficient, neither the IgG to IgG4 and the pancreatic to salivary amylase clearance
indices as markers of glomerular charge selectivity or the fractional dextran
clearances as marker of glomerular size selectivity change significantly during
trandolapril. These negative findings suggest that restoration of glomerular size and
charge selectivity does not contribute to the antiproteinuric response of ACE
inhibition. However, the evidence grows that the used markers in the present study
do not appropriately reflect changes in glomerular charge selectivity. ACE inhibition
may therefore be able to restore glomerular charge selectivity in non-diabetic renal
disease. Preliminary experimental data indeed demonstrate an increase of the
heparan sulfate content of the glomerular basement membrane and restoration of
glomerular charge selectivity to albumin during effective reduction of proteinuria by
the ACE inhibitor lisinopril in adriamycin nephrotic rats [38-39].
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Introduction
Proteinuria has been associated with a defect in the glomerular filtration
barrier which leads to passage of large and anionic macromolecules into the urine
[1-3]. The charge-selective function of the glomerular barrier has been studied in
clinical research by changes in the clearance ratio of endogenous proteins similar in
size, but differing in charge. For this purpose serum proteins have been advocated
such as positively charged IgG (MW 150 kD, pI 5.8-7.3) versus negatively charged
IgG4 (MW 150 kD, pI 5.5-6.0), and pancreatic amylase (PA, MW 56 kD, pI 7.0)
versus salivary amylase (SA, MW 56 kD, pI 5.9-6.4) [4-5]. A relatively greater loss of
anionic IgG4 or SA has been considered to reflect loss of charge selectivity.
IgG/IgG4 and PA/SA were indeed found to be decreased in conditions of diabetic
and non-diabetic albuminuria [3,5-7].
  It remains questionable whether both IgG/IgG4 and PA/SA reflect ‘true’
glomerular charge selectivity. Urinary loss of IgG is associated with a size selective
defect rather than with a charge selective defect [2]. The index of IgG/IgG4
clearance may therefore be seriously influenced by changes in glomerular size
selectivity. In contrast to IgG, amylase has a molecular size which is nearly that of
albumin. One might therefore expect PA/SA to be a more appropriate marker of
charge selectivity than IgG/IgG4. Unfortunately, no direct comparison of both indices
has yet been published.
We therefore analyzed both charge selectivity indices IgG/IgG4 and PA/SA in
relation to non-diabetic albuminuria over a wide range. In addition, we tested for the
effect of size selective characteristics in subjects with macro-albuminuria.
Methods
Subjects
Renal clearance studies were performed in 15 healthy controls and 37
patients with non-diabetic renal disease of various etiology. In this population 22
subjects had normo-albuminuria (urinary albumin excretion [UAE] of less than 20
mg/min), 7 subjects had micro-albuminuria (UAE 20-200 mg/min) and 23 subjects had
macro-albuminuria (UAE more than 200 mg/min). Characteristics of these groups are
presented in table 1. The groups have a comparable age, body surface area as well
as gender distribution. Blood pressure was not significantly different between the
groups, whereas serum albumin is lower in patients with macro-albuminuria, and
serum creatinine and cholesterol are higher in patients with macro- and micro-
albuminuria compared to patients with normo-albuminuria (p<0.05). The group of
normo-albuminuric subjects consisted of 15 healthy subjects and 7 subjects with
essential hypertension. The micro-albuminuric group consisted of 4 subjects with
hypertensive renal disease,  1 IgA nephropathy, and 2 unknown diagnosis. The
macro-albuminuric group consisted of 8 patients with membranous glomerulopathy,
5 focal glomerulosclerosis, 3 hypertensive renal disease, 2 IgA nephropathy, 1Chapter 5
81
membranoproliferative glomerulonephritis, 1 Wegener’s  glomerulonephritis and 3
unknown diagnosis. Three of the patients with normo-albuminuria, 4 of the micro-
albuminuric patients, and 7 of the macro-albuminuric patients used antihypertensive,
diuretic, or immunosuppressive treatment during the study. Only 1 out of 7 patients
with micro-albuminuria and 5 out of 22 patients with macro-albuminuria used ACE
inhibitors. All participants gave their informed consent to participate in this study
which was approved by the local Medical Ethical Committee.
Study protocol
Each participant collected one 24-hour urine collection on the day preceding
the renal function study day which was carried out at our outpatient renal function
laboratory. At the study day patients received a bolus injection of renal function
tracers 
125I-iothalamate and 
131I-hippuran followed by a constant infusion of these
tracers in the right anticubital vein from 8:00 a.m. After a 2-hr equilibration period,
two clearance periods were performed from 10:00 to 12:00 a.m. and 12:00 to 14:00
p.m. Bracketed blood samples were collected for each urine collection during the
clearance study. GFR and ERPF were calculated as the mean from the two
clearance periods, according to a previously described method [8]. Throughout the
study day patients remained in sitting position, except when voiding. Patients were
allowed to take their usual breakfast at 8:30 a.m. Thereafter patients received no
food, but drank at least 250 ml/hr beverages to establish a sufficient diuresis. Sitting
blood pressure was recorded at 9:00 a.m. with an automated device (Dinamap®)
during 15 minutes at 1 minute intervals. Fasting blood samples were drawn at 7:30
a.m. for determination of albumin, IgG, IgG4, total amylase, and pancreatic amylase.
Fractional clearances of the involved proteins were calculated as the clearance of
the protein relative to the endogenous creatinine clearance from 24-hr urine
samples. The fractional clearance of IgG to albumin was used as an index of
glomerular size selectivity in the macro-albuminuric patients.
Laboratory procedures
Serum and urinary creatinine were determined with an automated multi-
analyzer (SMA-C-II®, Technicon Instruments Inc.,Tarry Town, NY, USA), whereas
urinary protein was determined with the pyrogalloll red-molybdate method [9]. Urine
samples for the determination of albumin, IgG and IgG4 were 1:1 diluted with a
mixture of  40 mM phosphate buffer, 100 mM glucose and 10 g/l BSA to prevent
degradation of proteins during storage by -20ºC until analysis [10-11]. Serum
albumin and IgG were measured by nephelometry (Behring Nephelometer Analyzer,
Behringwerke AG, Marburg, Germany). The intra- and interassay coefficient of
variation were 3.6% and 5.0%, respectively. Urinary albumin and IgG were
measured by an in-house developed ELISA, as described previously [11]. The lower
detection limit of urinary albumin was 0.01 mg/l, whereas the intra- and interassay
CV were 4.2% and 7.0%, respectively. The lower detection limit of urinary IgG was
1.5 µg/l, whereas the intra- and interassay CV were 5.0% and 9.2%, respectively.
Urinary and serum IgG4 were measured by a solid phase immunoenzymaticGlomerular charge selectivity and albuminuria
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sandwich method [12]. The lower detection limit of IgG4 was 2 ng/l, whereas the
intra- and interassay CV were 6.6% and 9%, respectively. Total and pancreas
amylase activity were measured within three weeks after the study day, since the
storage of sera and urine samples at 4ºC did not decrease amylase activity for at
least 4 weeks. Serum and urine amylase activity were estimated in duplicate using a
enzymatic colorimetric assay with ethylidine protected 4-nitrophenylmaltoheptaoside
as substrate (Boehringer, Mannheim, Germany). Serum and urine pancreatic
isoamylase activity was determined in duplicate by a commercially available
pancreatic a-Amylase EPS kit which used double monoclonal antibodies to inhibit
salivary isoamylase (Boehringer, Mannheim, Germany) [13]. Salivary amylase was
calculated as the difference between total and pancreatic amylase. The intra- and
interassay CV for total amylase activity were 5.1% and 6.0%, respectively, and for
pancreatic amylase activity 5.4% and 10.6%, respectively.
Table 1. Characteristics of normo-albuminuric (Normo), micro-albuminuric (Micro),
and macro-albuminuric (Macro) subjects.
Normo Micro Macro
Number 22 7 23
UalbuminE (mg/min) 4 [3-17] 136 [36-200]* 2153 [375-13611]*
#
Gender 7f/15m 2f/5m 5f/18m
Age (yr) 48 [25-66] 52 [32-65] 45 [18-74]
BSA (m
2) 1.96 [1.53-2.28] 1.91 [1.73-2.34] 1.91 [1.58-2.47]
Uprotein (g/day) 0.0 0.0 [0.0-0.6] 5.9 [0.8-21.5]*
#
SBP (mmHg) 124 [110-148] 127 [110-156] 133 [101-204]
DBP (mmHg) 74 [54-97] 79 [69-96] 77 [49-115]
Screatinine (mmol/l) 93 [80-117] 111 [101-259]* 117 [65-460]*
Salbumin (g/l) 44 [37-51] 44 [34-47] 35 [16-45]*
#
Scholesterol (mmol/l) 5.3 [3.8-7.8] 5.9 [5.1-7.2] 6.7 [4.4-11.4]*
Abbreviations are: UalbuminE = urinary albumin excretion; BSA = body surface area; Uprotein =
proteinuria; SBP = systolic blood pressure; DBP = diastolic blood pressure; S = serum; f = female; m
= male. *p<0.05 versus normo. 
#p<0.05 versus micro.
Analysis
Data are expressed as median and range, unless otherwise indicated. IgG4
was not detectable in 24-hr urine specimens of 7 normo-albuminuric and 1 micro-
albuminuric patients. Salivary amylase was not detectable in urine of 1 patient with
macro-albuminuria. Additionally, data on fractional protein clearances or both indices
from 3 normo-albuminuric and 2 macro-albuminuric patients fell outside the range of
mean–3.038SD (n=43; a<0.05) and were therefore excluded from further analysis,
leaving 12 normo-albuminuric, 6 micro-albuminuric and 20 macro-albuminuricChapter 5
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subjects in the study. Fractional clearances of albumin, IgG, and IgG4 were
logarithmically transformed to test relations between variables using Spearman’s
regression analysis or a stepwise multiple regression analysis which includes
variables with a level of significance of 0.05 or less. Tested variables were age,
gender, proteinuria, MAP, creatinine clearance, GFR, ERPF, fractional clearance of
albumin, IgG, IgG4, PA, and SA, IgG/IgG4, PA/SA, IgG/albumin and use of
concomitant medication. Differences between groups were tested with non-
parametric ANOVA or Wilcoxon’s rank sum test. Statistical significance was
assumed at a p-level less than 0.05.
Table 2. Serum protein levels, fractional protein clearances, and charge selectivity
indices in normo-albuminuric (Normo), micro-albuminuric (Micro) and macro-
albuminuric (Macro) subjects.
Normo Micro Macro
Number patients 12 6 20
UalbuminE (mg/min) 4 [3-17] 147 [36-200]* 2301 [608-13611]*
#
Clcr (ml/min/1.73m
2) 98 [53-137] 49 [29-73]* 66 [38-118]*
GFR (ml/min/1.73m
2) 107 [40-147] 55 [39-72]* 73 [30-113]*
ERPF (ml/min/1.73m
2) 421 [172-654] 240 [135-300]* 306 [135-989]
Salbumin (g/l) 48.0 [38.8-50.6] 43.0 [33.2-50.4] 35.7 [12.9-48.4]*
#
Clalbumin (10
-6) 0.7 [0.4-2.5] 51 [11-131]* 979 [186-8964]*
#
SIgG (g/l) 11.7 [9.0-13.6] 11.5 [7.2-15.4] 9.5 [3.0-20.0]
ClIgG (10
-6) 0.9 [0.6-2.9] 15 [4-53]* 182 [28-951]*
#
SIgG4 (g/l) 0.54 [0.29-1.55] 0.52 [0.01-0.72] 0.21 [0.01-2.70]
ClIgG4 (10
-6) 0.4 [0.2-2.4] 20 [3-82]* 292 [17-1997]*
#
SPA (U/l) 42 [24-73] 62 [49-178] 58 [9-118]
ClPA (%) 1.4 [0.3-3.4] 0.7 [0.1-4.8] 1.2 [0.1-4.2]
SSA (U/l) 45 [31-95] 60 [21-107] 72 [9-153]
ClSA (%) 0.8 [0.1-1.7] 0.2 [0.1-5.0] 1.0 [0.2-4.4]
IgG/IgG4 2.43 [1.21-3.26] 1.01 [0.29-1.41]* 0.75 [0.06-2.13]*
PA/SA 2.32 [1.25-4.64] 1.65 [0.50-4.23] 1.19 [0.01-2.21]*
IgG/albumin 0.19 [0.07-0.48]
Abbreviations are: UalbuminE = urinary albumin excretion; Clcr = creatinine clearance; S = serum; Cl =
fractional renal clearance; PA = pancreatic amylase; SA = salivary amylase. * p<0.05 versus normo
and 
#p<0.05 versus micro.Glomerular charge selectivity and albuminuria
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Figure 1. Individual data and mean with 95% confidence interval of IgG/IgG4 (left panel) and PA/SA
(right panel) in patient groups with normo-albuminuria (n=12), micro-albuminuria (n=6), and macro-
albuminuria (n=20). *p<0.05 versus normo-albuminuria.
Results
Patients with macro-albuminuria showed a significant higher fractional
clearance of IgG and IgG4 as compared to patients with micro-albuminuria and
normo-albuminuria (p<0.001), whereas patients with micro-albuminuria had a higher
fractional clearance of IgG and IgG4 compared to normo-albuminuric patients
(p<0.001) (Table 2). The IgG/IgG4 index in patients with micro- and macro-
albuminuria was significantly lower compared to patients with normo-albuminuria
(p<0.001) (Figure 1). The fractional clearances of PA and SA were not different
between the groups (Table 2), whereas the PA/SA index was lower in patients with
macro-albuminuria as compared to micro- and normo-albuminuric patients (p<0.001)
(Figure 1).  Both a reduction of IgG/IgG4 (r=-0.752, p<0.001) and PA/SA (r=-0.520,
p<0.001) are correlated with an increase of the fractional clearance of albumin in the
total population of 38 subjects. In addition, IgG/IgG4 correlated significantly with
PA/SA (r=0.492; p<0.01), although this relation was not very strong. We tested the
contribution of both charge selectivity indices on the variance of fractional albumin
clearance by means of multiple regression analysis. This analysis showed that
fractional IgG clearance (b=0.89; p<0.001) and fractional IgG4 clearance (b=0.34;
p=0.024) are the covariates of the fractional clearance of albumin in our total
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population (r=0.97; n=38). The fractional IgG clearance contributes to the variance
of the fractional clearance of albumin by 96.6%, whereas the fractional IgG4
clearance has only a minor contribution of 0.5%.
In the group of 20 macro-albuminuric subjects no significant relation was
observed anymore between IgG/IgG4 and PA/SA. Remarkably, both indices
correlated with the size selective index IgG/albumin in an opposite way. A reduction
of IgG/IgG4 was related with a reduction of IgG/albumin (r=0.509, p<0.05), whereas
a reduction of PA/SA was related with an increase of IgG/albumin (r=-0.521, p<0.05)
(Figure 2). Multiple regression analysis revealed that the fractional clearance of IgG
(b=0.93; p<0.001), the IgG/albumin index (b=-2.06; p<0.001), use of concomitant
medication (b=0.10; p=0.015), and ERPF (b=1.8*10
-4; p=0.035) are the covariates of
fractional albumin clearance in the subjects with macro-albuminuria (r=0.99; n=20).
Fractional IgG clearance contributes to the variance of fractional albumin clearance
by 73.6%, IgG/albumin by 23.9%, use of concomitant medication by 0.9% and ERPF
by 0.6%, respectively.
Discussion
A reduction of the charge selective indices IgG/IgG4 and PA/SA was related
with an increase of fractional albumin clearance in our population. This progressive
preferential loss of anionic substances with increasing albuminuria suggests
progressive loss of glomerular charge selectivity. It has been suggested that a
decrease in the heparan sulfate content of the glomerular basement membrane may
be responsible for this phenomenon [14]. Previous studies concerning IgG/IgG4
focused on characterization of diabetic renal disease. Patients with micro- and
macro-albuminuria had a reduced IgG/IgG4 compared to normo-albuminurics [3,6].
The fact that IgG/IgG4 tended to normalize in macro-albuminuric diabetics has been
explained by the progressive loss of glomerular size selectivity at this stage of
diabetic nephropathy [3,6]. Our study showed the first data on IgG/IgG4 in non-
diabetic renal disease, which seem to compare well with data in diabetic renal
disease: IgG/IgG4 was reduced in the stage of micro- and macro-albuminuria
compared to normo-albuminuric controls. Previous studies on PA/SA showed
contrasting results between diabetic and non-diabetic renal disease. PA/SA was not
significantly reduced in diabetic patients with micro- or macro-albuminuria compared
to normo-albuminurics [15], although PA/SA was suggested to be a prognostic
marker of diabetic renal disease [16]. In non-diabetic renal disease, patients with
nephrotic range proteinuria had a reduced PA/SA compared to healthy controls,
whereas patients with albuminuria smaller than 100 mg/day had an index
comparable to healthy controls [5,7]. In addition, non-diabetic albuminuria was found
to be negatively related to PA/SA [7]. Our study showed comparable data on PA/SA
with previous reports on non-diabetic renal disease: only macro-albuminuria was
associated with a reduced PA/SA, whereas PA/SA in the stage of micro-albuminuria
did not differ from normo-albuminuric controls. Thus, our data on IgG/IgG4 andGlomerular charge selectivity and albuminuria
86
PA/SA in relation to the level of albuminuria compare well with those of the literature.
With respect to this similarity, it is important to realize that our results are not
affected by the frequent use of ACE inhibitors which may reduce the level of
albuminuria through changes in glomerular charge selectivity [17].
Figure 2. Correlation between the size-selective index IgG/albumin and IgG/IgG4 (left panel), as well
as PA/SA (right panel) in subjects with macro-albuminuria (n=20).
 
 
 Apart from the fact that our data compare well with those of the literature, we
are the first who compared both charge selective indices directly with eachother.
This allowed us to show some discrepancies between both indices with respect to
characterization of non-diabetic albuminuria in the present study. Surprisingly,
IgG/IgG4 and PA/SA did not correlate in the stage of micro-albuminuria, while this
stage reflects a defect in the charge selective function of the glomerular filtration
barrier [2,3]. Two remarks can be made with respect to this observation. First, we
have to consider that this group of micro-albuminurics is very small and has an
impaired renal function which is usually not the case in the stage of micro-
albuminuria [18]. Second, the fractional tubular reabsorption of proteins which is
known to be charge dependent may have influenced fractional protein clearances
and thus the indices of glomerular charge selectivity in conditions of micro-
albuminuria [19]. Since the tubular reabsorption of IgG is approximately 90% and of
amylase is 45% [20], this may generate differences between IgG/IgG4 and PA/SA in
the stage of micro-albuminuria.
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 A second discrepancy between IgG/IgG4 and PA/SA was observed with
respect to their opposite correlation with the IgG/albumin index in macro-albuminuric
subjects. This suggests that changes in glomerular size selectivity have their impact
in a different way on IgG/IgG4 and PA/SA. It is not possible from these data to
determine the correct ratio between renal size and charge selectivity defects in the
stage of macro-albuminuria. However, it is unlikely that macro-albuminuria is
associated with intact size and charge selectivity as suggested by the correlation
between PA/SA and IgG/albumin. The results of the multiple regression analysis
showed that the variance in albumin clearance is predominantly explained by the
renal clearance of IgG in our overall population and by the renal clearance of IgG
and the IgG/albumin index in macro-albuminuric subjects. Since IgG only pass the
filtration barrier in conditions of a size selective defect, the variance of albumin
clearance seems to be dependent from impaired size selectivity in our population.
The reduction of IgG/IgG4 and PA/SA towards 1 with increasing albuminuria may
rather be explained by fact that differently charged macromolecules pass the
filtration barrier irrespective of their charge due to impaired size selectivity than by a
progressive loss of renal charge selectivity. That glomerular size selectivity plays a
predominant role could have been expected because of the renal histological
diagnoses of our included macro-albuminuric subjects. It may well have been that
glomerular charge selectivity has a predominant role in the variance of albuminuria
of patients with minimal lesions nephrotic syndrome or patients with micro-
albuminuria [21].
In conclusion, both charge selective indices do not appear to correlate in
micro-albuminuria. In addition, the presence of a size selective defect has an
opposing effect on both charge selective indices. Although the reduction of IgG/IgG4
and PA/SA with increasing albuminuria suggests a progressive charge selective
defect, albuminuria in our population is almost entirely explained by a size selective
defect. These data seriously question whether either one or both charge selective
indices IgG/IgG4 and PA/SA do specifically reflect glomerular charge selectivity.
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Introduction
Measurement of fractional clearances of neutral dextrans with broad
molecular size distribution is a well-known and appropriate method to obtain insight
in the size selective function of the glomerular filtration barrier [1-3]. In contrast to
endogenous proteins, clearance of dextrans is not influenced by charge dependent
filtration or by reabsorption or secretion by tubules [1-2]. Previous clinical studies
which analyzed fractional dextran clearances attributed significantly to the
understanding of the pathophysiology of the glomerular filtration barrier [4-45]. In
short, nephrotic range proteinuria of various origin is associated with a loss of
glomerular size selectivity reflected by an increased fractional clearance of large
dextrans and a decreased fractional clearance of small dextrans in comparison to
normal conditions. By means of a heteroporous model of glomerular size selectivity,
increased fractional clearances of large dextrans can be explained by an increased
fraction of the filtrate which passes without restrictions through large pores in the
glomerular basement membrane. Loss of ultrafiltration capacity due to reduction of
hydraulic permeability of the glomerular capillary wall reduces filtration of small
dextrans through the second pathway of small and size-restrictive pores [14].
The laboratory procedure as described by Granath et al. forms the backbone
of measurement of fractional dextran clearances [46-47]. In short, polydisperse
dextrans in plasma and urine samples are separated in narrow fractions according to
their molecular size by gel permeation chromatography (GPC) on precalibrated
columns, whereas the dextran concentration in the collected molecular size fractions
is estimated by the anthrone assay [48]. This allows an accurate calculation of the
renal dextran clearances relative to the glomerular filtration rate over a broad range
of molecular sizes. Most studies on renal dextran sieving in human nephropathy
used this laboratory procedure, whereas several more recent studies introduced an
alternative laboratory approach for the measurement of fractional dextran clearances
(Table 1). In retrospect, studies differ with respect to methods of dextran infusion
(bolus with or without continuous infusion of different dextrans), sample preparation
(no protein precipitation or protein precipitation with different agents in different
concentrations), calibration (different number and polydispersity of standard
dextrans), size-exclusion chromatographic (GPC or HPLC), and dextran detection
(anthrone assay or on-line refractometry).
To date, no systematic comparison has been published on those different
laboratory methods, except for one comparison of different methods of dextran
infusion [49]. In the present study, we therefore compared different methods of
sample protein precipitation, column calibration, size-exclusion chromatography, and
dextran detection. We secondly analyzed whether use of different dextran size-
exclusion chromatography and dextran detection methods induce differences in the
measurement of fractional dextran clearances in healthy subjects and patients with
non-diabetic proteinuria.Chapter 6
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Table 1. Review on laboratory procedures used in clinical studies which analyzed
glomerular size selectivity by fractional dextran clearances.
Author Year Infusion Prec Calibration Chrom Detect
Mogensen
4 1968 130 mg/kgD40 ZnSO4 GPC Anthron
Mogensen
5 1971 130 mg/kgD40 ZnSO4 GPC Anthron
Carrie
6 1980 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Carrie
7 1980 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Carrie
8 1982 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Winetz
9 1981 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Winetz
10 1982 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Myers
11 1982 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Myers
12 1982 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Friedmann
13 1983 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Deen
14 1985 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Shemesh
15 1986 130 mg/kgD40 - GPC Anthron
Shemesh
16 1986 130 mg/kgD40 - GPC Anthron
Tomlanovich
17 1987 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Rosenberg
18 1987 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Ala-Houhala
19 1987 60 mg/kg D40 TCA T40/T70/T250 HPLC Anthron
Ala-Houhala
20 1987 60 mg/kg D40 TCA T40/T70/T250 HPLC Anthron
Nakamura
21 1988 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Chan
22 1988 130 mg/kgD40 - T10/T40/T70 HPLC RI
Loon
23 1989 130 mg/kgD40 - T10/T40/T70 HPLC RI
Golbetz
24 1989 130 mg/kgD40 - GPC Anthron
Morelli
25 1990 130 mg/kgD40 - T10/T40/T70 GPC Anthron
De Zeeuw
26 1990 70 mg/kg D40 TCA 5% HPLC Anthron
Myers
27 1991 130 mg/kgD40 - D9-D14 (Granath) HPLC RI
Remuzzi
28 1991 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Remuzzi
29 1991 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Guasch
30 1991 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Thomas
31 1991 130 mg/kgD70 TCA 10% 11 standards FPLC RI
Wiegmann
32 1992 60 mg/kg D40 TCA 4 Sigma standards HPLC RI
Scandling
33 1992 130 mg/kgD40 - D9-D14 (Granath) HPLC RI
Loon
34 1992 130 mg/kgD40 D9-D13 (Granath) HPLC RI
Zietse
35 1992 70 mg/kg D40 us T10/T40/T70 GPC Anthron
Remuzzi
36 1993 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Guasch
37 1993 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Ikegaya
38 1994 130 mg/kgD40 - GPC Anthron
Ting
39 1994 130 mg/kgD40 Plasma GPC Anthron
Guasch
40 1994 130 mg/kgD40 - T10/T40/T70 GPC Anthron
Hartmann
41 1994 130 mg/kgD40 - 1 standard GPC Anthron
Thomas
42 1994 130 mg/kgD70 TCA 10% 11 standards FPLC RI
Myers
43 1995 130 mg/kgD40 - D9-D13 (Granath) HPLC RI
Ambalavanan
44 1996 130 mg/kgD40 Plasma GPC Anthron
Koopman
45 1996 70 mg/kgD70 TCA 10% 6 standards HPLC RI
Abbreviations are: Prec = precipitation method; ZnSO4 = zinc sulfate; TCA = trichloroacetic acid; us
= unspecified precipitation method; Plasma = only plasma precipitation; Calibration = standard
dextrans for calibration; Chrom = size-exclusion chromatography method; Detect = dextran detection
method; RI = on-line refractometry.Laboratory procedure to measure dextran
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Methods
Sample preparation
Blood and urine samples are deproteinized before assay to prevent
interference of proteins during dextran detection and to prevent contamination of
polymer HPLC columns. We analyzed protein and dextran recovery after sample
protein precipitation by trichloroacetic acid (TCA), at low and high concentration, and
zinc sulfate. For this purpose, we used plasma spiked with a 2 mg/ml equivalent
mixture of dextran-40 (Rheomacrodex®, Pharmacia, Uppsala, Sweden) and dextran-
70 (Macrodex®, Pharmacia, Uppsala, Sweden) and urine from a proteinuric patient
with a dextran concentration of 2.5 mg/ml, which can be considered an average
concentration. On the one hand, 100% TCA was added to samples to a final
concentration of 5 or 20%. After centrifugation during 5 minutes (16000 rpm),
supernatants were titrated to pH 7.0 with NaOH. On the other hand, a mixture of 1 ml
10% zinc sulfate, 1 ml 1N NaOH, and 1 ml mobile phase were added to 1 ml sample
followed by centrifugation during 5 minutes (16000 rpm). Supernatants had a pH of
7.0.
Size-exclusion chromatography
Gel permeation chromatography (GPC) was performed on a 90 by 1.5 cm
Sephacryl S-300 column (Pharmacia, Uppsala, Sweden). A 0.01 M Tris buffer with
0.15 M NaCl and 1 mM EDTA at pH 7.0 was used as mobile phase. A 1.0 ml sample
was applicated to the column, whereas fractions of approximately 2.9 ml were
collected in polystyrene tubes (Greiner, Alphen aan de Rijn, The Netherlands) in a
Biorad 2128 fraction collector (Biorad, Hercules, CA, USA). This setup allowed us to
perform two assays during 24 hours.
High performance liquid chromatography (HPLC) was performed on two
polymer columns in series (BIO-Gel SEC 30XL and BIO-Gel SEC 40XL, each 300 by
7.8 mm; Biorad, Hercules, CA, USA) which were protected by a guard column (BIO-
Gel XL, 40 by 6 mm; Biorad, Hercules, CA, USA). The other components which we
used were a Jasco 880-PU HPLC pump (Jasco, Tokyo, Japan), a Waters U6K
injector (Waters Corporation, Milford, MA, USA), a Biorad 1775 refractive index
monitor (Biorad, Hercules, CA, USA), and a Biorad 2128 fraction collector (Biorad,
Hercules, CA, USA). A 0.02 M phosphate buffer at pH 7.0 was used as mobile phase
(0.5 ml/min). The pressure ranged between 20 and 30 kg/cm
2. A 0.1 ml sample was
injected, whereas fractions of approximately 0.43 ml were collected in polystyrene
tubes. This setup allowed us to perform six assays during 24 hours.
Dextran detection
Dextran concentration in each fraction from GPC and HPLC assays was
determined using the anthrone assay [48]. Fractions of plasma and urine from one
subject were analyzed in the same anthrone assay in which 0.4 ml sample was
mixed with 1 ml anthrone reagent. The mixture was immersed in a boiling water bath
for 16 minutes. The absorbency at 625 nm was converted to dextran concentrationChapter 6
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by the simultaneous measurement of absorbency of dextran samples with known
concentration over a range from 0 to 0.11 mg/ml.
During HPLC, dextran concentration in plasma and urine samples was also
measured by on-line refractometry [50]. The detection signal was digitized and
analyzed using commercially available software (JCL6000, Jones Chromatography
Inc, Littleton, Colorado, USA).
Table 2. Molecular weight characteristics of standard dextrans.
Mw (kD) Mn (kD) Mw/Mn (Mw* *Mn)
½ (kD) Rst1 (Å) Rst2 (Å) Rst3 (Å)
F8 10.2 5.7 1.80 7.6 20.7 23.7 27.6
F40 36.7 24.3 1.51 29.9 39.0 42.9 48.0
F75 71.0 39.4 1.80 52.9 50.8 58.1 64.3
T10 10.6 6.6 1.60 8.4 21.6 24.1 28.0
T40 40.4 28.9 1.40 34.1 41.4 44.8 50.3
T70 73.2 45.8 1.60 57.9 52.9 59.0 65.2
D9 11.7 10.7 1.09 11.2 24.4 24.9 29.3
D10 19.1 18.5 1.03 18.8 31.1 31.3 36.2
D11 40.4 38.9 1.04 39.6 44.2 44.8 50.3
D13 72.1 62.6 1.15 67.1 56.6 58.5 64.8
Abbreviations are: Mw = mass average molecular mass; Mn = number average molecular mass;
Mw/Mn = polydispersity; (Mw*Mn)
½  = molecular weight correction for polydispersity; Rst1 = Stokes
radius calculated from 0.33 * ((Mw*Mn)
½)
0.463 as in the present study; Rst2 = Stokes radius calculated
from 0.33 * Mw
0.463 according to Granath et al. [46]; Rst3 = Stokes radius calculated from 0.448 *
Mw
0.437 according to Oliver et al. [52].
Calibration
GPC and HPLC systems were calibrated at 6 week intervals using three
commercially available standard dextrans F8, F40, and F75 (Serva, Heidelberg,
Germany) with specified weight average molecular weight (Mw) and number-average
molecular weight (Mn) (Table 2). The void volume V0 of the gel column was
estimated at GPC by the elution volume of blue dextran (Pharmacia, Uppsala,
Sweden; Mw 2000 kD) and at HPLC by the elution volume of dextran-500
(Pharmacia, Uppsala, Sweden; Mw 500 kD). The total volume of the gel column Vt
was estimated at GPC by the elution volume of vitamin B12 (Mw <1 kD) and at HPLC
by the elution volume of glucose (Mw < 1 kD). The fractional volume available to the
solute (KAV) was calculated from KAV = ( Ve - V0 ) / ( Vt - V0 ), where Ve is the elution
volume of the solute [51]. Effective molecular radii for the individual dextran fractions
were estimated from the linear relationship between KAV and the Stokes radius (Rst)Laboratory procedure to measure dextran
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of the standard dextrans [46]. As in most previous studies which used standard
dextrans with high polydispersity (Mw/Mn > 1.3), Rst was  related to molecular weight
by the formula: Rst = 0.33 * M 
0.463 [46]. M in this formula represents the molecular
weight assigned to the peak position in the elution pattern of a standard dextran. We
calculated M of each standard dextran by the formula M = (Mw* Mn)
½ to correct for
polydispersity of standard dextrans [50]. In the results section the influence of this
correction on fractional dextran clearances will be evaluated. In addition, application
of another relation between Rst and molecular weight (Rst = 0.49 * M 
0.437 [52]) derived
from calibration with standard dextrans with very low polydispersity (Mw/Mn < 1.15)
will be evaluated with respect to fractional dextran clearances.
In an additional experiment, we compared three different sets of standard
dextrans (Table 2) by performing four consecutive calibrations at the HPLC system
with the anthrone assay for each set of standard dextrans.
Variance of dextran assay
We analyzed the variance of GPC and anthrone assay, HPLC and anthrone
assay, and HPLC with on-line refractometry by 10 consecutive assays of a plasma
sample spiked with a 2 mg/ml equivalent mixture of Rheomacrodex® and
Macrodex®, and an urine sample from a proteinuric patient with a dextran
concentration of 2.5 mg/ml. This allows calculation of variance of dextran
concentration in plasma and urine, and the urine-to-plasma index of dextran
concentration at each molecular size for each used method. Recovery tests showed
that dextran recovery during assays of plasma and urine supernatants were not
significant different from 100%.
In addition, the variance of the anthrone assay was tested by 20 consecutive
measurements of mobile phase samples spiked with dextrans with concentrations
from 0.00 to 0.11 mg/ml during one assay.
Dextran clearance studies
Dextran clearances were studied in 15 healthy subjects and 17 patients with
proteinuria of non-diabetic origin. All healthy subjects denied a history of renal
disease, hypertension, or diabetes. At the time of evaluation each healthy subject
was found to be normotensive, normoglycemic, and without proteinuria. Patients had
biopsy proven non-diabetic renal disease (8 focal segmental glomerulosclerosis, 6
membranous glomerulopathy, 1 IgA nephropathy, 1 minimal change disease, and 1
membranoproliferative glomerulonephritis), diastolic blood pressure below 110
mmHg, creatinine clearance more than 40 ml/min, proteinuria more than 3.0 g/day,
and no need for concomitant medication. Patients with diabetes mellitus, edema or
renovascular hypertension were not allowed to participate. Antihypertensive, diuretic
and immunosuppressive drugs were withdrawn for at least 4 weeks before
enrollment. This study was carried out according to the principles of the Declaration
of Helsinki. Healthy subjects and patients gave their informed consent for
participation in this protocol, which was approved by the local Medical Ethical
Committee.Chapter 6
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Each participant collected one 24-hour urine on the day before the renal
dextran clearance study. During the in-hospital clearance study subjects received a
bolus injection of renal function tracers 
125I-iothalamate and 
131I-hippuran at 7:45 a.m.
in the right anticubital vein followed by a constant infusion of these tracers till 15:30
p.m. Following an equilibration period till 10:00 a.m., two clearance periods from
10:00 to 12:00 a.m. and 12:00 to 14:00 p.m. were performed to estimate GFR and
ERPF. At 14.00 p.m. an injection of 20 ml dextran-1 (Promiten®, Pharmacia,
Uppsala, Sweden) was given to prevent anaphylactic reactions during the
subsequent dextran infusion. At 14:15 p.m. a 15-minute infusion of a mixture of 60
mg/kg Rheomacrodex® and 60 mg/kg Macrodex® was administered. After 30
minutes equilibration one clearance period from 15:00 to 15:30 p.m. was performed
with bracketed plasma samples to estimate dextran clearances. Throughout the
study day patients remained in supine position, except when voiding. Patients were
allowed to take their usual breakfast at 8:30 a.m. Thereafter patients received no
food, but had to drink at least 250 ml/hr to establish a sufficient diuresis. From 14:00
to 15:00 p.m. patients received an oral water load of 15 ml/kg to promote diuresis for
estimation of fractional dextran clearances.
Blood pressure was recorded at 9:00 a.m. with an automated device
(Dinamap®) during 15 minutes at 1 minute intervals. Serum and urinary chemistry
were determined with an automated multi-analyzer (SMA-C-II®, Technicon
Instruments Inc.,Tarry Town, NY, USA), whereas urinary protein was determined
with the pyrogalloll red-molybdate method [53]. GFR and ERPF were calculated
according to a previously described method using a constant infusion of 
125I-
iothalamate and 
131I-hippuran, respectively [54]. Plasma and urine dextran samples
were precipitated with 100% TCA to a final concentration of 20% and supernatants
were stored at 4￿C. At the next day, dextran clearances were estimated by GPC and
anthrone assay, HPLC and anthrone assay, and HPCL and on-line refractometry.
This allows a comparison of the three different laboratory methods with respect to
absolute values of dextran sieving coefficients in healthy subjects and patients with
non-diabetic proteinuria as well as their ability to discriminate on glomerular size
selectivity to dextrans between both study groups. Dextran clearances were
assessed relative to GFR as estimated by 
125I-iothalamate clearances.
Logarithmically transformed fractional dextran clearances were plotted against the
molecular radius to compose renal dextran sieving curves over a range from 30 to
60Å. Urinary albumin and IgG excretion, as well as albumin and IgG clearance
relative to creatinine clearance, were measured from the 24-hour urine samples
according to a previously described method [55]. Glomerular size selectivity to
proteins was expressed as the clearance of IgG relative to that of albumin, whereas
aselective proteinuria is characterized by an index greater than 0.20 [56].Laboratory procedure to measure dextran
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Figure 1. Effect of plasma precipitation with TCA 20% (panel A), TCA 5% (panel B), and zinc sulfate
(panel C) on the elution pattern of dextran detected by anthrone assay (open squares) or on-line
refractometry (closed circles). RI = units of on-line refractometry; [dextran] = dextran concentration by
anthrone assay.
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Data analysis
Data are expressed as mean and SD, unless otherwise indicated. Differences
between and within groups were tested with (un)paired student-T test. Statistical
significance was assumed at a p-level smaller than 5%.
Results
Sample preparation
Plasma was the most accurately deproteinized using 20% TCA with a protein
recovery of only 0.2% (Table 3). Treatment of plasma with 5% TCA or ZnSO4
resulted in a significant higher remaining protein sample concentration of
respectively 2.5 and 3.4%. Plasma supernatants which were deproteinized by 5%
TCA and ZnSO4 showed a concomitant peak in the dextran elution pattern during
on-line refractometry which was not detectable by anthrone assay (Figure 1). Urine
was completely deproteinized by 5 and 20% TCA, whereas protein recovery in urine
after ZnSO4 precipitation amounted 0.6%. Dextran recovery in plasma and urine
supernatants was significantly higher after 20% TCA precipitation compared to 5%
TCA and ZnSO4 precipitation (Table 3). However, dextran recovery in plasma
supernatant was greater than 100% after 20% TCA precipitation, whereas it was not
significantly different from 100% after 5% TCA or zinc sulfate deproteinization.
Dextran recovery in urine supernatant was not significantly different from 100% after
20% TCA precipitation, whereas a significant loss of 11% dextrans occurred in urine
supernatants after 5% TCA and ZnSO4 precipitation.
We decided to use sample precipitation with 20% TCA to avoid disturbances
by proteins in plasma and urine supernatant during on-line refractometry in our
further analyses.
Table 3. Remaining relative protein and dextran concentration after deproteinization
of plasma and urine samples with 20% TCA, 5% TCA and ZnSO4.
Plasma protein Urine protein Plasma dextran Urine dextran
20% TCA 0.2–0.3 0.0 118–9 97–7
5% TCA 2.5–0.4* 0.0 94–8* 89–6*
ZnSO4 3.4–0.1* 0.6–0.2* 96–8* 89–10*
Data are expressed as mean–SD. * p<0.05 versus 20% TCA.
Calibration
The calibration procedure revealed a variability smaller than 5% for GPC and
HPLC systems during the study (Table 4). The influence of the molecular weight
correction for polydispersity of standard dextrans and of the application of differentLaboratory procedure to measure dextran
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relations between Rst and molecular weight is depicted in figure 2. Fractional dextran
clearances progressively increase over the entire molecular size range if the
molecular weight correction would be omitted. A further rightward shift of fractional
dextran clearances from 40Å, but not in the low molecular size range, would be
induced if the relation between Rst and molecular weight according to Oliver et al.
[52] would be applicated in stead of that according to Granath et al. [46].
Calibration with three different sets of standard dextrans revealed significant
differences in fractional dextran clearances (Figure 2). Fractional dextran clearances
were lower in the molecular size range from 40 to 60Å in case standard dextrans
from Serva were used instead of those from Pharmacia. Dextran sieving coefficients
were lower in the molecular size range smaller than 46Å and higher in the molecular
size range greater than 50Å in case standard dextrans from Serva were used in
stead of standard dextrans with very low polydispersity provided by Dr. Granath.
Notably, this latter difference is of a magnitude that is representative of the
difference in dextran sieving between healthy subjects and patients with nephrotic
range proteinuria.
Table 4. Variability in calibration at GPC and HPLC during one year using the
standard dextrans F8, F40 and F75 (n=9; upper part) and a comparison of calibration
with three different sets of standard dextrans at HPLC and anthrone assay (n=4;
lower part).
Assay Slope CV (%) Constant CV (%)
F8/F40/F75 GPC+ant -0.0112–0.0004 3.4 0.889–0.029 3.3
HPLC+ant -0.0126–0.0003 2.0 0.845–0.020 2.5
HPLC+RI -0.0124–0.0004 2.8 0.809–0.040 5.1
F8/F40/F75 HPLC+ant -0.0120–0.0004 3.5 0.854–0.021 2.5
T10/T40/T70 HPLC+ant -0.0109–0.0003 2.5 0.822–0.007 0.9
D9/D10/D11/D13 HPLC+ant -0.0097–0.0003 2.8 0.720–0.013 1.8
Data are expressed as mean–SD. CV = coefficient of variance; ant = anthrone assay; RI = on-line
refractometry.
Variance of dextran assay
Repetitive assays of a plasma supernatant with dextran by GPC and anthrone
assay showed a variance of dextran concentration between 14 and 25% over a
range from 30 to 60Å. HPLC and anthrone assay showed a comparable variance in
that range (17 to 20%), whereas HPLC and on-line refractometry showed a clearly
lower variance of maximally 4% (Figure 3). Repetitive assays of an urine supernatantChapter 6
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Figure 2. Left panel: effect of differences in the calibration procedure on fractional dextran clearances
in one healthy subject; Applications used in the present study (closed circles), applications used by
Granath et al. [46] without molecular weight correction for polydispersity of standard dextrans (open
squares), applications used by Oliver et al. [52] without molecular weight correction for polydispersity
of standard dextrans (closed triangles). Right panel: effect of calibration with different sets of standard
dextrans on fractional dextran clearances in one healthy subject; F8, F40, and F75 (Serva,
Heidelberg, Germany, closed circles); T10, T40, and T70 (Pharmacia, Uppsala, Sweden, open
squares); D9, D10, D11, and D13 (Dr. K.A. Granath, Uppsala, Sweden, closed triangles).
with dextran by GPC and anthrone assay showed a variance of dextran
concentration from 8 to 18% in the range from 30 to 52Å, whereas it increased up to
43% for dextrans of 60Å. HPLC and anthrone assay showed a slightly higher
variance in the range from 30 to 48Å, and much higher variances for dextrans
greater than 52Å (up to 78%). HPLC and on-line refractometry revealed the lowest
variance of maximally 7% for dextrans from 30 to 48Å, but the variance increased up
to 200% for dextrans greater than 56Å. Subsequent calculation of urine-to-plasma
dextran concentration index revealed highest variance for GPC and anthrone assay
and the lowest variance for HPLC and on-line refractometry in the range from 30 to
48Å. GPC and anthrone assay showed the lowest variance in the range from 54 to
60Å, whereas HPLC and anthrone assay or on-line refractometry showed clearly
higher variances.
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Figure 3. Variance of plasma dextran concentration (A), urine dextran concentration (B), and urine to
plasma index (C) as measured by GPC and anthrone assay (closed bars), HPLC and anthrone assay
(open bars), and HPLC and on-line refractometry (cross-hatched bars).
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Reproducibility tests on the anthrone assay showed that control samples
without dextrans had an extinction coefficient of 0.002–0.008 with a variance higher
than 200%. Samples with 0.005 mg/ml dextran showed an extinction coefficient of
0.075–0.014 with a variance of 19%, whereas samples with a dextran concentration
from 0.010 to 0.110 mg/ml had a variance of extinction coefficients ranging from 3 to
7%. GPC and HPLC assays revealed dextran concentrations smaller than 0.005
mg/ml from 52 to 60Å in urine supernatant.
Table 5. Baseline characteristics of healthy subjects and patients with non-diabetic
proteinuria.
Healthy subjects Patients
Age (years) 43–12 42–15
Gender (f/m) 5/10 4/13
BSA (m
2) 1.99–0.21 1.94–0.17
Uprotein (g/day) 0 7.8–5.2*
Salbumin (g/l) 44–3 35–6*
Scholesterol (mmol/l) 5.1–0.9 7.2–2.9*
Systolic blood pressure (mmHg) 126–11 142–27*
Diastolic blood pressure (mmHg) 70–8 81–14*
GFR (ml/min/1.73m
2) 107–17 76–23*
ERPF (ml/min/1.73m
2) 447–81 392–207
FF (%) 24–2 21–4*
UalbuminE (mg/min) 5–4 3465–3588*
UIgGE (mg/min) 2–1 156–202*
Clalbumin (10
-5) 8–4 1443–2048*
ClIgG (10
-5) 11–5 194–177*
IgG/albumin index - 0.16–0.06
Data are expressed as mean–SD. Abbreviations are: f = female; m = male; BSA = body surface area;
Uprotein = proteinuria; Salbumin = serum albumin; Scholesterol = serum cholesterol; UalbuminE = urinary
albumin excretion; UIgGE = urinary IgG excretion; Clalbumin = fractional albumin clearance; ClIgG =
fractional IgG clearance. * p<0.05 versus healthy subjects.
Dextran clearance studies
Healthy subjects and patients showed comparable age, gender distribution,
and body surface area. Patients had proteinuria of 7.8–5.2 g/day with an IgG to
albumin clearance index of 0.16 (range: 0.07 to 0.25). Only 5 of the 17 patients
showed an IgG to albumin clearance index greater than 0.20. Patients demonstrated
higher systolic and diastolic blood pressure, and serum cholesterol, but a lower
GFR, FF, and serum albumin than healthy subjects (Table 5). Neither GFR, ERPF,
or filtration fraction changed significantly from baseline values during dextranLaboratory procedure to measure dextran
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infusion in healthy subjects or patients. The dextran sieving coefficients within both
groups depended on the used dextran assay. GPC and anthrone assay showed
significant higher dextran sieving coefficients than HPLC and anthrone assay from
30 to 54Å in healthy subjects and from 42 to 58Å in patients (Figure 4). GPC and
anthrone assay revealed lower dextran sieving coefficients than HPLC and anthrone
assay from 30 to 36Å in patients. HPLC and on-line refractometry revealed
significant lower dextran sieving coefficients than HPLC and anthrone assay from
36-54Å in healthy subjects and from 36-52Å in patients.
The dextran assays also differed with respect to their ability to discriminate on
glomerular size selectivity to dextrans between healthy subjects and patients with
non-diabetic proteinuria. GPC and anthrone assay revealed the well-known
differences in dextran sieving (Figure 5). Patients have higher dextran sieving
coefficients from 58 to 60Å and lower dextran sieving coefficients from 30 to 40Å. In
contrast, HPLC and anthrone assay elicited no significant differences between
dextran sieving in both groups, although patients showed a trend of increased
dextran sieving coefficients for dextrans larger than 50Å. HPLC and on-line
refractometry revealed significant higher dextran sieving coefficients from 46 to 52Å
in patients, but it did not show significant differences in the low molecular weight
dextran range as well as in the range from 54 to 60Å. Irrespective of the performed
dextran assay, the fractional clearance of dextran 56Å was not significantly related
with the fractional IgG clearance or the IgG to albumin index in our patients.
Discussion
The present study is the first to show that considerable quantitative and
qualitative variations in fractional dextran clearances are generated when one varies
the different available laboratory methods with respect to sample preparation,
calibration, size-exclusion chromatography and dextran detection. The standard and
most frequently used laboratory assay to measure fractional dextran clearances
consists of size-exclusion chromatography by GPC, and measurement of dextran
concentration in eluted fractions by the anthrone assay [46-47]. This procedure is
known to be complex, time-consuming, elaborate, and susceptible to interfering
factors such as changes in flow rate, variability of calibration, errors in collection of
eluted fractions, or disturbances in dextran detection. Because of that, HPLC and
on-line refractometry have been introduced as alternative methods of size-exclusion
chromatography and dextran detection [50]. HPLC assays are of shorter duration,
allow use of smaller samples, and include control of flow rate and pressure. On-line
refractometry prevents variability due to errors in fraction collection and enables
more sensitive detection of dextrans greater than 65Å [19-20,45]. Despite the
mentioned advantages of HPLC and on-line refractometry, some doubts may arise
upon their performance. Thomas et al. [31,42] using HPLC and on-line refractometry
failed to detect increased fractional clearances of dextrans greater than 50Å in
patients with membranous glomerulopathy and nephrotic proteinuria, whereasChapter 6
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fractional clearances of dextrans greater than 50Å were increased in patients with
thin membrane nephropathy without proteinuria. Wiegmann et al. [32] using HPLC
and on-line refractometry observed a flow through large aselective pores  in diabetic
patients with micro-albuminuria which is comparable to that in diabetic patients with
nephrotic range proteinuria [7,10,12,13,17,21,25]. A previous non-published study
from our own department using HPLC and anthrone assay failed to detect
improvement of glomerular size selectivity by dextran sieving during antiproteinuric
treatment with ACE inhibition, while glomerular size selectivity to proteins
significantly improved [26]. Remarkably, no analysis has been published so far that
compared the new techniques with the standard techniques on quantitative and
qualitative aspects of measurement of fractional dextran clearances.
Figure 4. Dextran sieving curves of healthy subjects (A) and patients with non-diabetic proteinuria (B)
as measured by GPC and anthrone assay (closed squares), HPLC and anthrone assay (open
squares), and HPLC and on-line refractometry (closed triangles). *p<0.05 GPC and anthrone assay
versus HPLC and anthrone assay; 
#p<0.05 HPLC and anthrone assay versus HPLC and on-line
refractometry.
The first aspect of the present study involved methods of dextran sample
preparation. Initially, dextran samples were not specifically prepared for size-
exclusion chromatography or no information has been presented on the method of
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sample preparation. In later studies, dextran samples were prepared before assay by
precipitation of proteins to prevent damage of polymer gels and interference of
dextran detection by proteins. The most applicated agents for protein precipitation of
dextran samples are trichloroacetic acid in varying concentration and zinc sulfate.
We observed that complete deproteinization of plasma was only achieved if TCA
was used to a final concentration of 20%, whereas a small amount of proteins were
recovered from plasma supernatant after 5% TCA and zinc sulfate deproteinization.
Zinc sulfate deproteinization also revealed small protein recovery in urine
supernatant. Incomplete protein precipitation is not of great importance in case
dextran concentration is measured by the anthrone assay, since this assay is not
affected by proteins [48]. In contrast, a small amount of protein in supernatant clearly
interfered with the dextran elution profile during on-line refractometry. One previous
study showed no confounding peaks during HPLC and on-line refractometry when
dextran samples were precipitated by picric acid [49]. After precipitation with picric
acid, dextran is recovered from supernatant by precipitation with nine volumes
ethanol, lyophilizing, and reconstituting in eluens. This revealed a small, but
significant fractionation of dextran as well as 10% loss of dextrans with low
molecular weight [49]. No data are published so far on the influence of TCA or zinc
sulfate on dextran recovery. We observed that dextran recovery in plasma
supernatant was higher than 100% by 20% TCA precipitation and dextran recovery
in urine supernatant was less than 100% by 5% TCA and zinc sulfate precipitation.
The consequence for dextran sieving coefficients seems to be limited, since urine to
plasma dextran concentration index over the entire molecular size range is
comparable for each of the protein precipitation methods. Altogether, it is of great
importance to choose a precipitation method which completely deproteinizes
samples without co-precipitation of dextrans, or to choose a dextran detection
method which is not disturbed by proteins in case of incomplete protein precipitation.
Sample preparation by 20% TCA precipitation is the method of choice in case of
dextran detection by anthrone assay or on-line refractometry, although precipitation
by picric acid may be an alternative method in case of on-line refractometry.
We secondly studied the variability of calibration of GPC and HPLC systems
by fractionation of standard dextrans with known molecular weight distribution and
polydispersity. It is known that macromolecules like proteins do not reveal accurate
calibration for size-exclusion chromatography of dextran [50]. To avoid major errors
in size-exclusion chromatography of dextran over a long period, it is essential to
perform a frequent and uniform calibration [47]. The variability of calibration at GPC
and HPLC in the present study reflects an optimal and comparable accuracy of size-
exclusion chromatography. However, the absolute values of fractional dextran
clearances significantly alter through molecular weight correction for polydispersity
of standard dextrans or application of different relations between Rst and molecular
weight of standard dextrans in the calibration procedure. The molecular weight
correction induces lower absolute fractional dextran clearances over the molecular
size range from 30 to 60Å in the present study compared to most previous studies.
The impact of this correction will be greater in case more polydisperse standardChapter 6
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dextrans are used for calibration. Despite this molecular weight correction however,
differences in polydispersity of standard dextrans still revealed serious changes of
fractional dextran clearances in relation to its molecular size as shown by the
comparison of calibration with three different sets of standard dextrans.
Figure 5. Dextran sieving curves of healthy subjects (open circles) and patients with non-diabetic
proteinuria (closed squares) as measured by GPC and anthrone assay (A), HPLC and anthrone assay
(B), and HPLC and on-line refractometry (C). *p<0.05 patients with non-diabetic proteinuria versus
healthy subjects.
These differences in fractional dextran clearances are certainly not a
chromatographic or detection error since the calibrations were performed on a stable
HPLC system with the regular anthrone assay. Altogether, one should consider that
the use of sets of standard dextrans with differences in polydispersity for calibration
induce differences in dextran sieving coefficients. Size-exclusive chromatographic
systems have therefore to be frequently and uniformly calibrated with one set of
standard dextrans preferably with a low polydispersity (<1.1). An alternative
approach is to calibrate with only one sample of a dextran with known broad
molecular mass distribution [57]. This method requires no software to calculate
calibration regression lines and is not affected by limited number and spread of
calibration dextrans and could therefore be more suitable for routine laboratories.
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Thirdly, we compared the variability of the GPC and anthrone assay, HPLC
and anthrone assay and HPLC and on-line refractometry. So far, no direct
comparison of the assays has been published previously. The GPC and anthrone
assay revealed an intra-assay variance of dextran sieving coefficients between 10
and 20% in the range from 30 to 50Å and a variance up to 100% for dextrans greater
than 50Å [56]. These high variances in the high molecular weight range was
explained by a lack of sensitivity to detect low dextran concentrations by the
anthrone assay. Interstudy variance of dextran sieving coefficients in healthy
subjects amounted between 6.4% for 30Å to and 2.7 to 3.8% for the remaining
fractions by GPC and anthrone assay [33]. HPLC and on-line refractometry revealed
variances lower than 10% [43,45]. With respect to the present comparison, it could
be expected that GPC is more sensitive to variance than HPLC, since GPC last
longer and are less well controlled with respect to flow and temperature conditions
than HPLC. Furthermore, the anthrone assay could be less accurate in detection of
low dextran concentrations, whereas on-line refractometry may be affected by non-
precipitated proteins. In the present analysis, HPLC is indeed superior to GPC with
respect to variance of urine-to-plasma dextran concentration in the range from 30 to
48Å, whereas on-line refractometry is indeed superior to the anthrone assay.
However in the range from 54 to 60Å, GPC is superior to HPLC independent of the
method of dextran detection. The high variances of dextran concentrations from 54
to 60Å are due to the poor sensitivity of dextran detection by anthrone assay as well
as on-line refractometry in that range. This may imply that only large differences in
glomerular size selectivity to dextrans or smaller differences in a large number of
patients can be detected by the tested dextran assays. In this respect, differences in
glomerular size selectivity between healthy subjects and patients with proteinuria
greater than 3 gram/day as well as changes in glomerular size selectivity during
considerable reduction of proteinuria have been detected.
We fourth measured fractional dextran clearances in healthy subjects and
patients with non-diabetic proteinuria with each of the three dextran assays. One
might expect that the dextran sieving coefficients in a patient are independent of the
assay which has been used. We however observed significant differences between
GPC and HPLC with anthrone assay or on-line refractometry in both study groups.
Except for those quantitative differences, the dextran assays also showed qualitative
differences in the comparison between healthy subjects and patients with
proteinuria. Only GPC and anthrone assay revealed differences in dextran sieving
between both groups which are in agreement with previous studies on this issue:
patients with proteinuria showed increased dextran sieving coefficients from 58 to
60Å and decreased dextran sieving coefficients from 30 to 40Å. HPLC and anthrone
assay tended to reveal increased dextran sieving coefficients from 50 to 60Å, but
this difference failed to reach statistical significance. HPLC and on-line refractometry
revealed significantly increased dextran sieving coefficients from 46 to 52Å in
patients. In contrast with previous studies [20,23,45], HPLC and anthrone or on-line
refractometry failed to detect differences in the low molecular weight range between
healthy subjects and patients with proteinuria. The important question is which of ourChapter 6
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tested assays represents the true state of glomerular size selectivity. Considering
the presence of rather selective proteinuria in our patients, it may have been
expected that dextran sieving coefficients from 54 to 60Å are comparable in both
groups, whereas fractional clearances of dextrans smaller than 40Å are decreased
in patients with proteinuria. None of the three assays revealed such a dextran
sieving pattern. On the one hand, GPC and anthrone assay showed the lowest
variance of urine-to-plasma dextran concentration for dextrans greater than 54Å and
revealed significant higher fractional clearances of dextrans in that range. HPLC and
on-line refractometry which showed the lowest variance from 30-48Å revealed
increased fractional clearances of dextrans from 46-52Å. On the other hand, GPC
and anthrone assay reveals the highest variance of urine-to-plasma dextran
concentrations in the low molecular size range, but it is the only assay which reveals
the expected lower dextran clearances from 30 to 40Å in patients with proteinuria.
We suggest that HPLC is inferior to GPC with respect to size-exclusion
chromatography of dextrans because of differences in gel characteristics or by
pressure-induced differences in retention, since we can exclude other factors like
differences in sample preparation and conservation, calibration, or dextran
detection. It appears that GPC and anthrone assay is the most sensitive assay to
detect impaired glomerular size selectivity by fractional dextran clearances despite
its high variance in the range of interest. That neither of the dextran assays reveals
a significant relation between fractional dextran clearance and fractional IgG
clearance or IgG to albumin index may be explained by the characteristics of our
patients as well as by the limitations of protein clearances and -indices for
measurement of glomerular size selectivity.
It has to be considered that differences in clearance protocols may well have
a role in differences between studies with respect to fractional dextran clearances.
First, different tracers for estimation of GFR have been used. Radioactive labeled
iothalamate does not interfere with dextran detection. In contrast, inulin is detected
by the anthrone assay [48]. Although it does not adversely affect fractional
clearances of high molecular weight dextrans, fractional clearances of small
dextrans may thus be overestimated by simultaneous detection of inulin and dextran
[56]. Second, dextran has to be infused in small concentrations to prevent changes
in renal hemodynamics. The recommended dosage of dextran indeed did not change
GFR or ERPF from baseline values in the present study in accordance with data
from Mogensen et al. [5]. Third, differences in fractional dextran clearances are
induced by different methods of infusion [49]. It has been recommended to use bolus
and continuous infusion of dextran to avoid changes in plasma concentration of
small dextrans due to their rapid renal clearance. Bolus infusion without continuous
infusion of small dextrans reveals lower fractional dextran clearances in the low
molecular weight range. We indeed showed lower fractional clearances in that range
in both our groups as compared to previous studies which used bolus and
continuous infusion.
In conclusion, differences in laboratory methods induce quantitative and
qualitative differences in fractional dextran clearances. We prefer 20% TCA sampleLaboratory procedure to measure dextran
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deproteinization, a frequent and uniform calibration procedure with one set of
calibration dextrans with low polydispersity, size-exclusion chromatography by GPC,
and dextran detection by anthrone assay. Since use of this laboratory procedure still
reveal a high variance in dextran sieving coefficients in the important pore size
range from 54 to 60Å, it may well be that only major differences in glomerular size
selectivity are detected. Concentration of dextran samples or improvement of
dextran detection techniques would be helpful in gaining more sensitivity to measure
changes in glomerular size selectivity by fractional dextran clearances.
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Introduction
Urinary loss of proteins is a well-known feature of patients with renal disease
and is usually the result of a glomerular leakage of serum proteins [1]. It may lead to
a spectrum of clinical sequelae such as sodium and water retention and an
increased risk of infectious, thrombo-embolic, and cardiovascular complications [2].
Proteinuria has also been identified as one of the independent risk factors for
progressive renal function loss in patients with renal disease [3]. In vitro studies
demonstrate that proteinuria promotes and aggravates the development of
glomerulosclerosis and tubulointerstitial scarring in most forms of glomerulonephritis
due to its intrinsic renal toxicity and its secondary metabolic effects such as
hyperlipidemia [4-5]. To date, reduction of proteinuria has become a therapeutically
strategy in clinical nephrology, since it retards the progressive loss of renal function
in chronic renal disease [6-10].
Angiotensin-converting enzyme (ACE) inhibitors have been established as
superior antiproteinuric agents in comparison to other antihypertensive agents, since
long-term treatment with ACE inhibition results in a 50% lowering of proteinuria, whereas
other antihypertensive agents have only a small or no effect on proteinuria [11]. This
potent antiproteinuric effect of ACE inhibitors could indeed be associated with a
greater renoprotective effect in non-diabetic renal disease [6, 8, 10].
The present thesis aims to elucidate some of the remaining questions on the
mechanism of the antiproteinuric effect of ACE inhibition in non-diabetic renal
disease with emphasis on the role of alterations in hemodynamic conditions and
glomerular charge selectivity.
Although ACE inhibitors also have a greater antiproteinuric capability than
calcium channel antagonists overall, the antiproteinuric effect of calcium channel
antagonists seems to depend on the type of calcium channel antagonist [11]. A
limited number of open-label studies which are all carried out in hypertensive non-
insulin dependent diabetic patients demonstrated that the non-dihydropyridine
calcium channel antagonists verapamil and diltiazem have an antiproteinuric effect
similar to that of ACE inhibitors, whereas the dihydropyridine calcium channel
antagonists such as nifedipine have a significant smaller antiproteinuric effect [12-
14]. It has also been demonstrated that combination treatment of ACE inhibitors and
non-dihydropyridine calcium channel antagonists induce an additive antiproteinuric
effect [12-13].
Chapter 1
In contrast to the observations in hypertensive diabetic patients, we observed
that the antiproteinuric efficacy of verapamil was significantly less than that of the
ACE inhibitor trandolapril (15% versus 50%) in 11 patients with non-diabetic renal
disease [15]. Verapamil did not significantly change blood pressure or renal
hemodynamics, whereas trandolapril reduced blood pressure and filtration fraction.Summary
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Since the change in proteinuria correlated with the change in blood pressure during
verapamil, the small antiproteinuric effect of verapamil may be explained by the
failure of verapamil to reduce blood pressure in our non-diabetic population. This
lack of blood pressure reduction may be explained by differences in study
population: we analyzed normotensive non-diabetic patients in contrast to previous
studies which all analyzed hypertensive diabetic patients. A fixed combination of
verapamil and trandolapril at half doses showed similar effects at hemodynamics
and proteinuria as trandolapril at full dose in our non-diabetic population. This
suggests, but not proves, that the combination of both agents provides additional
antiproteinuric efficacy in non-diabetic renal disease.
In conclusion, the antiproteinuric effect of ACE inhibition is greater than that of
the non-dihydropyridine calcium channel antagonist verapamil in patients with non-
diabetic renal disease and normal blood pressure. The antiproteinuric effect of
verapamil seems to be largely dependent on the magnitude of blood pressure
reduction in a non-diabetic population.
Since the capability of ACE inhibitors to lower blood pressure is comparable to
that of other antihypertensives, it is unlikely that the greater antiproteinuric effect of ACE
inhibitors is the consequence of differences in blood pressure reduction [11]. The greater
antiproteinuric effect of ACE inhibitors can neither be explained by their specific renal
vasodilatation which results in a greater reduction of glomerular capillary pressure. It
has been demonstrated that the antiproteinuric effect of ACE inhibitors gradually
increases from 10 to 15% during acute ACE inhibition to 50% after 4 weeks of ACE
inhibition, whereas the degree of blood pressure reduction and renal vasodilatation
did not further change after the acute effect of ACE inhibition [16]. In addition,
angiotensin II failed to reverse the antiproteinuric effect after three months ACE
inhibition, although it completely reversed the blood pressure reduction and renal
vasodilatation during ACE inhibition [17]. The alterations of blood pressure or renal
hemodynamics may be only important for the acute antiproteinuric effect of ACE
inhibition.
Chapter 2
We demonstrated that the ACE inhibitor enalaprilat induced an acute
reduction of blood pressure and proteinuria (11% and 11%, respectively) which was
comparable to that of the antihypertensive control agent nitroprusside (14% and
13%, respectively) [18]. In contrast to ACE inhibition, nitroprusside did not induce
vasodilatation of the efferent arteriole of the glomerulus which resulted in a reduction
of the filtration fraction. It therefore appears that the acute blood pressure reduction
of ACE inhibition results in an acute antiproteinuric effect in patients with non-
diabetic renal disease. Since angiotensin II increased glomerular permeability to
proteins by its acute hemodynamic effects [19-23], the acute antiproteinuric effect of
ACE inhibition may be the result of angiotensin II-dependent reductions of blood
pressure. Complete reversal of blood pressure reduction as well as renal
vasodilatation by angiotensin II indeed increased proteinuria to baseline levelsSummary
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during the acute antiproteinuric effect of enalaprilat, although this response showed
great individual variability.
In conclusion, systemic perturbation of angiotensin II during acute ACE
inhibition resulted in a relatively small reduction of proteinuria due to the
transmission of a lower systemic blood pressure into the glomerulus. The specific
renal vasodilatation during acute ACE inhibition did not contribute to the acute
antiproteinuric effect of ACE inhibition.
The superior antiproteinuric effect of ACE inhibition as well as its time course
may be the consequence of intrinsic effects at the glomerular capillary wall.
Proteinuria in non-diabetic renal disease is primarily the consequence of an
increased intrinsic permeability of the glomerular capillary wall which results in
impairment of glomerular size and charge selectivity [1, 24-26]. Glomerular size
selectivity has been preferably measured by the fractional clearance of neutral
dextran with a broad molecular size distribution [27]. An increase of the number and
the diameter of large pores in the glomerular capillary wall enhances the urinary loss
of large dextrans in conditions of non-diabetic proteinuria [1, 28-29]. Glomerular size
selectivity restored during the maximal antiproteinuric effect of ACE inhibition,
independently of the renal hemodynamic alterations [30-34]. Glomerular charge
selectivity has been measured by the fractional clearance of differently charged
dextrans or proteins with a similar molecular size [35-41]. A reduction of fixed
anionic sites in the glomerular capillary wall due to an impaired expression or
synthesis of the negatively charged glycosaminoglycan side chains of heparan
sulfate proteoglycan enhances the urinary loss of anionic macromolecules in
conditions of proteinuria [1, 42-43]. It is unknown whether glomerular charge
selectivity also contributes to the antiproteinuric effect of ACE inhibitors in non-
diabetic renal disease.
Chapter 3
Adriamycin nephrotic rats showed an impaired glomerular charge selectivity
as reflected by a relatively greater increase of the renal clearance of native anionic
rat albumin compared to charge-modified neutral rat albumin. We observed that
effective reduction of proteinuria by the ACE inhibitor lisinopril in adriamycin
nephrotic rats is associated with a restoration of glomerular charge selectivity to
albumin. In addition, the time course of the antiproteinuric effect was similar to that
of the restoration of glomerular charge selectivity to albumin. Although albumin is
charge-dependently reabsorbed by tubular cells [40], it could be argued that the
beneficial effect of lisinopril at glomerular charge selectivity was not affected by this
charge-dependent tubular reabsorption of albumin.
In conclusion, restoration of glomerular charge selectivity to albumin is an
important determinant of the antiproteinuric response of ACE inhibition as well as its
time course in adriamycin nephrotic rats. Since adriamycin nephrotic rats have also
been characterized by a glomerular size selective defect [44], the antiproteinuricSummary
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effect of ACE inhibition as well as its time course may still be the consequence of a
gradual structural restoration of glomerular size as well as charge selectivity.
Chapter 4
Patients with non-diabetic proteinuria showed a concomitant glomerular size
and charge selective defect in comparison to healthy subjects. Fractional dextran
clearances tended to increase for dextran with a molecular size larger than 50Å and
decreased for dextran with a molecular size smaller than 44Å. Since charge-modified
albumin cannot be applied in humans because of its risks of renal and extrarenal
toxicity [45], the fractional clearance indices of neutral IgG to anionic IgG4 as well as
neutral pancreatic amylase to anionic salivary amylase were used to measure
glomerular charge selectivity [37-38]. Both indices were reduced in our patients
compared to healthy subjects. Six weeks treatment with the ACE inhibitor
trandolapril induced a 50% reduction of proteinuria in our patients. The fractional
clearances of albumin, IgG and IgG4 significantly decreased, whereas the fractional
clearances of pancreatic and salivary amylase did not change during ACE inhibition.
We did neither observe a change in fractional dextran clearances or an increase of
the IgG to IgG4 or pancreatic to salivary amylase clearance indices.
In conclusion, we are not able to demonstrate a restoration of glomerular size
and charge selectivity at a maximal antiproteinuric effect of ACE inhibition in our
patients with non-diabetic renal disease.
An important question is whether ACE inhibitors are able to restore glomerular
charge selectivity or not. It may be that ACE inhibition did not restore glomerular
charge selectivity in patients with non-diabetic proteinuria because impaired
glomerular charge selectivity has a less important role in patients with non-diabetic
proteinuria than in adriamycin nephrotic rats. In addition, the use of different
methods to measure glomerular charge selectivity may explain our discrepant results
on the effect of ACE inhibition at glomerular charge selectivity. The fractional
clearances of differently charged albumin, IgG and amylase have all been able to
demonstrate a glomerular charge selective defect in conditions of proteinuria. We
firstly demonstrated  a restoration of glomerular charge selectivity during ACE
inhibition by the measurement of fractional clearances of differently charged albumin
in adriamycin nephrotic rats. Albumin and amylase have a comparable molecular
size which is considerably smaller than that of IgG. The urinary excretion of IgG has
been rather associated with a glomerular size selective defect than a glomerular
charge selective defect [24]. It may therefore be expected that differently charged
amylase is more suitable to detect a restoration of glomerular charge selectivity than
differently charged IgG. However, neither the renal amylase or IgG clearances
reflected changes in glomerular charge selectivity during ACE inhibition. The
comparable  decrease of renal IgG and IgG4 clearances, whereas the renal
clearances of pancreatic and salivary amylase did not change, rather suggests a
restoration of glomerular size selectivity during ACE inhibition.Summary
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Chapter 5
The IgG to IgG4 and pancreatic to salivary amylase clearance indices were
directly compared in non-diabetic subjects with albuminuria over a wide range. Both
indices decreased in a comparable way with increasing albuminuria [46]. Although
this suggests the presence of a progressive glomerular charge selective defect in
non-diabetic renal disease, multiple regression analysis revealed that only the
fractional IgG clearance, but not the glomerular charge selective indices, did
contribute to the variance of albuminuria. In addition, serious discrepancies were
observed between both glomerular charge selective indices in the presence of a
glomerular size selective defect in patients with albuminuria greater than 300
mg/day. A greater glomerular size selective defect was associated with a smaller
glomerular charge selective defect as reflected by the IgG to IgG4 index as well as
with a greater glomerular charge selective defect as reflected by the pancreatic to
salivary amylase index.
In conclusion, glomerular charge selectivity at least measured with the IgG to
IgG4 and pancreatic to salivary amylase clearance indices does not contribute to the
variance of albuminuria in patients with non-diabetic renal disease. This may explain
why a restoration of glomerular charge selectivity did not contribute to the
antiproteinuric response of ACE inhibition in our patients with non-diabetic renal
disease. Both glomerular charge selectivity indices do furthermore not reflect
glomerular charge selectivity in a comparable way in patients with a glomerular size
selective defect. It therefore remains uncertain whether one or both indices do reflect
glomerular charge selectivity in the expected way during antiproteinuric treatment.
Another comparative study on the IgG to IgG4 and pancreatic to salivary
amylase clearance indices recently demonstrated that the fractional clearances of
IgG subclasses were affected by the charge-dependent differences in tubular
reabsorption and the pancreatic to salivary amylase clearance index lost accuracy
with progressive loss of tubular function [47]. The IgG to IgG4 and the pancreatic to
salivary amylase clearance indices should be very carefully interpreted with respect
to their capability to reflect glomerular charge selectivity in non-diabetic renal
disease. Although dextran sulfate, despite its susceptibility for desulfatation during
ultrafiltration, and ficoll sulfate have been advocated as more accurate markers of
glomerular charge selectivity in clinical research [36, 48-49], their merits for the
measurement of changes in glomerular charge selectivity during antiproteinuric
treatment has still to be established.
If a restoration of glomerular charge selectivity did not contribute to the
antiproteinuric response of ACE inhibition in our patients, one would expect that
glomerular size selectivity was restored. Two previous clinical studies indeed
showed restoration of glomerular size selectivity as measured by fractional dextran
clearances at the time of a maximal antiproteinuric effect of ACE inhibition in
patients with non-diabetic renal disease [33-34]. We demonstrated a smaller
glomerular size selective defect at baseline in presence of proteinuria which isSummary
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comparable to that in those previous studies. It may be that the glomerular size
selective defect is smaller because of the stage of the underlying renal disease,
since our patients showed a higher GFR and lower blood pressure. Another factor
may be the differences between our and previous studies with respect to the used
laboratory procedure for measurement of fractional dextran clearances. These
differences may affect the accuracy to measure glomerular size selectivity.
Chapter 6
We demonstrated that differences in methods of sample deproteinization,
calibration, size-exclusion chromatography, and dextran detection induce
considerable variations in the absolute fractional clearance of dextran [50]. A
comparison of the three most frequently applied laboratory methods to measure
fractional dextran clearances revealed that only the laboratory method which we
used in our study detects a glomerular size selective defect in non-diabetic patients
with proteinuria as compared to healthy subjects. This method consists of sample
deproteinization by 20% trichloroacetic acid (TCA), size-exclusion chromatography
by gel permeation chromatography (GPC), and dextran detection by the anthrone
assay. However, this laboratory procedure was still characterized by a high variation
of fractional dextran clearances (30-60%) in the molecular size range of importance
for the measurement of glomerular size selectivity.
In conclusion, the high variation of the used laboratory method for
measurement of fractional dextran clearances may explain why no restoration of
glomerular size selectivity could be detected during reduction of proteinuria by ACE
inhibition in our patients with non-diabetic renal disease.
Concentration of dextran samples or improvement of dextran detection
techniques would be helpful in gaining more sensitivity to measure fractional dextran
clearances. The measurement of fractional clearances of the polymer ficoll has been
considered a more sensitive method to monitor the size selective function of the
glomerular capillary wall due to its more globular configuration than dextran [1, 36,
51]. However, this marker has still to prove its merits for the  measurement of
changes in glomerular size selectivity during antiproteinuric treatment.
Mechanism of the antiproteinuric effect of ACE inhibition
We propose the following concept for the reduction of proteinuria by ACE
inhibition in non-diabetic renal disease. ACE inhibition acutely reduces proteinuria to
a small extent by the transmission of a lower systemic blood pressure into the
glomerulus. This acute antiproteinuric effect is completely dependent of systemic
angiotensin II perturbations. The subsequent gradual increase of the antiproteinuric
effect of ACE inhibitors is the consequence of a gradual repair of biochemical and
structural defects in the glomerular capillary wall which restores glomerular  size and
charge selectivity. This effect of prolonged ACE inhibition is not dependent of
systemic angiotensin II perturbations and may explain why the reduction of
glomerular capillary pressure during ACE inhibition is not directly related with theSummary
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time course of the antiproteinuric effect [17]. A reduction in glomerular capillary
pressure may still indirectly alter the structure and composition of the glomerular
capillary wall by hemodynamically-induced effects at locally generated growth
factors such as postulated by the concept of vascular remodeling [52]. In favor of this
hypothesis, all antiproteinuric interventions which reduced glomerular capillary
pressure, such as ACE inhibition [30-31], NSAID [53-55], low protein intake [56], and
cyclosporin A [57-58], restored glomerular size selectivity in patients with non-
diabetic renal disease, whereas nifedipine did not show these renal effects [59]. The
structure and composition of the glomerular capillary wall may also be altered by
non-hemodynamical intrarenal effects of ACE inhibition. It has to be due to intrarenal
angiotensin II perturbations by ACE inhibition, since ACE inhibitors and angiotensin
II receptor antagonists demonstrated comparable effects in experimental and human
non-diabetic renal disorders [60-64]. In vitro studies demonstrated that an activated
intrarenal renin-angiotensin system induced proliferative responses of glomerular,
mesangial, and tubular cells, as well as activated mononuclear cells in several renal
disease models [65]. ACE inhibition downregulated the angiotensin II dependent
intrarenal expression of growth factors such as endothelin and TGFß which are
associated with reduced glomerular hypertrophy as well as glomerular permeability
to proteins [66-69]. Miller et al. [70] demonstrated that a reduction of glomerular
hypertrophy without concomitant changes in glomerular capillary pressure during a
low protein diet was associated with less epithelial cell detachment and albuminuria
in the rat remnant kidney model. It is however not possible to differentiate whether
glomerular permselectivity is restored through hemodynamic-dependent or
independent structural changes of the glomerular capillary wall during ACE
inhibition.
Structural glomerular effects of ACE inhibition
Although the antiproteinuric effect of ACE inhibition is associated with
restored glomerular size and charge selectivity, the number of studies on the
structural effect of ACE inhibition at the glomerular capillary wall is very limited. The
restoration of glomerular size selectivity by ACE inhibition should be the result of
structural changes in the GBM and epithelial cell layer which can be associated with
improved pore size characteristics. Iordache et al. [71] demonstrated no significant
changes in the thickness of the glomerular basement membrane, the frequency and
width of epithelial slit diaphragms, and the width and height of epithelial foot
processes during effective reduction of proteinuria during ACE inhibition in a rat
model which spontaneously develops glomerulosclerosis. Amann et al. [72]
demonstrated that only ACE inhibition, but not nifedipine or monoxidil, prevented
epithelial cell hypertrophy in the rat remnant kidney model. It seems that the
conventional electron microscopy is not capable to detect structural changes which
explain restored glomerular size selectivity. High resolution electron microscopy may
be useful to detect changes in the intrinsic organization of the GBM and the
epithelial cell layer. The restoration of glomerular charge selectivity may be due to a
gradual restoration of structural anionic sites in the glomerular capillary wall. ACESummary
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inhibition indeed increased the heparan sulfate content of the glomerular basement
membrane in the adriamycin nephrosis rat model and in a diabetic rat model [73-74].
It is however unknown whether these changes correlated with restoration of
glomerular charge selectivity.
In conclusion, further studies on the effect of ACE inhibition at the structure
and composition of the glomerular capillary wall are needed to explain the beneficial
effects of ACE inhibition at glomerular size and charge selectivity.
Future perspectives
Reduction of proteinuria contributes to the arrest or attenuation of the
progression rate of renal function loss in chronic renal disease. Although ACE
inhibitors have nowadays an important role in the accomplishment of an optimal
reduction of proteinuria, it has to be considered that the antiproteinuric effect of ACE
inhibition shows a great variation among individual patients. It is crucial to achieve
an antiproteinuric effect as optimal as possible during ACE inhibition in the individual
patient, since patients with the lowest amount of proteinuria during treatment with
ACE inhibition showed the least progression of renal function loss in non-diabetic
renal disease [75-76].
Several factors are identified which modulate the antiproteinuric effect of ACE
inhibition. First, genetic predisposition of patients seems to be of importance, since
ACE gene polymorphism affects the individual antiproteinuric response. Patients
with the ID and DD genotypes were more susceptible to the antiproteinuric response
of ACE inhibition [77]. In addition, the antiproteinuric response of ACE inhibition was
only dependent on the dietary sodium intake in non-diabetic patients with the DD
genotype [78]. Second, environmental influences which activate the renin-
angiotensin system such as dietary salt restriction or diuretic treatment enhanced
the individual antiproteinuric response to ACE inhibition [79-80]. Third, the circadian
rhythm of proteinuria seems to be a modulating factor for the antiproteinuric effect of
ACE inhibition, since ACE inhibition did not reduce proteinuria during the nighttime
[81]. It is worthwhile to study how the individual treatment with ACE inhibitors can be
optimized by improving environmental influences and testing alternative dosage
strategies in patients.
The antiproteinuric effect in the individual patient can also be enhanced by
the combination treatment of ACE inhibition with another antiproteinuric intervention.
ACE inhibitors combined with NSAID or a low protein diet showed an additional
antiproteinuric efficacy in patients with non-diabetic renal disease [82-83]. This effect
has been associated with the different effects of these interventions at glomerular
hemodynamics which further reduce glomerular capillary pressure. Considering the
hemodynamic-independent effects of ACE inhibition at glomerular permselectivity
however, it may also be that NSAID and a low protein diet induce structural changes
of the glomerular capillary wall in a different way than ACE inhibitors. The
combination treatment of ACE inhibitors with non-dihydropyridine calcium channel
antagonists also provided additional antiproteinuric efficacy, at least in hypertensive
non-insulin dependent diabetic patients [12-13]. Calcium channel antagonistsSummary
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elicited their antiproteinuric effect independently of changes in glomerular capillary
pressure [84-85]. The additional antiproteinuric efficacy of this combination
treatment may be explained by different effects of ACE inhibition and calcium
channel antagonism at the structure of the glomerular capillary wall. Especially the
non-dihydropyridine calcium channel antagonists verapamil and diltiazem have been
demonstrated favorable effects at glomerular size selectivity and the heparan sulfate
content of the glomerular capillary wall in experimental renal disease [86-88].
Additional studies on the antiproteinuric and renoprotective efficacy of combination
treatment with ACE inhibitors and non-dihydropyridine calcium channel antagonists
in non-diabetic renal disease are necessary to clarify whether this combination
strategy is indeed a new tool which improves long-term renal prognosis. Other
agents which may induce an additional antiproteinuric effect when combined with
ACE inhibitors are the angiotensin II receptor antagonists [89] or the endothelin
receptor antagonists [90]. Studies on the antiproteinuric efficacy of such a
combination treatment in patients with non-diabetic renal disease are not available.
The present thesis extends the knowledge on the mechanism of the
antiproteinuric effect of ACE inhibition since it demonstrated that a restoration of
glomerular charge selectivity may contribute to the antiproteinuric effect of ACE
inhibition. This observation may have clinical significance for the prevention of renal
disease. It is known that micro-albuminuria precedes the progressive urinary loss of
proteins in many renal disorders. Micro-albuminuria is associated with impaired
glomerular charge selectivity due to a loss of anionic sites in the glomerular capillary
wall. The reduction of micro-albuminuria by ACE inhibition which may result from
restored glomerular charge selectivity slows the progressive loss of renal function.
This beneficial effect may be due to the prevention of a progressive glomerular size
selective defect and urinary loss of proteins. This hypothesis advocates the use of
ACE inhibitors at stages of non-diabetic renal disease which are just characterized
by the presence of micro-albuminuria. It has to be demonstrated in future studies
whether the renoprotective effects of ACE inhibitors are indeed due to their
beneficial effects at the structure and composition of the glomerular capillary wall in
non-diabetic renal disease. The repair of anionic sites in the glomerular capillary
wall by ACE inhibition may still reduce the glomerular size and charge selective
defect in more advanced stages of non-diabetic renal disease. In this respect, it is
interesting that administration of danaparoid sodium which is a heparanoid
consisting of sulfated glycosaminoglycans of mainly heparan sulfate is able to
reduce proteinuria in patients with overt diabetic nephropathy [91]. Restoration of
glomerular charge selectivity due to a repair of anionic sites in the glomerular
capillary wall may be an important factor to improve the long-term prognosis in
progressive renal disease.
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Nederlandstalige samenvatting
Inleiding
De nieren zijn opgebouwd uit circa een miljoen filtereenheden, zogenaamde
glomeruli, die elk bestaan uit een kluwen van kleine bloedvaten omgeven door een
kapsel. Effectieve filtratie van het bloed vindt plaats omdat de vaatwand van de
bloedvaten in de glomerulus onbeperkt doorlaatbaar is voor vocht en kleine
moleculen, terwijl grote moleculen de vaatwand niet passeren. Het vocht en de
doorgelaten moleculen worden als urine uitgescheiden. Eiwitten kunnen normaliter
de vaatwand niet of nauwelijks passeren en verschijnen dus niet in de urine. Het is
gebleken dat eiwitten minder goed doorgelaten worden naarmate ze groter of meer
negatief geladen zijn. Dit noemt men grootte- en ladingselectiviteit van de
glomerulus. Het is te verklaren door de aanwezigheid van poriën met een bepaalde
grootte en een overwegend negatieve lading in de glomerulaire vaatwand. Patiënten
met een nierziekte kunnen een verhoogde doorlaatbaarheid van de glomerulaire
vaatwand hebben waardoor er eiwit in de urine verschijnt (proteinurie). Hierbij is de
grootte- en ladingselectiviteit gestoord. Grotere en meer negatief geladen eiwitten
worden meer uitgescheiden in de urine. Dit is het gevolg van veranderingen in de
glomerulaire vaatwand waardoor de grootte van poriën toeneemt en de negatieve
lading van de vaatwand afneemt.
Met name indien de proteinurie meer dan 3 gram per dag bedraagt kan dit
een aantal verstrekkende gevolgen hebben zoals vochtophopingen in de weefsels
(oedeem) en vatbaarheid voor het krijgen van infecties, trombose en hart- en
vaatziekten. Bovendien is gebleken dat het aanwezig zijn van proteinurie één van de
belangrijke risicofactoren is voor het verslechteren van de nierfunctie op de lange
termijn. Ook hoge bloeddruk en verhoogd cholesterol zijn bekende risicofactoren
voor nierfunctieverlies op de lange termijn. Het is aangetoond dat een afname van
de aanwezige proteinurie de nierfunctie op de lange termijn beter behoudt.
Proteinurie kan verminderd worden door behandeling met medicijnen, waarbij de
angiotensine-converting enzym (ACE) remmers worden beschouwd als medicijnen
van eerste keus. ACE remmers zijn bloeddrukverlagende medicijnen die de
proteinurie met 50% verlagen. Dit in tegenstelling tot alle andere
bloeddrukverlagende medicijnen die de proteinurie niet of slechts in geringe mate
verlagen (minder dan 20%). Door dit groter vermogen van ACE remmers om de
proteinurie te verlagen zijn ze ook beter in staat om de lange termijn nierfunctie te
behouden dan de andere bloeddrukverlagende medicijnen.
In dit proefschrift willen we het werkingsmechanisme van het proteinurie
verlagend effect van ACE remmers nader verklaren.
In recente onderzoeken is aangetoond dat het bloeddrukverlagend
medicament verapamil (een calcium antagonist) een vergelijkbare afname van
bloeddruk en proteinurie veroorzaakt als ACE remmers bij patiënten met verhoogde
bloeddruk en proteinurie ten gevolg van suikerziekte. Combinatie behandeling vanAfsluiting
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verapamil en een ACE remmer bij deze patiënten resulteerde zelfs in een extra
proteinurie verlagend effect zonder dat de bloeddruk verder daalde.
Hoofdstuk 1
In dit hoofdstuk wordt het proteinurie verlagend effect van verapamil
vergeleken met dat van de ACE remmer trandolapril. Nu echter voor de eerste keer
bij patiënten zonder suikerziekte met proteinurie hoger dan 3 gram per dag (niet-
diabetische proteinurie) en een normale bloeddruk. In tegenstelling tot de eerdere
onderzoeken vonden wij dat verapamil de proteinurie minder verlaagde dan de ACE
remmer (15 ten opzichte van 50%). Hierbij is opvallend dat verapamil de bloeddruk
bij onze patiënten niet verlaagde, terwijl de ACE remmer dit wel deed. Dit is
waarschijnlijk te wijten aan het feit dat wij patiënten met een normale bloeddruk
onderzochten. Het bleek dat de mate van proteinurie afname door verapamil
afhankelijk was van de mate van bloeddrukdaling. Wij konden niet bewijzen dat een
combinatie van verapamil en de ACE remmer trandolapril een extra afname van
proteinurie veroorzaakte.
Verapamil laat dus geen overtuigend proteinurie verlagend effect bij patiënten
met niet-diabetische proteinurie en een normale bloeddruk zien. De ACE remmer
heeft daarentegen het bekende proteinurie verlagend effect bij deze patiënten.
Alhoewel er al veel onderzoek verricht is naar het werkingsmechanisme van
het proteinurie verlagend effect van ACE remmers is dit nog niet volledig
opgehelderd. Er is lang gedacht dat het extra proteinurie verlagend effect van ACE
remmers ten opzichte van de andere bloeddrukverlagende medicijnen veroorzaakt
wordt door de beïnvloeding van de nierdoorbloeding door ACE remmers. Er treedt
namelijk een dusdanige bloedvatverwijding op in de glomerulus dat de
nierdoorbloeding toeneemt en de druk in de glomerulus verder afneemt dan het
effect van de bloeddrukverlaging. Hierdoor zou er minder eiwit in de urine terecht
kunnen komen. Eerder onderzoek van onze afdeling laat echter een verschillend
beloop van het proteinurie verlagend effect en het effect op de bloeddruk en
nierdoorbloeding tijdens ACE remming zien. De proteinurie neemt geleidelijk af tot
50% na 4 weken behandeling. De bloeddrukdaling en toename van nierdoorbloeding
is echter al maximaal aanwezig binnen enkele uren na start van de behandeling. Het
lijkt er dus op dat het effect van ACE remmers op de bloeddruk of nierdoorbloeding
slechts een rol kunnen spelen bij de afname van proteinurie direct na start van de
behandeling.
Hoofdstuk 2
In dit hoofdstuk wordt uitgezocht of de daling van bloeddruk of de toename
van nierdoorbloeding inderdaad een rol spelen bij het acute proteinurie verlagend
effect van ACE remmers bij patiënten met niet-diabetische proteinurie groter dan 3
gram per dag. Na toediening van de eerste dosis ACE remmer (enalaprilaat) daaldeAfsluiting
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de bloeddruk en de proteinurie met 10 tot 15%, en nam de nierdoorbloeding met 15
tot 20% toe. Tijdens toediening van een ander bloeddrukverlagend medicament
(nitroprusside) daalde de bloeddruk en proteinurie in vergelijkbare mate, maar trad
er geen toename van de nierdoorbloeding op zoals bij de ACE remmer. Toediening
van angiotensine II, het hormoon waarvan de aanmaak door ACE remmers wordt
geremd, tijdens ACE remming resulteerde in een stijging van de bloeddruk en een
afname van de nierdoorbloeding. Hierbij nam de proteinurie toe tot de
uitgangswaarde, alhoewel deze reactie per individu grote verschillen liet zien.
De kleine afname van proteinurie met 10 tot 15% direct na start van de
behandeling met ACE remmers wordt dus verklaard door de bloeddrukdaling en niet
door de toename van de nierdoorbloeding.
De vraag blijft hoe de extra afname van proteinurie tot 50% tijdens het vervolg
van de behandeling met ACE remmers veroorzaakt wordt, en waarom deze afname
zo geleidelijk intreedt. Dit kan verklaard worden door een geleidelijk herstel van de
gestoorde grootte- en ladingselectiviteit bij patiënten met proteinurie. Grootte
selectiviteit is in eerdere onderzoeken bij voorkeur gemeten door dextranen met een
variërende molecuul grootte toe te dienen. Dextranen zijn niet geladen
suikermoleculen. Met een complexe laboratorium bepaling is vast te stellen hoeveel
dextranen met een bepaalde molecuul grootte in de urine terechtkomen. Het is
aangetoond dat het maximaal proteinurie verlagend effect van ACE remmers
gepaard gaat met een herstel van de grootte selectiviteit: de uitscheiding in de urine
van grotere dextranen neemt af, terwijl de uitscheiding van kleinere dextranen niet
afneemt.
Ladingselectiviteit kan gemeten worden met behulp van de uitscheiding in de
urine van eiwitten of dextranen met eenzelfde molecuul grootte, maar met een
verschillende molecuul lading. Het is nog onbekend of een gestoorde
ladingselectiviteit kan herstellen door behandeling met ACE remmers. Een
verbetering van ladingselectiviteit zou gepaard moeten gaan met relatief minder
uitscheiding van negatief geladen eiwitten of dextranen in de urine.
Hoofdstuk 3
In dit hoofdstuk is de ladingselectiviteit geanalyseerd tijdens verlaging van
proteinurie met een ACE remmer (lisinopril) bij ratten. De proteinurie bij deze ratten
is veroorzaakt door de stof adriamycine te injecteren. Om de ladingselectiviteit te
meten hebben we twee verschillend geladen eiwitten van dezelfde grootte, maar met
een verschillende lading toegediend: albumine dat negatief geladen is en albumine
waarvan de lading door ons is geneutraliseerd.
Adriamycine ratten hadden in vergelijking met gezonde ratten een grotere
uitscheiding van negatief geladen albumine in de urine. Dus er is inderdaad sprake
van een gestoorde ladingselectiviteit bij adriamycine ratten. Behandeling met de
ACE remmer verlaagde de proteinurie geleidelijk met een maximaal effect na 3
weken. Hierbij is de uitscheiding van negatief geladen albumine in de urine minder
dan die van neutraal geladen albumine. Dit betekent dat het proteinurie verlagendAfsluiting
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effect van lisinopril samengaat met een herstel van de ladingselectiviteit. Nog
belangrijker was de bevinding dat het herstel van de ladingselectiviteit en de afname
van proteinurie eenzelfde geleidelijke beloop hadden.
Het herstel van de ladingselectiviteit van de glomerulaire vaatwand speelt dus
een belangrijke rol bij het proteinurie verlagend effect van ACE remmers, in ieder
geval bij adriamycine ratten.
Hoofdstuk 4
In dit hoofdstuk is zowel de grootte- als ladingselectiviteit geanalyseerd
tijdens behandeling met een ACE remmer (trandolapril) bij patiënten met niet-
diabetische proteinurie groter dan 3 gram per dag. Grootte selectiviteit werd
gemeten met behulp van dextranen. Bij mensen kan de ladingselectiviteit niet
gemeten worden door toediening van verschillend geladen albumine. Injectie van het
neutraal geladen albumine kan namelijk schadelijke afweerreacties oproepen.
Daarom is de ladingselectiviteit gemeten met behulp van de uitscheiding in de urine
van verschillend geladen eiwitten met een vergelijkbare grootte die aanwezig zijn in
het bloed: neutraal geladen IgG en negatief geladen IgG4 alsmede neutraal geladen
pancreas amylase en negatief geladen speeksel amylase.
Patiënten hadden in vergelijking met gezonde vrijwilligers een grotere
uitscheiding van grotere dextranen, negatief geladen IgG4 en negatief geladen
speeksel amylase. Er was dus sprake van zowel een gestoorde grootte- als
ladingselectiviteit bij de patiënten. Na 6 weken behandeling met de ACE remmer
nam de proteinurie met 50% af. Hierbij trad er echter geen verandering op van de
uitscheiding van dextranen en verschillend geladen amylase in de urine. De
uitscheiding van negatief en neutraal geladen IgG in de urine nam in gelijke mate af.
Er kon dus geen herstel van zowel de grootte- als ladingselectiviteit aangetoond
worden tijdens het maximale proteinurie verlagend effect van ACE remmers.
Een belangrijke vraag is of ACE remmers nu wel of niet een gestoorde
ladingselectiviteit kunnen herstellen. Het zou kunnen dat geen herstel van
ladingselectiviteit kon worden aangetoond bij patiënten met proteinurie omdat de
gestoorde ladingselectiviteit een minder belangrijke rol speelt bij patiënten dan bij
adriamycine ratten met proteinurie. Afgezien daarvan kan het gebruik van
verschillende methoden om de ladingselectiviteit te meten een oorzaak zijn voor de
tegengestelde resultaten in hoofdstuk 3 en 4. Met de uitscheiding van verschillend
geladen albumine, IgG en amylase is wel een verschil in ladingselectiviteit aan te
tonen tussen af- en aanwezigheid van proteinurie. Het is echter nooit beschreven
met deze methoden dat een gestoorde ladingselectiviteit kan herstellen tijdens
medicamenteuze verlaging van proteinurie. De molecuul grootte van albumine en
amylase is vergelijkbaar, maar veel kleiner dan die van IgG. De uitscheiding van het
eiwit IgG in de urine wordt grotendeels verklaard door een gestoorde grootte
selectiviteit, en nauwelijks door een gestoorde ladingselectiviteit. Gezien het feit dat
met albumine een herstel van ladingselectiviteit wordt aangetoond, zou je
verwachten dat een herstel van ladingselectiviteit te meten moet zijn met deAfsluiting
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uitscheiding van verschillend geladen amylase, maar niet met verschillend geladen
IgG. Het is echter opvallend dat zowel de uitscheiding van verschillend geladen IgG
als verschillend geladen amylase geen verandering van ladingselectiviteit aantoont
tijdens ACE remming.
Hoofdstuk 5
In dit hoofdstuk vergelijken we de uitscheiding in de urine van verschillend
geladen IgG en verschillend geladen amylase bij een grote groep mensen met niet-
diabetische proteinurie variërend van 0 tot 20 gram per dag. Een hogere proteinurie
ging gepaard met een vergelijkbaar grotere uitscheiding van negatief geladen IgG4
en speeksel amylase ten opzichte van neutraal geladen IgG en pancreas amylase.
Dit suggereert dat zowel de uitscheiding van IgG als amylase in de urine een
toenemend gestoorde ladingselectiviteit weergeeft bij een hogere proteinurie. Als je
echter andere factoren die de proteinurie kunnen beïnvloeden meenam in een
rekenkundig model bleek dat de hoogte van de proteinurie niet afhankelijk was van
de gestoorde ladingselectiviteit gemeten met verschillend geladen IgG of amylase.
De hoogte van de proteinurie leek met name afhankelijk te zijn van de mate van de
gestoorde grootte selectiviteit. Het bleek bovendien dat er bij een toenemend
gestoorde grootte selectiviteit relatief minder negatief geladen IgG4 dan neutraal
geladen IgG, maar relatief meer negatief geladen speeksel amylase dan neutraal
geladen pancreas amylase in de urine werd uitgescheiden.
Al met al lijkt het aandeel van een gestoorde ladingselectiviteit gemeten met
IgG of amylase aan de proteinurie bij onze patiënten klein. Dit betekent dat een
herstel van ladingselectiviteit nauwelijks een rol kan spelen tijdens afname van
proteinurie door ACE remmers. Daarbij komt nog dat een verandering in de
uitscheiding van IgG en amylase op basis van molecuul lading tegengesteld is bij
een verandering in grootte selectiviteit. Dit betekent dat één of beide methoden niet
geschikt kunnen zijn om de ladingselectiviteit juist weer te geven tijdens een afname
van proteinurie door ACE remming bij patiënten met een gestoorde grootte
selectiviteit.
Als de ladingselectiviteit zo’n geringe rol speelt zou je in ieder geval een
herstel van grootte selectiviteit verwachten tijdens ACE remming. Twee eerdere
onderzoeken toonden inderdaad een herstel van grootte selectiviteit aan tijdens
ACE remming bij patiënten met niet-diabetische proteinurie. In deze onderzoeken is
de grootte selectiviteit ook gemeten door dextranen toe te dienen. Maar hierbij zijn er
wel verschillende laboratorium methoden gebruikt om de molecuul grootte van
dextranen te bepalen. Het is opvallend dat de grootte selectiviteit bij onze patiënten
minder gestoord lijkt dan bij patiënten uit die eerdere onderzoeken, terwijl de
proteinurie nagenoeg vergelijkbaar is. Dit kan het gevolg zijn van de ernst van de
onderliggende nierziekte omdat onze patiënten ook een betere nierfunctie en lagere
bloeddruk hadden. We kunnen echter niet uitsluiten dat de verschillen in de
gebruikte laboratorium methoden de mate van gestoorde grootte selectiviteit of de
mate van herstel van gestoorde grootte selectiviteit beïnvloeden.Afsluiting
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Hoofdstuk 6
In dit hoofdstuk vergelijken we de drie meest gebruikte laboratorium
methoden om de molecuul grootte van dextranen vast te stellen. Het bleek dat alleen
de methode die wij in hoofdstuk 4 hebben gebruikt in staat is om een verschil in
grootte selectiviteit weer te geven tussen gezonde mensen en patiënten met niet-
diabetische proteinurie groter dan 3 gram per dag. Deze methode behelst het op
molecuul grootte scheiden van dextranen met gel permeatie chromatografie (GPC)
en de dextraan concentratie meting met de anthron bepaling. Het blijft de vraag
waarom wij met deze methode geen herstel van grootte selectiviteit konden meten.
Mogelijk is dit het gevolg van de vastgestelde, aanzienlijke variatie van deze
methode, waardoor kleine verschillen in grootte selectiviteit niet meetbaar kunnen
zijn bij een kleine groep patiënten.
Het mechanisme van het proteinurie verlagend effect van ACE remmers
Wij denken dat het proteinurie verlagend effect van ACE remmers op de
volgende manier verklaard kan worden. De eerste dosis ACE remmer heeft een
kleine afname van proteinurie ten gevolg welke verklaard kan worden door de
gelijktijdige afname van de bloeddruk. Dit effect van ACE remmers is geheel
afhankelijk van de veranderingen in angiotensine II concentratie in de bloedbaan.
Voortgezette behandeling met ACE remmers verlaagt de proteinurie geleidelijk
verder tot 50% na 4 weken. Dit beloop gaat gepaard met een geleidelijk herstel van
de ladingselectiviteit van de glomerulaire vaatwand bij adriamycine ratten. Om te
bevestigen dat ACE remmers ook bij patiënten de ladingselectiviteit kunnen
herstellen zullen andere methoden gebruikt moeten worden dan het meten van de
urine uitscheiding van verschillend geladen IgG of verschillend geladen amylase.
Alhoewel ACE remmers de grootte selectiviteit kunnen herstellen, is het nog
onbekend of dit ook het geleidelijke beloop van de afname van proteinurie verklaart.
Het meten van dextraanuitscheiding in de urine met de huidig beschikbare
laboratorium methode is niet nauwkeurig genoeg om zulke geleidelijke
veranderingen in grootte selectiviteit aan te tonen.
Hiernaast blijft het onbekend of een geleidelijk herstel van grootte- en
ladingselectiviteit van de glomerulaire vaatwand veroorzaakt wordt door een direct
effect van de ACE remmer op de poriën in de vaatwand of door een indirect effect
via de toegenomen nierdoorbloeding waardoor de druk in de glomerulus extra daalt.
Verwachtingen
Voor de huidige individuele patiënt met proteinurie ten gevolg van een
nierziekte is het van zeer groot belang om de proteinurie zo maximaal mogelijk te
verminderen. Hiernaast dienen andere risicofactoren voor nierfunctieverlies zo
optimaal mogelijk vermeden te worden. Dit verhoogt de kans op het behoud van de
nierfunctie op de lange termijn. Kennis van het werkingsmechanisme van het
proteinurie verlagend effect van ACE remmers kan bijdragen om zo’n maximaal
effect te bereiken. Het is bekend dat het effect van ACE remmers beïnvloedt wordtAfsluiting
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door omgevingsfactoren, zoals het gebruik van een zoutbeperkt dieet of
plastabletten, en erfelijke factoren. Voor de individuele patiënt zou op basis van
deze factoren een ideaal klimaat voor behandeling met ACE remmers geschapen
kunnen worden. Hierbij kan het gecombineerd gebruik van ACE remmers en andere
proteinurie verlagende behandelingen resulteren in een extra afname van
proteinurie indien de behandelingen verschillend en aanvullend aangrijpen op de
glomerulus. Het is bekend dat gelijktijdige behandeling met een ACE remmer en een
eiwitbeperkt dieet een dergelijk effect heeft. Ook de combinatie van een ACE
remmer met verapamil zou dit kunnen bewerkstelligen. Verder onderzoek dient uit te
wijzen hoe verschillende factoren ingepast moeten worden en welke behandelingen
met ACE remmers gecombineerd kunnen worden om tot een optimaal effect van
ACE remmers op proteinurie te komen.
Herstel van een gestoorde ladingselectiviteit door ACE remmers kan mogelijk
een belangrijke stap zijn voor preventie van nierziekten die met proteinurie gepaard
gaan. Het wordt aangenomen dat gezonde mensen met een lichte mate van
eiwitverlies in de urine (micro-albuminurie) een groter risico hebben op het krijgen
van nierziekten. Aangezien micro-albuminurie verklaard wordt door een gestoorde
ladingselectiviteit, kan vroegtijdige behandeling met ACE remmers mogelijk
voorkomen dat een gestoorde ladingselectiviteit leidt tot grotere schade op de lange
termijn. Uiteraard dient deze hypothese in toekomstige onderzoeken getest te
worden.Afsluiting
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Informatie over de auteur
De auteur van dit proefschrift is geboren op 12 juli 1966 te Didam in
Nederland. Na afronding van het atheneum B in 1984 te Enschede is hij begonnen
met de studie Geneeskunde aan de Rijksuniversiteit Groningen. Na het artsexamen
in 1992, heeft hij tot juli 1996 als arts-onderzoeker gewerkt op de afdeling Nefrologie
van het Academisch Ziekenhuis Groningen (hoofd: Prof. dr. P.E. de Jong). In deze
periode zijn de onderzoeken uitgevoerd welke in dit proefschrift zijn beschreven.
Vanaf juli 1996 heeft de schriftelijke afronding van het proefschrift plaatsgevonden
naast de opleiding tot internist in het Martini Ziekenhuis Groningen (opleiders: Dr. L.
Wijnja en Dr. J.D.M. Gökemeijer).
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Dankwoord
Het schrijven van een dankwoord twee en een half jaar na het vertrek van de
afdeling Nefrologie van het Academisch Ziekenhuis Groningen heeft z’n voordelen.
Aangename herinneringen borrelen zo weer op, terwijl minder aangename
herinneringen naar de achtergrond verdrongen zijn.
Prof. dr. Paul de Jong en Prof. dr. Dick de Zeeuw hebben vanaf 1992 zorg
gedragen voor mijn opleiding tot wetenschapper. Dick zei altijd: “dat proefschrift, dat
komt er wel, maar die opleiding dat is de hoofddoelstelling”. Ik ben jullie zeer
erkentelijk voor mijn leerzame onderzoekstijd. Dat we niet altijd dezelfde ideeën
hadden over het onderzoek en de rest is hiervan slechts een bevestiging.
Vele andere betrokkenen die een belangrijke bijdrage geleverd hebben aan
dit proefschrift wil ik hartelijk danken. Gezonde vrijwilligers en patiënten met
proteinurie die onbaatzuchtig en standvastig dagenlang urine verzameld hebben,
continue bloeddrukmetingen ondergingen en eindeloze nierfunctie metingen
doorstonden. De mannen van het verzendlaboratorium onder leiding van dhr. Jan
Ritse(l)ma die zorgden voor urine volume metingen op de milliliter nauwkeurig en
adequate verzending van monsters. Mevr. Rina de Jong en mevr. Petra Visser die
op het laboratorium immunochemie alle eiwitbepalingen hebben uitgevoerd.
Medewerkers van het vaatlaboratorium Interne Geneeskunde die onder leiding van
Dr. A.J. Smit voorafgaand aan elke nierfunctiemeting bereid waren om een
zogenaamde fluoresceine test te doen. Medewerkers van het nucleair geneeskundig
laboratorium onder leiding van mevr. A.K. van Zanten die de nierfunctiebepalingen
en radiolabeling van albumine hebben uitgevoerd. Het secretariaat Nefrologie onder
leiding van Rieta Graler die de altijd dringende hand- en spandiensten voor hun
rekening hebben genomen. De bijdragen van de medewerkers van de hypertensie
polikliniek, de nierfunctiekamer en het laboratorium Nefrologie verdienen een nadere
toelichting. Op de hypertensie polikliniek werden alle patiënten die deelnamen aan
onderzoek door Nel Heslinga-Kuiper en later Corrie Nieuwenhout optimaal begeleid.
Marja van Kammen, Alie Drent-Bremer, Erika Konneman en Saskia Vorderman
(tevens research typiste) zorgden voor een zorgvuldige uitvoering van de
nierpompen en afname van research monsters. Hierbij was het met de dames
gezelligheid troef, zodanig dat de deur van het koffiehok menigmaal dicht moest. Het
laboratorium Nefrologie heeft mij menigmaal verbijsterd. Niet alleen de lokatie, maar
ook de inrichting en het arbeidsethos deed mij realiseren: “this is real research,
men”. In deze ondoordringbare jungle is het mede dankzij Feiko Jilderda, Erik
Hamminga en Janneke van der Wal gelukt om de laboratorium projecten tot een
goed einde te brengen. Hierbij mag de uitdrukking “bloed, zweet en tranen” wat mij
betreft aangevuld worden met zoutzuur.
De “AIO brothers and sisters in crime” wil ik danken omdat ze medebepalend
zijn geweest voor de onderzoekssfeer. In de eerste plaats mijn paranimf Ron
Gansevoort. Niet alleen is hij mijn voorganger die een gespreid onderzoeksbedje
afleverde, hij is ook altijd vraagbaak nummer 1, positivo nummer 1 en met mij samenAfsluiting
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fervent B-film liefhebber als we weer eens aan de rol waren. Ron, gelukkig heeft mijn
rug het overleefd en is de pijn te dragen. Ook Pieter, Frits-Hein, Annet, Wiebe-
Douwe, Jacco, Hanneke, Marcel en Erik van kamer E4.17 en B1.13 zijn
onvergetelijk. Jullie bewerkstelligden onbegrijpelijke vertraging van het onderzoek
door langdurige, (on)belangrijke prietpraat, maar ook welkome versnelling door
toevallige, zeer nuttige hulp. Het jaarlijks terugkerend hoogtepunt was het bezoek
aan het ASN congres in de Verenigde Staten. Deze gelegenheid grepen wij
dankbaar aan om met z’n allen op één hotelkamer te verblijven, zodat er voldoende
dollars aan het buitenprogramma besteed konden worden. Het bleken er nooit
voldoende te zijn!
Tot slot wil ik mijn ouders danken. Jullie hebben mij altijd gestimuleerd om
uitdagingen zoals dit promotie-onderzoek aan te gaan, én af te ronden uiteraard.
Nog belangrijker is het voor mij geweest dat ik af en toe de promotie kon vergeten
omdat jullie, samen met Joost, Michiel, Mayke, en de rest van de familie Hemmelder
en Hudepohl voor de broodnodige en ontspannende afleiding bleven zorgen.
Marie-Margreeth, jij hebt mij verboden om jou, Stef en Thomas te danken in
dit dankwoord. Dat zal ik dan maar op een betere manier doen.